UCSF HELEN DILLER FAMILY COMPREHENSIVE CANCER CENTER
kmUU300MXic
kmUU300MXic
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
<strong>UCSF</strong> <strong>HELEN</strong> <strong>DILLER</strong><br />
<strong>FAMILY</strong> <strong>COMPREHENSIVE</strong><br />
<strong>CANCER</strong> <strong>CENTER</strong><br />
American Society of Clinical Oncology Annual Meeting<br />
June 3-7, 2016<br />
Chicago, IL<br />
<strong>UCSF</strong> Presentation Brochure
Committed to Advancing<br />
Development of Improved<br />
Cancer Therapies, Imaging<br />
Modalities, and Biomarkers<br />
As president of the <strong>UCSF</strong> Helen Diller Family Comprehensive Cancer<br />
Center, one of my key priorities is to initiate and advance programs<br />
that are developing new anticancer drugs making significant impact<br />
on helping cancer patients live longer and better lives. I recognize this<br />
goal is best accomplished by working in partnership with the broader<br />
life science industry. This searchable abstract book of <strong>UCSF</strong> research<br />
presented at ASCO is a resource for potential partners interested in<br />
identifying world-class faculty engaged in clinical oncology research.<br />
As an NCI-designated comprehensive cancer center, <strong>UCSF</strong> is<br />
recognized for our outstanding science, extensive resources, depth<br />
and breadth of our research in basic, clinical, and/or population<br />
sciences, as well as cutting edge research that bridges these<br />
scientific areas. Practically this means that our clinicians and basic<br />
scientists work closely together to (1) identify, develop and optimize<br />
novel therapeutics for biological efficacy and clinical utility, (2) assess<br />
tumor status and responsiveness to current therapies, (3) develop<br />
biomarkers for patient stratification and therapeutic response and (4)<br />
advance supportive care options to mitigate the toxicities associated<br />
with chemotherapy.<br />
Alan Ashworth, PhD, FRS<br />
President, <strong>UCSF</strong> Helen Diller<br />
Family Comprehensive<br />
Cancer Center<br />
Senior Vice President<br />
for Cancer Services,<br />
<strong>UCSF</strong> Health<br />
As is evident from the breadth and depth the research being<br />
presented at this year’s ASCO, <strong>UCSF</strong> is home to many of world’s<br />
finest oncology scientists and clinicians. I invite you learn more about<br />
our work and expertise by reaching out to our faculty. If you have any<br />
additional questions or need any assistance with your outreach, please<br />
contact the Director of Strategic Alliances for the Cancer Center:<br />
Cammie Edwards ( ).<br />
Wishing you a very productive meeting and we look forward to<br />
future discussions and collaborations.<br />
Professor of Medicine,<br />
Division of Hematology/<br />
Oncology, Department<br />
of Medicine<br />
Alan Ashworth, PhD, FRS<br />
President, <strong>UCSF</strong> Helen Diller Family Comprehensive Cancer Center<br />
2
HDFCCC Overview<br />
A Designated NCI Comprehensive<br />
Cancer Center Since 1999<br />
The “comprehensive” designation—NCI’s highest ranking, awarded only<br />
after a rigorous evaluation process—recognizes <strong>UCSF</strong>’s excellence in<br />
basic research, clinical research, population based research, outreach and<br />
education, and our ability to integrate these diverse research approaches to<br />
cancer and turn them into clinical practice.<br />
Our Success is Driven by Our Faculty<br />
HDFCCC Membership: 397 Members & Associate Members<br />
2 Nobel Laureates<br />
3 Albert Lasker Award winners<br />
8 Howard Hughes Medical Investigators<br />
13 Members of the National Academy of Sciences<br />
20 Members of the Institute of Medicine<br />
18 Fellows of the American Academy of Arts and Sciences<br />
4 Fellows of the Royal Society<br />
3
HDFCCC Overview<br />
Working Together Advancing the<br />
Understanding and Treatment of Cancer<br />
Multi-Disciplinary Research Programs<br />
• Breast Oncology<br />
• Cancer Control<br />
• Cancer Genetics<br />
• Cancer, Immunity, and Microenvironment<br />
• Developmental Therapeutics<br />
• Hematopoietic Malignancies<br />
• Neurologic Oncology<br />
• Pediatric Malignancies<br />
• Prostate Cancer<br />
• Tobacco Control<br />
Multi-Disciplinary Clinical Programs<br />
• GU Oncology (non Prostate)<br />
• GI (includes Pancreas Cancer)<br />
• Thoracic Oncology<br />
• Cutaneous Oncology<br />
• Head and Neck Cancer<br />
• Sarcoma<br />
• Endocrine<br />
• Gynecologic Oncology<br />
• Breast Oncology<br />
• Prostate Cancer<br />
Key Initiatives<br />
• Cancer Imaging<br />
• Cancer Immunotherapeutics<br />
• Global Oncology<br />
• Center for BRCA Research<br />
• <strong>UCSF</strong> 500<br />
• Target Validation Initiative<br />
Advancing the Next Wave of Cancer Treatment Breakthroughs<br />
Whether it is pioneering novel clinical trial designs, discovering, developing and bringing to<br />
the clinic revolutionary treatments such as immunotherapies or harnessing the power of big<br />
data to drive faster, personalized and more effective cures, <strong>UCSF</strong> leads in advancing the next<br />
wave of cancer treatment breakthroughs. With a culture of collaboration, a commitment to<br />
excellence and access to cutting-edge laboratory and clinical technologies, <strong>UCSF</strong> faculty<br />
work tirelessly to improve clinical outcomes for cancer patients everywhere.
HDFCCC Overview<br />
Core Capabilities<br />
Supporting Our Programs<br />
• Biostatistics<br />
• Clinical Research Support<br />
• Genome Analysis<br />
• Laboratory for Cell Analysis<br />
• Immunohistochemistry & Molecular Pathology<br />
• Mouse Pathology<br />
• Preclinical Therapeutic Testing<br />
• Bio-specimen Banking<br />
• Tobacco Biomarkers<br />
• Bioinformatics<br />
• Computational Biology<br />
Approximately one-quarter of the<br />
University’s ~2,200 full-time faculty<br />
members work in cancer research or<br />
cancer care.<br />
<strong>UCSF</strong> consistently ranks among<br />
the top U.S. biomedical research<br />
organizations in cancer-specific<br />
federal funding. In 2015, <strong>UCSF</strong><br />
received more than $85M from the<br />
National Cancer Institute.<br />
5
Partnering with<br />
<strong>UCSF</strong> HDFCCC<br />
<strong>UCSF</strong> faculty have a long history of working with industry<br />
partners translating discoveries into products that ultimately<br />
improve patient care. We are experienced in establishing and<br />
executing on a wide range of successful partnerships. If you are<br />
interested in learning more about working with the HDFCCC<br />
and its faculty, please contact:<br />
Cammie Edwards, PhD<br />
Director of Strategic Alliances, HDFCCC<br />
• On average, <strong>UCSF</strong> has 200-300 new invention disclosures per year<br />
• An estimated 90 life science start-up companies have been spawned<br />
from the University’s labs, including Genentech, Chiron, and Intellikine<br />
• Included among <strong>UCSF</strong> patents are top revenue producers, such as<br />
- Hepatitis B vaccine<br />
- Bovine growth hormone<br />
- Barrier repair lipids<br />
- Yeast expression vector<br />
- Magnetic resonance imaging<br />
<strong>UCSF</strong> IN THE NEWS (Click on title to read story)<br />
New Cancer Immunotherapy Clinic Offers Unique Studies of Promising Treatments<br />
https://www.ucsf.edu/news/2016/04/402411/new-cancer-immunotherapy-clinic-offers-unique-studies-promising-treatments<br />
New <strong>UCSF</strong> Center for BRCA Research Expands Care for Increased Cancer Risk<br />
http://cancer.ucsf.edu/news/2016/04/19/new-ucsf-center-for-brca-research-expands-care-for-increased-cancer-risk.7470<br />
Better Survival for Colon Cancer Patients with Left-Sided Tumors<br />
Location Matters, Says Study to Be Presented at ASCO<br />
http://cancer.ucsf.edu/news/2016/05/18/better-survival-for-colon-cancer-patients-with-left-sided-tumors.7638<br />
Berger, Bluestone Named to White House Cancer Moonshot Expert Panel<br />
http://cancer.ucsf.edu/news/2016/04/06/berger-bluestone-named-to-white-house-cancer-moonshot-expert-panel.7418<br />
Read interview with <strong>UCSF</strong>’s Dr. Michael Korn on<br />
“When to Suspect Germline Abnormality from Genetic Testing Results”<br />
- ASCO daily news [ http://am.asco.org/dn ] | print version: June 6, 2016
Presentations<br />
Presentations<br />
View full abstracts on line at:<br />
http://am.asco.org/abstracts<br />
*<strong>UCSF</strong> authors in bold<br />
Updated data from a phase II dose finding trial of single agent<br />
isatuximab (SAR650984, anti-CD38 mAb) in relapsed/refractory<br />
multiple myeloma (RRMM).<br />
Authors*: Joshua Ryan Richter, Thomas G. Martin, Ravi Vij, Craig Cole, Djordje Atanackovic, Jeffrey A. Zonder,<br />
Jonathan L. Kaufman, Joseph Mikhael, William Bensinger, Meletios A. Dimopoulos, Todd M. Zimmerman,<br />
Nikoletta Lendvai, Parameswaran Hari, Enrique M. Ocio, Cristina Gasparetto, Shaji Kumar, Corina Oprea,<br />
Eric Charpentier, Stephen Anthony Strickland, Jesus San Miguel<br />
Abstract #: 8005<br />
Presentation Date/Time: Friday, June 3: 3:00 - 6:00 PM<br />
Location: E354b<br />
Session: Hematologic Malignancies - Plasma Cell Dyscrasias<br />
Citation: J Clin Oncol 34, 2016 (suppl; abstr 8005)<br />
Martin Research Interests: A leading expert in hematology-oncology, Dr. Thomas Martin is the associate<br />
director of the Myeloma Institute and director of the Unrelated Donor Transplantation Program for adults<br />
at <strong>UCSF</strong> Medical Center. He is also the clinical research directory of hematologic malignancies, or blood<br />
cancers, at the <strong>UCSF</strong> Helen Diller Family Comprehensive Cancer Center. His research interests include<br />
developing treatments for myeloma and leukemia as well as expanding the use of bone marrow transplants.<br />
He has a special interest in umbilical cord blood transplants and is involved in efforts to improve the<br />
outcomes following unrelated donor transplants.<br />
http://cancer.ucsf.edu/research/multiple-myeloma/mmti/mmti_team#martin<br />
*<strong>UCSF</strong> authors in bold<br />
7
Presentations<br />
Plasma asparaginase activity and asparagine depletion in patients<br />
with acute lymphoblastic leukemia (ALL) treated with pegaspargase<br />
(SS-PEGE. coli L-asparaginase): Results from Children’s Oncology<br />
Group (COG) study AALL07P4.<br />
Authors*: Reuven J. Schore, Meenakshi Devidas, Archie Bleyer, Gregory H. Reaman, Naomi J. Winick,<br />
Mignon L. Loh, Elizabeth A. Raetz, William L. Carroll, Stephen Hunger, Anne L. Angiolillo<br />
Abstract #: 10508<br />
Presentation Date/Time: Friday, June 3: 3:00 - 6:00 PM<br />
Location: S504<br />
Session: Pediatric Oncology I<br />
Citation: J Clin Oncol 34, 2016 (suppl; abstr 10508)<br />
__________________________________________________________________________<br />
MONARCH1: Results from a phase II study of abemaciclib, a CDK4<br />
and CDK6 inhibitor, as monotherapy, in patients with HR+/HER2-<br />
breast cancer, after chemotherapy for advanced disease.<br />
Authors*: Maura N. Dickler, Sara M. Tolaney, Hope S. Rugo, Javier Cortes, Véronique Diéras, Debra A. Patt,<br />
Hans Wildiers, Martin Frenzel, Andrew Koustenis, Jose Baselga<br />
Abstract #: 510<br />
Presentation Date/Time: Friday, June 3: 4:30 - 6:00 PM<br />
Location: Hall D1<br />
Session: Future Directions in Breast Cancer Treatment: New Drugs, New Markers<br />
Citation: J Clin Oncol 34, 2016 (suppl; abstr 510)<br />
Rugo Research Interests: Dr. Rugo, Director of Breast Oncology & Clinical Trials Education, is PI on multiple<br />
clinical trials focusing on combining novel targeted therapeutics to improve the treatment of both early & late<br />
stage breast cancer (BC). She also works on studies to improve supportive care for early & late stage BC<br />
patients, including with <strong>UCSF</strong>’s Advanced Breast Cancer Program. Dr. Rugo has numerous collaborations with<br />
large academic medical centers & consortia in order to expand the novel therapies available to patients. She<br />
was the director of the 2016 ASCO Breast Cancer Education Committee meeting, is a member of the Alliance<br />
& is a founding member of the Breast Cancer Research Consortium where she co-leads the triple negative<br />
working group. She is on the novel agents committee for the neoadjuvant multi-center I SPY2 trial. At <strong>UCSF</strong>,<br />
Dr. Rugo runs the Breast Forum, a bimonthly educational session for breast cancer patients, families & friends<br />
from throughout the bay area.<br />
http://cancer.ucsf.edu/people/profiles/rugo_hope.3648<br />
*<strong>UCSF</strong> authors in bold<br />
8
Presentations<br />
Phase II trials of cetuximab plus combined modality therapy (CMT) in<br />
squamous cell carcinoma of the anal canal (SCCAC) with and without<br />
human immunodeficiency virus (HIV) infection.<br />
Authors*: Madhur Garg, Fengmin Zhao, Jeannette Y. Lee, Joseph A. Sparano, Joel Palefsky, David H. Henry,<br />
William Wachsman, Lakshmi Rajdev, David Michael Aboulafia, Lee Ratner, Lisa A. Kachnic, Edith P. Mitchell,<br />
Adedayo A. Onitilo, Ronald T. Mitsuyasu, Al Bowen Benson<br />
Abstract #: 3522<br />
Presentation Date/Time: Saturday, June 4: 8:00 - 11:30 AM<br />
Location: Hall A Poster Board # 219<br />
Session: Gastrointestinal (Colorectal) Cancer<br />
Citation: J Clin Oncol 34, 2016 (suppl; abstr 3522)<br />
__________________________________________________________________________<br />
Blood-based biomarkers in patients (pts) with metastatic colorectal<br />
cancer (mCRC) treated with FOLFOX or FOLFIRI plus bevacizumab<br />
(Bev), cetuximab (Cetux), or bev plus Cetux: Results from CALGB<br />
80405 (Alliance).<br />
Authors*: Andrew B. Nixon, Alexander Sibley, Ace Joseph Hatch, Yingmiao Liu, Chen Jiang, Flora Mulkey,<br />
Mark D. Starr, John C. Brady, Donna Niedzwiecki, Federico Innocenti, Alan P. Venook, Howard S. Hochster,<br />
Heinz-Josef Lenz, Bert H. O’Neil, Kouros Owzar, Herbert Hurwitz<br />
Abstract #: 3597<br />
Presentation Date/Time: Saturday, June 4: 8:00 - 11:30 AM<br />
Location: Hall A, Poster Board #294<br />
Session: Gastrointestinal (Colorectal) Cancer<br />
Citation: J Clin Oncol 34, 2016 (suppl; abstr 3597)<br />
Venook Research Interests: Dr. Alan Venook is a nationally renowned expert in colorectal and liver cancers at<br />
the <strong>UCSF</strong> Helen Diller Family Comprehensive Cancer Center. He is highly regarded for his expertise in the<br />
effective use of the newest approaches and therapies to the treatment of colorectal cancer, as well treating<br />
primary and metastatic tumors to the liver. Dr. Venook has chaired and/or authored six major studies within<br />
the cooperative groups and he now Chairs the GI Committee of the Alliance for Clinical Trials in Oncology<br />
(formerly CALGB.)<br />
http://cancer.ucsf.edu/people/profiles/venook_alan.3698<br />
*<strong>UCSF</strong> authors in bold<br />
9
Presentations<br />
A phase 2 study of galunisertib, a novel transforming growth factorbeta<br />
(TGF-β) receptor I kinase inhibitor, in patients with advanced<br />
hepatocellular carcinoma (HCC) and low serum alpha fetoprotein (AFP).<br />
Authors*: Sandrine J. Faivre, Armando Santoro, Edward Gane, Robin Kate Kelley, I Ollivier Hourmand,<br />
Eric Assenat, Ivelina Gueorguieva, Ann Cleverly, Durisala Desaiah, Michael M. F. Lahn, Eric Raymond,<br />
Karim A. Benhadji, Gianluigi Giannelli<br />
Abstract #: 4070<br />
Presentation Date/Time: Saturday, June 4: 8:00 - 11:30 AM<br />
Location: Hall A, Poster Board #62<br />
Session: Gastrointestinal (Noncolorectal) Cancer<br />
Citation: J Clin Oncol 34, 2016 (suppl; abstr 4070)<br />
__________________________________________________________________________<br />
A randomized, double-blinded, placebo-controlled phase II trial of<br />
gemcitabine (gem) plus nab-paclitaxel (nab-P) plus apatorsen (A) or<br />
placebo (Pl) in patients (pts) with metastatic pancreatic cancer (mPC):<br />
The RAINIER trial.<br />
Authors*: Andrew H. Ko, Patrick Brian Murphy, James D. Peyton, Dianna Shipley, Ahmed Al-Hazzouri,<br />
Francisco Antonio Rodriguez, Mark Sanders Womack, Henry Q. Xiong, David Michael Waterhouse,<br />
Margaret A. Tempero, Shuangli Guo, Cassie Michelle Lane, Christopher Earwood, Laura M. DeBusk,<br />
Johanna C. Bendell<br />
Abstract #: 4119<br />
Presentation Date/Time: Saturday, June 4: 8:00 - 11:30 AM<br />
Location: Hall A, Poster Board #111<br />
Poster Session: Gastrointestinal (Noncolorectal) Cancer<br />
Citation: J Clin Oncol 34, 2016 (suppl; abstr 4119)<br />
Ko Research Interests: My work focuses on gastrointestinal malignancies, where I have developed and<br />
led multiple clinical trials, both within <strong>UCSF</strong> and across multiple sites. I am interested in the development<br />
and evaluation of new therapeutic agents ranging from novel cytotoxics to molecular targeted agents to<br />
immunotherapies, with a particular emphasis in pancreatic cancer. This work entails collaborating with<br />
laboratory-based investigators on translational science to identify individual patient/tumor characteristics that<br />
influence prognosis and response to specific therapies. I lead the <strong>UCSF</strong> site committee for gastrointestinal<br />
cancer-specific clinical trial development and serve as chair of the scientific Protocol Review Committee.<br />
Nationally, I sit on the editorial board for multiple peer-reviewed oncology journals, am a member of NCI’s<br />
Pancreatic Cancer Task Force and the NCCN Pancreatic Cancer guidelines committee.<br />
http://cancer.ucsf.edu/people/profiles/ko_andrew.3444<br />
*<strong>UCSF</strong> authors in bold<br />
10
Presentations<br />
CRS-207 immunotherapy expressing mesothelin, combined with<br />
chemotherapy as treatment for malignant pleural mesothelioma (MPM).<br />
Authors*: Raffit Hassan, Evan W. Alley, Hedy L. Kindler, Scott Joseph Antonia, Thierry Marie Jahan,<br />
Somayeh Honarmand, Katherine McDougall, Chan C. Whiting, Nitya Nair, Amanda Enstrom, Ed Lemmens,<br />
Takahiro Tsujikawa, Sushil Kumar, Lisa M Coussens, Aimee Murphy, Anish Thomas, Dirk G. Brockstedt<br />
Abstract #: 8558<br />
Presentation Date/Time: Saturday, June 4: 8:00 - 11:30 AM<br />
Location: Hall A, Poster Board #186<br />
Session: Lung Cancer - Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers<br />
Citation: J Clin Oncol 34, 2016 (suppl; abstr 8558)<br />
__________________________________________________________________________<br />
Pembrolizumab (pembro) plus chemotherapy as front-line therapy for<br />
advanced NSCLC: KEYNOTE-021 cohorts A-C.<br />
Authors*: Shirish M. Gadgeel, James Stevenson, Corey J. Langer, Leena Gandhi, Hossein Borghaei,<br />
Amita Patnaik, Liza Cosca Villaruz, Matthew A. Gubens, Ralph J. Hauke, James Chih-Hsin Yang,<br />
Lecia V. Sequist, Robert D. Bachman, Joy Yang Ge, Harry Raftopoulos, Vassiliki Papadimitrakopoulou<br />
Abstract #: 9016<br />
Presentation Date/Time: Saturday, June 4: 8:00 - 11:30 AM<br />
Location: Hall A, Poster Board #339<br />
Session: Lung Cancer - Non-Small Cell Metastatic<br />
Citation: J Clin Oncol 34, 2016 (suppl; abstr 9016)<br />
Gubens Research Interests: Matthew Gubens is a thoracic oncologist who treats patients with lung cancer,<br />
mesothelioma and other thoracic malignancies, including thymoma and thymic carcinoma, which are rare<br />
tumors of the mediastinum. His research involves designing clinical trials to study new compounds and<br />
treatment strategies in lung cancer. He and his colleagues have a special interest in translational medicine,<br />
and are actively working to translate laboratory-based findings to the clinic, especially for patients with<br />
epidermal growth factor receptor (EGFR) mutations. The group is also active in trials evaluating new<br />
immunotherapy approaches in thoracic malignancies. Dr. Gubens is a member of the American Society of<br />
Clinical Oncology, the International Association for the Study of Lung Cancer and the International Thymic<br />
Malignancy Interest Group.<br />
http://profiles.ucsf.edu/matthew.gubens<br />
*<strong>UCSF</strong> authors in bold<br />
11
Presentations<br />
Pembrolizumab vs docetaxel for previously treated advanced NSCLC<br />
with a PD-L1 tumor proportion score (TPS) 1%-49%: Results from<br />
KEYNOTE-010.<br />
Authors*: Edward B. Garon, Roy S. Herbst, Dong-Wan Kim, Enriqueta Felip, Jose Luis Perez-Gracia, Ji-Youn Han,<br />
Julian R. Molina, Joo-Hang Kim, Catherine Dubos Arvis, Myung-Ju Ahn, Margarita Majem, Mary J. Fidler,<br />
Matthew A. Gubens, Gilberto Castro, Marcelo Garrido, Yue Shentu, Ellie Im, Gregory M. Lubiniecki, Paul Baas<br />
Abstract #: 9024<br />
Presentation Date/Time: Saturday, June 4: 8:00 - 11:30 AM<br />
Location: Hall A, Poster Board #347<br />
Session: Lung Cancer - Non-Small Cell Metastatic<br />
Citation: J Clin Oncol 34, 2016 (suppl; abstr 9024)<br />
Gubens Research Interests: Matthew Gubens is a thoracic oncologist who treats patients with lung cancer,<br />
mesothelioma and other thoracic malignancies, including thymoma and thymic carcinoma, which are rare<br />
tumors of the mediastinum. His research involves designing clinical trials to study new compounds and<br />
treatment strategies in lung cancer. He and his colleagues have a special interest in translational medicine,<br />
and are actively working to translate laboratory-based findings to the clinic, especially for patients with<br />
epidermal growth factor receptor (EGFR) mutations. The group is also active in trials evaluating new<br />
immunotherapy approaches in thoracic malignancies. Dr. Gubens is a member of the American Society of<br />
Clinical Oncology, the International Association for the Study of Lung Cancer and the International Thymic<br />
Malignancy Interest Group.<br />
http://profiles.ucsf.edu/matthew.gubens<br />
*<strong>UCSF</strong> authors in bold<br />
12
Presentations<br />
Long-term OS for patients with advanced NSCLC enrolled in the<br />
KEYNOTE-001 study of pembrolizumab (pembro).<br />
Authors*: Rina Hui, Leena Gandhi, Enric Carcereny Costa, Enriqueta Felip, Myung-Ju Ahn, Joseph Paul Eder,<br />
Ani Sarkis Balmanoukian, Natasha B. Leighl, Charu Aggarwal, Leora Horn, Amita Patnaik,<br />
Gary William Middleton, Matthew A. Gubens, Matthew David Hellmann, Jean-Charles Soria,<br />
Suresh S. Ramalingam, Gregory M. Lubiniecki, Jin Zhang, Bilal Piperdi, Edward B. Garon<br />
Abstract #: 9026<br />
Presentation Date/Time: Saturday, June 4: 8:00 - 11:30 AM<br />
Location: Hall A, Poster Board #349<br />
Session: Lung Cancer - Non-Small Cell Metastatic<br />
Citation: J Clin Oncol 34, 2016 (suppl; abstr 9026)<br />
Gubens Research Interests: Matthew Gubens is a thoracic oncologist who treats patients with lung cancer,<br />
mesothelioma and other thoracic malignancies, including thymoma and thymic carcinoma, which are rare<br />
tumors of the mediastinum. His research involves designing clinical trials to study new compounds and<br />
treatment strategies in lung cancer. He and his colleagues have a special interest in translational medicine,<br />
and are actively working to translate laboratory-based findings to the clinic, especially for patients with<br />
epidermal growth factor receptor (EGFR) mutations. The group is also active in trials evaluating new<br />
immunotherapy approaches in thoracic malignancies. Dr. Gubens is a member of the American Society of<br />
Clinical Oncology, the International Association for the Study of Lung Cancer and the International Thymic<br />
Malignancy Interest Group.<br />
http://profiles.ucsf.edu/matthew.gubens<br />
*<strong>UCSF</strong> authors in bold<br />
13
Presentations<br />
Phase I/II study of pembrolizumab (pembro) plus ipilimumab (ipi) as<br />
second-line therapy for NSCLC: KEYNOTE-021 cohorts D and H.<br />
Authors*: Matthew A. Gubens, Lecia V. Sequist, James Stevenson, Steven Francis Powell, Liza Cosca<br />
Villaruz, Shirish M. Gadgeel, Corey J. Langer, Amita Patnaik, Hossein Borghaei, Shadia Ibrahim Jalal, Joseph<br />
Fiore, Joy Yang Ge, Harry Raftopoulos, Leena Gandhi<br />
Abstract #: 9027<br />
Presentation Date/Time: Saturday, June 4: 8:00 - 11:30 AM<br />
Location: Hall A, Poster Board #350<br />
Poster Session: Lung Cancer - Non-Small Cell Metastatic<br />
Citation: J Clin Oncol 34, 2016 (suppl; abstr 9027)<br />
Gubens Research Interests: Matthew Gubens is a thoracic oncologist who treats patients with lung cancer,<br />
mesothelioma and other thoracic malignancies, including thymoma and thymic carcinoma, which are rare<br />
tumors of the mediastinum. His research involves designing clinical trials to study new compounds and<br />
treatment strategies in lung cancer. He and his colleagues have a special interest in translational medicine,<br />
and are actively working to translate laboratory-based findings to the clinic, especially for patients with<br />
epidermal growth factor receptor (EGFR) mutations. The group is also active in trials evaluating new<br />
immunotherapy approaches in thoracic malignancies. Dr. Gubens is a member of the American Society of<br />
Clinical Oncology, the International Association for the Study of Lung Cancer and the International Thymic<br />
Malignancy Interest Group.<br />
http://profiles.ucsf.edu/matthew.gubens<br />
*<strong>UCSF</strong> authors in bold<br />
14
Presentations<br />
Randomized phase 2 study of the safety, efficacy, and immune<br />
response of GVAX pancreas (with cyclophosphamide) and CRS-<br />
207 with or without nivolumab in patients with previously treated<br />
metastatic pancreatic adenocarcinoma (STELLAR).<br />
Authors*: Dung T. Le, Todd S. Crocenzi, Jennifer N. Uram, Eric R. Lutz, Daniel A. Laheru, Elizabeth A. Sugar,<br />
Robert H. Vonderheide, George A. Fisher, Andrew H. Ko, Aimee Murphy, Katherine McDougall, Sandy Ferber,<br />
Dirk G. Brockstedt, Elizabeth M. Jaffee<br />
Abstract #: TPS4153<br />
Presentation Date/Time: Saturday, June 4: 8:00 - 11:30 AM<br />
Location: Hall A, Poster Board #134a<br />
Session: Gastrointestinal (Noncolorectal) Cancer<br />
Citation: J Clin Oncol 34, 2016 (suppl; abstr TPS4153)<br />
Ko Research Interests: My work focuses on gastrointestinal malignancies, where I have developed and<br />
led multiple clinical trials, both within <strong>UCSF</strong> and across multiple sites. I am interested in the development<br />
and evaluation of new therapeutic agents ranging from novel cytotoxics to molecular targeted agents to<br />
immunotherapies, with a particular emphasis in pancreatic cancer. This work entails collaborating with<br />
laboratory-based investigators on translational science to identify individual patient/tumor characteristics that<br />
influence prognosis and response to specific therapies. I lead the <strong>UCSF</strong> site committee for gastrointestinal<br />
cancer-specific clinical trial development and serve as chair of the scientific Protocol Review Committee.<br />
Nationally, I sit on the editorial board for multiple peer-reviewed oncology journals, am a member of NCI’s<br />
Pancreatic Cancer Task Force and the NCCN Pancreatic Cancer guidelines committee.<br />
http://cancer.ucsf.edu/people/profiles/ko_andrew.3444<br />
*<strong>UCSF</strong> authors in bold<br />
15
Presentations<br />
Amethyst NSCLC trial: Phase 2, parallel-arm study of receptor<br />
tyrosine kinase (RTK) inhibitor, MGCD265, in patients (pts) with<br />
advanced or metastatic non-small cell lung cancer (NSCLC)<br />
with activating genetic alterations in mesenchymal-epithelial<br />
transition factor (MET).<br />
Authors*: Igor I. Rybkin, Ebenezer A. Kio, Ashiq Masood, Merrill Kingman Shum, Balazs Halmos,<br />
Collin M. Blakely, Keith D. Eaton, Neelesh Sharma, John J. Nemunaitis, Steven J. Saccaro, Yanis Boumber,<br />
Raul R. Mena, Hamid R. Mirshahidi, Pasi A. Janne, James Christensen, Richard C. Chao,<br />
Vanessa Roberts Tassell, Demiana Faltaos, Marshall T. Schreeder<br />
Abstract #: TPS9099<br />
Presentation Date/Time: Saturday, June 4: 8:00 - 11:30 AM<br />
Location: Hall A, Poster Board #422a<br />
Session: Lung Cancer - Non-Small Cell Metastatic<br />
Citation: J Clin Oncol 34, 2016 (suppl; abstr TPS9099)<br />
__________________________________________________________________________<br />
TIGER-3: A phase 3 multinational open-label randomized study of<br />
rociletinib vs investigator-choice chemotherapy in patients (pts) with<br />
epidermal growth factor receptor mutant-positive (EGFRm) non-small<br />
cell lung cancer (NSCLC) progressing on prior EGFR tyrosine kinase<br />
inhibitor (TKI) therapy and doublet chemotherapy.<br />
Authors*: James Chih-Hsin Yang, Sanjay Popat, Silvia Novello, Harry J.M. Groen, Maurice Perol,<br />
Enriqueta Felip, Frank Griesinger, Karen L. Reckamp, Jong-Seok Lee, Egbert F. Smit, Collin M. Blakely,<br />
Wallace L. Akerley, Young-Chul Kim, Lyudmila Bazhenova, Raffaele Califano, Richard Delmar Hall,<br />
Panayiotis Georgiou, Jeffrey D. Isaacson, Tony Golsorkhi, Heather A. Wakelee<br />
Abstract #: TPS9106<br />
Presentation Date/Time: Saturday, June 4: 8:00 - 11:30 AM<br />
Location: Hall A, Poster Board 425b<br />
Session: Lung Cancer - Non-Small Cell Metastatic<br />
Citation: J Clin Oncol 34, 2016 (suppl; abstr TPS9106)<br />
*<strong>UCSF</strong> authors in bold<br />
16
Presentations<br />
Genomic Profiling to distinguish poorly differentiated neuroendocrine<br />
carcinomas arising in different sites.<br />
Authors*: Emily K. Bergsland, Ritu Roy, Phil Stephens, Jeffrey S. Ross, Mark Bailey, Adam Olshen<br />
Abstract #: 4020<br />
Presentation Date/Time: Saturday, June 4: 8:00 - 11:30 AM<br />
Location: Hall A, Poster Board #12<br />
Poster Session: Gastrointestinal (Noncolorectal) Cancer<br />
Citation: J Clin Oncol 34, 2016 (suppl; abstr 4020)<br />
Bergsland Research Interests: My research is focused on the development and testing of novel, biologically<br />
based therapies for gastrointestinal malignancies, with an emphasis on neuroendocrine tumors (NETs). I am<br />
co-chair of the Neuroendocrine Tumor Task Force of the NCI Gastrointestinal Steering Committee, a NCCN<br />
Neuroendocrine Tumors Guidelines Panel member, Board of Directors member for NANETS, and co-chair<br />
of the 8th edition AJCC Expert Panel on staging for NETs. I am study chair for ALLIANCE A021202 (an<br />
ongoing randomized Phase II trial of pazopanib vs. placebo in patients with progressive carcinoid tumors).<br />
My current research focuses on data from three completed investigator-initiated Phase II clinical trials in NETs<br />
(a. FOLFOX/bevacizumab, b. everolimus plus erlotinib, and c. axitinib), fostering several collaborations with<br />
laboratory-based colleagues, and taking advantage of a fully annotated outcomes database (established in<br />
2010 and encompassing 600+ NET patients treated at <strong>UCSF</strong> since 2004).<br />
http://cancer.ucsf.edu/gi/emily-bergsland<br />
__________________________________________________________________________<br />
Head and Neck Cancer Updates from the American Society for<br />
Radiation Oncology<br />
Authors*: Sue Sun Yom<br />
Abstract #:<br />
Presentation Date/Time: Saturday, June 4: 8:20 - 8:40 AM<br />
Location: S100bc<br />
Education Session: Best of the Rest: Top Abstracts on Head and Neck Cancer from<br />
the 2015-2016 Oncology Meetings<br />
Citation:<br />
Yom Research Interests: Dr. Yom is an expert in head and neck, thoracic, and skin cancers and conducts<br />
research in quality of life and supportive care, patient-oriented decision making, and combinations of novel<br />
targeted therapies and immunotherapy with radiation therapy. She is the principal investigator of HN002,<br />
a national trial in de-intensified therapy for HPV+ oropharyngeal cancer. She serves on several national<br />
panels developing guidelines for appropriate care of head and neck cancers.<br />
http://profiles.ucsf.edu/sue.yom<br />
*<strong>UCSF</strong> authors in bold<br />
17
Presentations<br />
Comprehensive mutation analysis in NRG Oncology/RTOG 9813:<br />
A phase III trial of RT + TMZ vs RT + nu for anaplastic astrocytoma<br />
and mixed anaplastic oligoastrocytoma (Astrocytoma Dominant).<br />
Authors*: Erica Hlavin Bell, Joseph P McElroy, Jessica Fleming, Cynthia Dawn Timmers, Arup R Chakraborty,<br />
Andrea L Salavaggione, Susan Marina Chang, Kenneth D. Aldape, David Brachman, Helen Alice Shih,<br />
Peixin Zhang, Minesh P. Mehta, Arnab Chakravarti<br />
Abstract #: 2016<br />
Presentation Date/Time: Saturday, June 4: 1:00 - 4:30 PM<br />
Location: Hall A, Poster Board # 205<br />
Session: Central Nervous System Tumors<br />
Citation: J Clin Oncol 34, 2016 (suppl; abstr 2016)<br />
Chang Research Interests: My research interest is in the development of novel therapies for patients with brain<br />
tumors, as well as the assessment of novel imaging biomarkers in the management of patients. My research<br />
seeks to integrate advances in physiologic and metabolic imaging with tissue biomarkers in order to optimize<br />
the management of patients with glioblastoma (GBM). My clinical research evaluates a wide spectrum of<br />
therapeutic interventions that span chemotherapy, targeted agents, immunotherapy and convection enhanced<br />
delivery of novel agents. I am the site PI of an NIH-funded adult brain tumor consortium and am a member<br />
of the Brain Malignancy Steering Committee and the Developmental Therapeutics Study Section at the NIH. I<br />
am the program leader for the Neuro-Oncology Program at the HDFCCC. I am the clinical co-PI for the <strong>UCSF</strong><br />
Brain Tumor SPORE and a co-Leader of a SPORE Project evaluating the role of physiologic imaging in the<br />
determination of malignant progression of low-grade glioma.<br />
http://cancer.ucsf.edu/people/profiles/chang_susan.3565<br />
*<strong>UCSF</strong> authors in bold<br />
18
Presentations<br />
Validating RNAseq-signatures of vorinostat (VOR) sensitivity and<br />
resistance in patients with newly diagnosed glioblastoma (GBM)<br />
treated with VOR, temozolomide and radiation therapy in Alliance<br />
N0874/ABTC-0902.<br />
Authors*: S. Keith Anderson, C. Ryan Miller, Jann Nagina Sarkaria, Kurt A. Jaeckle, Jan C. Buckner,<br />
Keith L. Ligon, Karla V. Ballman, Dennis Frederic Moore, David Schiff, Manmeet Singh Ahluwalia,<br />
Eudocia Quant Lee, Laura E. Horvath, Elizabeth Robins Gerstner, Glenn Jay Lesser, Michael Prados,<br />
Stuart A. Grossman, Caterina Giannini, Patrick Y. Wen, Evanthia Galanis<br />
Abstract #: 2029<br />
Presentation Date/Time: Saturday, June 4: 1:00 - 4:30 PM<br />
Location: Hall A, Poster Board #218<br />
Session: Central Nervous System Tumors<br />
Citation: J Clin Oncol 34, 2016 (suppl; abstr 2029)<br />
Prados Research Interests: Dr. Prados is a world-recognized Neuro-oncology expert. He led the Adult<br />
Brain Tumor Consortium for over 15 years and founded the Pacific Pediatric Neuro-Oncology Consortium<br />
(PNOC), a multi-institutional consortium of now 15 major academic centers across the United States.<br />
Currently Dr. Prados is Professor Emeritus at <strong>UCSF</strong> devoting his efforts towards pediatric Neuro-Oncology<br />
clinical and translational research. He is the co-Project Leader of a pediatric brain tumor SPORE project<br />
at <strong>UCSF</strong> and is co-Project Leader of the PNOC. His major interests are early phase clinical trials research<br />
and the translational studies that precede and inform those trials in both adults and children. He is part of<br />
the Editorial board of Neuro-Oncology, Journal of Neuro-Oncology and Journal of Clinical Oncology, and<br />
a member of the NCI/CTEP Brain Malignancies Steering Committee. In 2014 he was awarded the Victor<br />
Levin Award for lifetime clinical research excellence from the Society of Neuro-Oncology.<br />
http://cancer.ucsf.edu/people/profiles/prados_michael.3603<br />
__________________________________________________________________________<br />
Encouraging survival with Toca 511 and Toca FC compared to external<br />
lomustine control.<br />
Authors*: Timothy Francis Cloughesy, Manish K. Aghi, Clark Chen, J. Bradley Elder, Santosh Kesari,<br />
Steven N. Kalkanis, George Kaptain, Joseph C. Landolfi, Tom Mikkelsen, Jana Portnow, Joan M. Robbins,<br />
Derek Ostertag, Asha Das, Alice Chu, Michael A. Vogelbaum<br />
Abstract #: 2030<br />
Presentation Date/Time: Saturday, June 4: 1:00 - 4:30 PM<br />
Location: Hall A, Poster Board #219<br />
Poster Session: Central Nervous System Tumors<br />
Citation: J Clin Oncol 34, 2016 (suppl; abstr 2030)<br />
*<strong>UCSF</strong> authors in bold<br />
19
Presentations<br />
Precision Medicine in recurrent glioblastoma: A feasibility trial<br />
conducted by the Ivy Foundation Early Phase Clinical Trials Consortium.<br />
Authors*: Michael Prados, John G. Kuhn, Howard Colman, Timothy Francis Cloughesy, Susan Marina Chang,<br />
Nicholas A. Butowski, John Frederick De Groot, Patrick Y. Wen, Keith L. Ligon, Ingo K. Mellinghoff,<br />
Andrew S. Chi, Joanna J Phillips, Annette M Molinaro, Rebecca Halperin, Nhan Tran, Michael E. Berens,<br />
John D. Carpten, David W. Craig, Sara A. Byron<br />
Abstract #: 2031<br />
Presentation Date/Time: Saturday, June 4: 1:00 - 4:30 PM<br />
Location: Hall A, Poster Board #220<br />
Poster Session: Central Nervous System Tumors<br />
Citation: J Clin Oncol 34, 2016 (suppl; abstr 2031)<br />
Prados Research Interests: Dr. Prados is a world-recognized Neuro-oncology expert. He led the Adult<br />
Brain Tumor Consortium for over 15 years and founded the Pacific Pediatric Neuro-Oncology Consortium<br />
(PNOC), a multi-institutional consortium of now 15 major academic centers across the United States.<br />
Currently Dr. Prados is Professor Emeritus at <strong>UCSF</strong> devoting his efforts towards pediatric Neuro-Oncology<br />
clinical and translational research. He is the co-Project Leader of a pediatric brain tumor SPORE project<br />
at <strong>UCSF</strong> and is co-Project Leader of the PNOC. His major interests are early phase clinical trials research<br />
and the translational studies that precede and inform those trials in both adults and children. He is part of<br />
the Editorial board of Neuro-Oncology, Journal of Neuro-Oncology and Journal of Clinical Oncology, and<br />
a member of the NCI/CTEP Brain Malignancies Steering Committee. In 2014 he was awarded the Victor<br />
Levin Award for lifetime clinical research excellence from the Society of Neuro-Oncology.<br />
http://cancer.ucsf.edu/people/profiles/prados_michael.3603<br />
*<strong>UCSF</strong> authors in bold<br />
20
Presentations<br />
Phase I/II study of VAL-083 in patients with recurrent glioblastoma.<br />
Authors*: Kent C. Shih, Manish R. Patel, Nicholas A. Butowski, Gerald Steven Falchook, Sani Haider Kizilbash,<br />
Jeffrey A. Bacha, Dennis Brown, Anne Steino, Richard Stephen Schwartz, Sarath Kanekal, Lorena Lopez,<br />
Howard A. Burris<br />
Abstract #: 2063<br />
Presentation Date/Time: Saturday, June 4: 1:00 - 4:30 PM<br />
Location: Hall A, Poster Board #250<br />
Session: Central Nervous System Tumors<br />
Citation: J Clin Oncol 34, 2016 (suppl; abstr 2063)<br />
Butowski Research Interests: My research includes translational research and a wide range of clinical trials,<br />
including those with convection-enhanced delivery (CED) with real-time MRI imaging, targeted agents,<br />
immunotherapy, and combination strategies. I am the Director of Translational Research in Neuro-Oncology<br />
and lead the translational effort on behalf of the <strong>UCSF</strong> Brain Tumor Research Center and Preclinical Core.<br />
My work has helped to create the groundwork for allied research in neuro-oncology and an extensive<br />
<strong>UCSF</strong> clinical trial portfolio for patients with primary brain and spine tumors, including an assortment of<br />
immunotherapy trials and surgically based trials. I have also designed investigator initiated trials, including a<br />
clinical trial employing intratumoral delivery with real-time MRI imaging as well as those with a range of novel<br />
targets, molecular markers and imaging biomarkers. I have also authored a number of peer-reviewed papers<br />
and presented work at national and international meetings.<br />
https://www.ucsfhealth.org/nicholas.butowski<br />
*<strong>UCSF</strong> authors in bold<br />
21
Presentations<br />
Pilot study of T cells redirected to EGFRvIII with a chimeric antigen<br />
receptor in patients with EGFRvIII+ glioblastoma.<br />
Authors*: Donald M. O’Rourke, MacLean Nasrallah, Jennifer J. Morrissette, Jan J. Melenhorst,<br />
Simon F. Lacey, Keith Mansfield, Maria Martinez-Lage, Arati Suvas Desai, Steven Brem, Eileen Maloney,<br />
Suyash Mohan, Sumei Wang, Gaurav Verma, Jean-Marc Navenot, Angela Shen, Zhaohui Zheng,<br />
Bruce Levine, Hideho Okada, Carl H. June, Marcela Valderrama Maus<br />
Abstract #: 2067<br />
Presentation Date/Time: Saturday, June 4: 1:00 - 4:30 PM<br />
Location: Hall A, Poster Board # 254<br />
Session: Central Nervous System Tumors<br />
Citation: J Clin Oncol 34, 2016 (suppl; abstr 2067)<br />
Okada Research Interests: As a translational physician scientist, Dr. Okada and his lab are focused on<br />
development of novel immunotherapeutic strategies for brain tumor patients. For example, Dr. Okada<br />
conducted one of the first immune gene therapy trials in patients with malignant glioma. His lab was also the<br />
first to identify and fully characterized cytotoxic T-lymphocyte epitopes for gliomas. Dr. Okada has also<br />
delineated the role of an integrin receptor very late activation antigen-4 and chemokine CXCL10 in efficient<br />
trafficking of T-cells to brain tumor sites. Dr. Okada has integrated these findings to develop a number of<br />
vaccine trials in both adult and pediatric glioma patients. More recently, his group developed a novel chimeric<br />
antigen receptor targeting glioblastoma cells, and are currently conducting a pilot trial.<br />
http://neurosurgery.ucsf.edu/index.php/about_us_faculty_okada.html<br />
*<strong>UCSF</strong> authors in bold<br />
22
Presentations<br />
Clinical and genomic characterization of metastatic small cell/<br />
neuroendocrine prostate cancer (SCNC) and intermediate atypical<br />
prostate cancer (IAC): Results from the SU2C/PCF/AARCWest Coast<br />
Prostate Cancer Dream Team (WCDT).<br />
Authors*: Eric Jay Small, Rahul Raj Aggarwal, Jiaoti Huang, Artem Sokolov, Li Zhang, Joshi J. Alumkal,<br />
Jack Youngren, Charles J. Ryan, Adam Foye, Robert Evan Reiter, Christopher P. Evans, Martin Gleave,<br />
Owen Witte, Josh Stuart, Theodore C. Goldstein, George V. Thomas, Lawrence D. True, Himisha Beltran,<br />
Mark A. Rubin, Tomasz M. Beer<br />
Abstract #: 5019<br />
Presentation Date/Time: Saturday, June 4: 1:00 - 4:30 PM<br />
Location: Hall A, Poster Board #276<br />
Poster Session: Genitourinary (Prostate) Cancer<br />
Citation: J Clin Oncol 34, 2016 (suppl; abstr 5019)<br />
Small Research Interests: The Stand Up To Cancer Dream Team led by Dr. Eric Small is exploring the<br />
idea that resistance to hormonal therapy occurs as a result of the prostate cancer cells using common<br />
cellular responses - what the Dream Team calls “adaptive pathways” - to escape the current prostate<br />
cancer therapies. They believe that, by identifying these pathways and inhibiting them, they will be able to<br />
overcome treatment resistance and profoundly improve the care of men affected by this fatal disease. This<br />
team is a six institution consortium to include UC Los Angeles, UC Davis, UC Santa Cruz, University of<br />
British Columbia, Oregon Health and Sciences University, with <strong>UCSF</strong> as the lead administrative site.<br />
http://cancer.ucsf.edu/people/profiles/small_eric.3671<br />
__________________________________________________________________________<br />
Characteristics and anticancer interventions (ACIs) in African American<br />
(AA) and Caucasian (CAU) patients (pts) treated with sipuleucel-T<br />
(sip-T): Real-world experience from the PROCEED registry.<br />
Authors*: Andrew J. Armstrong, Celestia S. Higano, Matthew R. Cooperberg, Chiledum Ahaghotu,<br />
Ronald F. Tutrone, Laurence H. Belkoff, Carl A. Olsson, Sanjay Goel, Robert Claude Tyler, Nancy N. Chang,<br />
Jennifer Susan LIll, A. Oliver Sartor<br />
Abstract #: 5025<br />
Presentation Date/Time: Saturday, June 4: 1:00 - 4:30 PM<br />
Location: Hall A, Poster Board # 282<br />
Session: Genitourinary (Prostate) Cancer<br />
Citation: J Clin Oncol 34, 2016 (suppl; abstr 5025)<br />
*<strong>UCSF</strong> authors in bold<br />
23
Presentations<br />
Persistence of AR signaling in small cell neuroendocrine prostate<br />
cancer (SCNC) and intermediate atypical carcinoma (IAC): Results from<br />
the SU2C/PCF/AACR West Coast Prostate Cancer Dream Team (WCDT).<br />
Authors*: Rahul Raj Aggarwal, Jack Youngren, Artem Sokolov, Jiaoti Huang, George V. Thomas,<br />
Lawrence D. True, Adam Foye, Joshi J. Alumkal, Charles J. Ryan, Tomasz M. Beer, Christopher P. Evans,<br />
Martin Gleave, Matthew Rettig, Joshua M. Stuart, Primo Lara, Theodore C. Goldstein, Li Zhang,<br />
Robert Evan Reiter, Kim N. Chi, Eric Jay Small<br />
Abstract #: 5045<br />
Presentation Date/Time: Saturday, June 4: 1:00 - 4:30 PM<br />
Location: Hall A, Poster Board #302<br />
Poster Session: Genitourinary (Prostate) Cancer<br />
Citation: J Clin Oncol 34, 2016 (suppl; abstr 5045)<br />
Small Research Interests: The Stand Up To Cancer Dream Team led by Dr. Eric Small is exploring the<br />
idea that resistance to hormonal therapy occurs as a result of the prostate cancer cells using common<br />
cellular responses - what the Dream Team calls “adaptive pathways” - to escape the current prostate<br />
cancer therapies. They believe that, by identifying these pathways and inhibiting them, they will be able to<br />
overcome treatment resistance and profoundly improve the care of men affected by this fatal disease. This<br />
team is a six institution consortium to include UC Los Angeles, UC Davis, UC Santa Cruz, University of<br />
British Columbia, Oregon Health and Sciences University, with <strong>UCSF</strong> as the lead administrative site.<br />
http://cancer.ucsf.edu/people/profiles/small_eric.3671<br />
*<strong>UCSF</strong> authors in bold<br />
24
Presentations<br />
IMAAGEN trial safety and efficacy update: Effect of abiraterone<br />
acetate and low-dose prednisone on prostate-specific antigen and<br />
radiographic disease progression in patients with nonmetastatic<br />
castration-resistant prostate cancer.<br />
Authors*: Charles J. Ryan, E. David Crawford, Neal D. Shore, Willie Underwood, Mary-Ellen Taplin,<br />
Anil Londhe, Peter St. John Francis, Jennifer Phillips, Tracy McGowan, Philip W. Kantoff<br />
Abstract #: 5061<br />
Presentation Date/Time: Saturday, June 4: 1:00 - 4:30 PM<br />
Location: Hall A, Poster Board # 318<br />
Poster Session: Genitourinary (Prostate) Cancer<br />
Citation: J Clin Oncol 34, 2016 (suppl; abstr 5061)<br />
Ryan Research Interests: Dr. Ryan’s clinical practice focuses predominantly on advanced prostate cancer<br />
as well as germ cell (testicular) tumors and other malignancies of the genitourinary tract. His clinical<br />
and research work centers on the design and conduct of clinical trials of novel therapies for advanced<br />
prostate cancer, specifically secondary hormonal therapies targeting adrenal androgen signaling, androgen<br />
receptor targeted therapy and chemotherapy. In addition to clinical trials, Dr. Ryan collaborates with many<br />
laboratories researching the role of the androgen receptor and other signaling mechanisms in prostate<br />
cancer patients.<br />
http://cancer.ucsf.edu/people/profiles/ryan_charles.3649<br />
*<strong>UCSF</strong> authors in bold<br />
25
Presentations<br />
Updated results: A phase I/IIa randomized trial of radium-223 +<br />
docetaxel versus docetaxel in patients with castration-resistant<br />
prostate cancer and bone metastases.<br />
Authors*: Michael J. Morris, Yohann Loriot, Christopher Sweeney, Karim Fizazi, Charles J. Ryan,<br />
Daniel H. Shevrin, Emmanuel S. Antonarakis, John Reeves, Kumari Chandrawansa, Martin Kornacker,<br />
Celestia S. Higano<br />
Abstract #: 5075<br />
Presentation Date/Time: Saturday, June 4: 1:00 - 4:30 PM<br />
Location: Hall A, Poster Board #332<br />
Session: Genitourinary (Prostate) Cancer<br />
Citation: J Clin Oncol 34, 2016 (suppl; abstr 5075)<br />
Ryan Research Interests: Dr. Ryan’s clinical practice focuses predominantly on advanced prostate cancer<br />
as well as germ cell (testicular) tumors and other malignancies of the genitourinary tract. His clinical<br />
and research work centers on the design and conduct of clinical trials of novel therapies for advanced<br />
prostate cancer, specifically secondary hormonal therapies targeting adrenal androgen signaling, androgen<br />
receptor targeted therapy and chemotherapy. In addition to clinical trials, Dr. Ryan collaborates with many<br />
laboratories researching the role of the androgen receptor and other signaling mechanisms in prostate<br />
cancer patients.<br />
http://cancer.ucsf.edu/people/profiles/ryan_charles.3649<br />
*<strong>UCSF</strong> authors in bold<br />
26
Presentations<br />
Immunogenicity of sipuleucel-T (Sip-T) in abiraterone (Abi)/<br />
enzalutamide (Enz) sensitive and resistant metastatic castrateresistant<br />
prostate cancer (mCRPC).<br />
Authors*: Eric Jay Small, Lawrence Fong, David I. Quinn, Charles G. Drake, Dwayne Campogan, Tuyen Vu,<br />
Nadeem Anwar Sheikh, Nancy N. Chang, Daniel Peter Petrylak<br />
Abstract #: 5077<br />
Presentation Date/Time: Saturday, June 4: 1:00 - 4:30 PM<br />
Location: Hall A, Poster Board # 334<br />
Poster Session: Genitourinary (Prostate) Cancer<br />
Citation: J Clin Oncol 34, 2016 (suppl; abstr 5077)<br />
Small Research Interests: The Stand Up To Cancer Dream Team led by Dr. Eric Small is exploring the<br />
idea that resistance to hormonal therapy occurs as a result of the prostate cancer cells using common<br />
cellular responses - what the Dream Team calls “adaptive pathways” - to escape the current prostate<br />
cancer therapies. They believe that, by identifying these pathways and inhibiting them, they will be able to<br />
overcome treatment resistance and profoundly improve the care of men affected by this fatal disease. This<br />
team is a six institution consortium to include UC Los Angeles, UC Davis, UC Santa Cruz, University of<br />
British Columbia, Oregon Health and Sciences University, with <strong>UCSF</strong> as the lead administrative site.<br />
http://cancer.ucsf.edu/people/profiles/small_eric.3671<br />
__________________________________________________________________________<br />
Preliminary results for the advanced salivary gland carcinoma cohort<br />
of the phase 1b KEYNOTE-028 study of pembrolizumab.<br />
Authors*: Roger B. Cohen, Jean-Pierre Delord, Toshihiko Doi, Sarina Anne Piha-Paul, Stephen V. Liu, Jill Gilbert,<br />
Alain Patrick Algazi, Sara Cresta, Ruey-Long Hong, Christophe Le Tourneau, Daphne Day, Andrea Varga,<br />
Elena Elez, John M. Wallmark, Sanatan Saraf, Anne Morosky, Jonathan D. Cheng, Bhumsuk Keam<br />
Abstract #: 6017<br />
Presentation Date/Time: Saturday, June 4: 1:00 - 4:30 PM<br />
Location: Hall A, Poster Board #339<br />
Session: Head and Neck Cancer<br />
Citation: J Clin Oncol 34, 2016 (suppl; abstr 6017)<br />
*<strong>UCSF</strong> authors in bold<br />
27
Presentations<br />
Predicting overall survival (OS) and progression-free (PFS) for oropharynx<br />
cancers (OPC) in NRG Oncology RTOG0129/0522 with nomograms.<br />
Authors*: Carole Fakhry, Qiang Zhang, Maura L. Gillison, Phuc Duy Nguyen, David Ira Rosenthal,<br />
Randal S. Weber, Louise Lambert, Andy Trotti, William Barrett, Wade Thorstad, Sue S Yom, Stuart J. Wong,<br />
John A. Ridge, Shyam S. Rao, James A. Bonner, Eric Vigneault, David Raben, Jonathan Harris, Quynh-Thu Le<br />
Abstract #: 6024<br />
Presentation Date/Time: Saturday, June 4: 1:00 - 4:30 PM<br />
Location: Hall A, Poster Board #346<br />
Session: Head and Neck Cancer<br />
Citation: J Clin Oncol 34, 2016 (suppl; abstr 6024)<br />
Yom Research Interests: Dr. Yom is an expert in head and neck, thoracic, and skin cancers and conducts<br />
research in quality of life and supportive care, patient-oriented decision making, and combinations of novel<br />
targeted therapies and immunotherapy with radiation therapy. She is the principal investigator of HN002,<br />
a national trial in de-intensified therapy for HPV+ oropharyngeal cancer. She serves on several national<br />
panels developing guidelines for appropriate care of head and neck cancers.<br />
http://profiles.ucsf.edu/sue.yom<br />
__________________________________________________________________________<br />
The prognostic role of gender, race and human papillomavirus (HPV)<br />
in oropharyngeal squamous cell cancer (OPC) and non-oropharyngeal<br />
head and neck squamous cell cancer (non-OP HNC).<br />
Authors*: Carole Fakhry, William H. Westra, Steven Wang, Annemieke VanZante, Yuehan Zhang,<br />
Eleni Marie Rettig, Alicia Wentz, Young Jun Kim, Justin A. Bishop, Wayne Koch, Christine Gail Gourin,<br />
Jeremy Richmon, David Eisele, Gypsyamber D’Souza<br />
Abstract #: 6068<br />
Presentation Date/Time: Saturday, June 4: 1:00 - 4:30 PM<br />
Location: Hall A, Poster Board #390<br />
Session: Head and Neck Cancer<br />
Citation: J Clin Oncol 34, 2016 (suppl; abstr 6068)<br />
*<strong>UCSF</strong> authors in bold<br />
28
Presentations<br />
Pembrolizumab for advanced papillary or follicular thyroid cancer:<br />
preliminary results from the phase 1b KEYNOTE-028 study.<br />
Authors*: Janice M. Mehnert, Andrea Varga, Marcia Brose, Rahul Raj Aggarwal, Chia-Chi Lin, Amy Prawira,<br />
Filippo de Braud, Kenji Tamura, Toshihiko Doi, Sarina Anne Piha-Paul, Jill Gilbert, Sanatan Saraf,<br />
Pradeep Thanigaimani, Jonathan D. Cheng, Bhumsuk Keam<br />
Abstract #: 6091<br />
Presentation Date/Time: Saturday, June 4: 1:00 - 4:30 PM<br />
Location: Hall A, Poster Board #413<br />
Session: Head and Neck Cancer<br />
Citation: J Clin Oncol 34, 2016 (suppl; abstr 6091)<br />
__________________________________________________________________________<br />
Impact of industry funding and collaboration in oncology RCTs.<br />
Authors*: Anne Linker, Nitin Roper, Annie Yang, Deborah Korenstein<br />
Abstract #: 6592<br />
Presentation Date/Time: Saturday, June 4: 1:00 - 4:30 PM<br />
Location: Hall A, Poster Board #78<br />
Poster Session: Health Services Research and Quality of Care<br />
Citation: J Clin Oncol 34, 2016 (suppl; abstr 6592)<br />
*<strong>UCSF</strong> authors in bold<br />
29
Presentations<br />
KEYNOTE-006 study of pembrolizumab (pembro) versus ipilimumab<br />
(ipi) for advanced melanoma: Efficacy by PD-L1 expression and line<br />
of therapy.<br />
Authors*: Adil Daud, Christian U. Blank, Caroline Robert, Igor Puzanov, Erika Richtig, Kim Allyson Margolin,<br />
Steven O’Day, Marta Nyakas, Jose Lutzky, Ahmad A. Tarhini, Elaine McWhirter, Christian Caglevic,<br />
Peter Mohr, Michael Millward, Marcus O. Butler, Honghong Zhou, Kenneth Emancipator, Scot Ebbinghaus,<br />
Nageatte Ibrahim, Georgina V. Long<br />
Abstract #: 9513<br />
Presentation Date/Time: Saturday, June 4: 1:00 - 4:30 PM<br />
Location: Hall A, Poster Board #118<br />
Poster Session: Melanoma/Skin Cancers<br />
Citation: J Clin Oncol 34, 2016 (suppl; abstr 9513)<br />
Daud Research Interests: Our group at <strong>UCSF</strong> is focused on developing new immunotherapy agents and<br />
specifically understanding the biology of the immune response to PD-1 in melanoma. We developed IL-<br />
12 gene therapy in melanoma and carried out the first in human clinical trial in 2005-2007. Based on this<br />
work, IL-12 electroporation is being explored in many cancers as an immune agent and as a combination<br />
treatment with PD-1 and other checkpoint inhibitors in melanoma. I have been involved in the development<br />
of anti-PD-1 antibodies for melanoma. With my colleagues Michael Rosenblum and Max Krummel at<br />
<strong>UCSF</strong>, we have developed a novel assay that profiles the intra-tumoral microenvironment in depth and can<br />
predict non-response to PD-1. We are currently exploring novel strategies for PD-1 non-responsive subsets<br />
of melanoma (and potentially other cancers).<br />
http://cancer.ucsf.edu/people/profiles/daud_adil.3622<br />
__________________________________________________________________________<br />
Anti-PD-1 therapy in patients with advanced melanoma and preexisting<br />
autoimmune disorders (AD) or major toxicity with ipilimumab (IPI).<br />
Authors*: Alexander M. Menzies, Douglas Buckner Johnson, Sangeetha Ramanujam, Victoria Atkinson,<br />
Annie N.M. Wong, John J Park, Jennifer Leigh McQuade, Alexander Noor Shoushtari, Katy K. Tsai,<br />
Zeynep Eroglu, Oliver Klein, Jessica Cecile Hassel, Jeffrey Alan Sosman, Alex Guminski, Ryan J. Sullivan,<br />
Antoni Ribas, Matteo S. Carlino, Michael A. Davies, Shahneen Kaur Sandhu, Georgina V. Long<br />
Abstract #: 9515<br />
Presentation Date/Time: Saturday, June 4: 1:00 - 4:30 PM<br />
Location: Hall A, Poster Board #120<br />
Session: Melanoma/Skin Cancers<br />
Citation: J Clin Oncol 34, 2016 (suppl; abstr 9515)<br />
*<strong>UCSF</strong> authors in bold<br />
30
Presentations<br />
Novel T cell exhaustion marker to predict monotherapy PD-1 compared<br />
to combination CTLA-4 and PD-1 response in melanoma.<br />
Authors*: Kimberly Loo, Katy K. Tsai, Mariela Pauli, Priscila Munoz Sandoval, Michael Alvarado,<br />
Alain Patrick Algazi, Michael Rosenblum, Adil Daud<br />
Abstract #: 9520<br />
Presentation Date/Time: Saturday, June 4: 1:00 - 4:30 PM<br />
Location: Hall A, Poster Board #125<br />
Poster Session: Melanoma/Skin Cancers<br />
Citation: J Clin Oncol 34, 2016 (suppl; abstr 9520)<br />
Daud Research Interests: Our group at <strong>UCSF</strong> is focused on developing new immunotherapy agents and<br />
specifically understanding the biology of the immune response to PD-1 in melanoma. We developed IL-<br />
12 gene therapy in melanoma and carried out the first in human clinical trial in 2005-2007. Based on this<br />
work, IL-12 electroporation is being explored in many cancers as an immune agent and as a combination<br />
treatment with PD-1 and other checkpoint inhibitors in melanoma. I have been involved in the development<br />
of anti-PD-1 antibodies for melanoma. With my colleagues Michael Rosenblum and Max Krummel at<br />
<strong>UCSF</strong>, we have developed a novel assay that profiles the intra-tumoral microenvironment in depth and can<br />
predict non-response to PD-1. We are currently exploring novel strategies for PD-1 non-responsive subsets<br />
of melanoma (and potentially other cancers).<br />
http://cancer.ucsf.edu/people/profiles/daud_adil.3622<br />
*<strong>UCSF</strong> authors in bold<br />
31
Presentations<br />
Preliminary results from phase II study of combination treatment with<br />
HF10, a replication-competent HSV-1 oncolytic virus, and ipilimumab in<br />
patients with stage IIIb, IIIc, or IV unresectable or metastatic melanoma.<br />
Authors*: Robert Hans Ingemar Andtbacka, Merrick I. Ross, Sanjiv S. Agarwala, Matthew H. Taylor,<br />
John T. Vetto, Rogerio Izar Neves, Adil Daud, Hung T. Khong, Richard S. Ungerleider, Aislyn Boran,<br />
Maki Tanaka, Kenneth F. Grossmann<br />
Abstract #: 9543<br />
Presentation Date/Time: Saturday, June 4: 1:00 - 4:30 PM<br />
Location: Hall A, Poster Board #148<br />
Session: Melanoma/Skin Cancers<br />
Citation: J Clin Oncol 34, 2016 (suppl; abstr 9543)<br />
Daud Research Interests: Our group at <strong>UCSF</strong> is focused on developing new immunotherapy agents and<br />
specifically understanding the biology of the immune response to PD-1 in melanoma. We developed IL-<br />
12 gene therapy in melanoma and carried out the first in human clinical trial in 2005-2007. Based on this<br />
work, IL-12 electroporation is being explored in many cancers as an immune agent and as a combination<br />
treatment with PD-1 and other checkpoint inhibitors in melanoma. I have been involved in the development<br />
of anti-PD-1 antibodies for melanoma. With my colleagues Michael Rosenblum and Max Krummel at<br />
<strong>UCSF</strong>, we have developed a novel assay that profiles the intra-tumoral microenvironment in depth and can<br />
predict non-response to PD-1. We are currently exploring novel strategies for PD-1 non-responsive subsets<br />
of melanoma (and potentially other cancers).<br />
http://cancer.ucsf.edu/people/profiles/daud_adil.3622<br />
*<strong>UCSF</strong> authors in bold<br />
32
Presentations<br />
Correlation between metastatic site and response to anti-<br />
Programmed Death-1 (PD-1) agents in melanoma.<br />
Authors*: Simone M. Goldinger, Katy K. Tsai, Paul Tumeh, Omid Hamid, Adi Nosrati, Kimberly Loo,<br />
Barbara Grimes, Alain Patrick Algazi, Mitchell P. Levesque, Reinhard Dummer, Adil Daud<br />
Abstract #: 9549<br />
Presentation Date/Time: Saturday, June 4: 1:00 - 4:30 PM<br />
Location: Hall A, Poster Board #154<br />
Poster Session: Melanoma/Skin Cancers<br />
Citation: J Clin Oncol 34, 2016 (suppl; abstr 9549)<br />
Daud Research Interests: Our group at <strong>UCSF</strong> is focused on developing new immunotherapy agents and<br />
specifically understanding the biology of the immune response to PD-1 in melanoma. We developed IL-<br />
12 gene therapy in melanoma and carried out the first in human clinical trial in 2005-2007. Based on this<br />
work, IL-12 electroporation is being explored in many cancers as an immune agent and as a combination<br />
treatment with PD-1 and other checkpoint inhibitors in melanoma. I have been involved in the development<br />
of anti-PD-1 antibodies for melanoma. With my colleagues Michael Rosenblum and Max Krummel at<br />
<strong>UCSF</strong>, we have developed a novel assay that profiles the intra-tumoral microenvironment in depth and can<br />
predict non-response to PD-1. We are currently exploring novel strategies for PD-1 non-responsive subsets<br />
of melanoma (and potentially other cancers).<br />
http://cancer.ucsf.edu/people/profiles/daud_adil.3622<br />
*<strong>UCSF</strong> authors in bold<br />
33
Presentations<br />
A randomized, phase 3, open-label study of nivolumab versus<br />
temozolomide (TMZ) in combination with radiotherapy (RT) in<br />
adult patients (pts) with newly diagnosed, O-6-methylguanine DNA<br />
methyltransferase (MGMT)-unmethylated glioblastoma (GBM):<br />
CheckMate-498.<br />
Authors*: John H. Sampson, Antonio Marcilio Padula Omuro, Matthias Preusser, Michael Lim,<br />
Nicholas A. Butowski, Timothy Francis Cloughesy, Lewis C. Strauss, Robert Raymond Latek, Prashni<br />
Paliwal, Michael Weller, David A. Reardon<br />
Abstract #: TPS2079<br />
Presentation Date/Time: Saturday, June 4: 1:00 - 4:30 PM<br />
Location: Hall A, Poster Board #265b<br />
Session: Central Nervous System Tumors<br />
Citation: J Clin Oncol 34, 2016 (suppl; abstr TPS2079)<br />
Butowski Research Interests: My research includes translational research and a wide range of clinical trials,<br />
including those with convection-enhanced delivery (CED) with real-time MRI imaging, targeted agents,<br />
immunotherapy, and combination strategies. I am the Director of Translational Research in Neuro-Oncology<br />
and lead the translational effort on behalf of the <strong>UCSF</strong> Brain Tumor Research Center and Preclinical Core.<br />
My work has helped to create the groundwork for allied research in neuro-oncology and an extensive<br />
<strong>UCSF</strong> clinical trial portfolio for patients with primary brain and spine tumors, including an assortment of<br />
immunotherapy trials and surgically based trials. I have also designed investigator initiated trials, including a<br />
clinical trial employing intratumoral delivery with real-time MRI imaging as well as those with a range of novel<br />
targets, molecular markers and imaging biomarkers. I have also authored a number of peer-reviewed papers<br />
and presented work at national and international meetings.<br />
https://www.ucsfhealth.org/nicholas.butowski<br />
__________________________________________________________________________<br />
Phase 2 study to evaluate the clinical efficacy and safety of<br />
MEDI4736 (durvalumab) in patients with glioblastoma (GBM).<br />
Authors*: David A. Reardon, Thomas Joseph Kaley, Jorg Dietrich, Michael Lim, Gavin P Dunn,<br />
Hui Kong Gan, Timothy Francis Cloughesy, Jennifer Leigh Clarke, Andrew J. Park, Mary J. Macri,<br />
Aileen Ryan, Toni Ricciardi, Vijay Reddy, Ralph Rudolph Venhaus<br />
Abstract #: TPS2080<br />
Presentation Date/Time: Saturday, June 4: 1:00 - 4:30 PM<br />
Location: Hall A, Poster Board #266a<br />
Session: Central Nervous System Tumors<br />
Citation: J Clin Oncol 34, 2016 (suppl; abstr TPS2080)<br />
*<strong>UCSF</strong> authors in bold<br />
34
Presentations<br />
ATLAS: A randomized, double-blind, placebo-controlled, phase 3<br />
trial of apalutamide (ARN-509) in patients with high-risk localized or<br />
locally advanced prostate cancer receiving primary radiation therapy.<br />
Authors*: Howard M. Sandler, Michael R. McKenzie, Bertrand F. Tombal, Edwina Baskin-Bey,<br />
Stephen J. Freedland, Mack Roach, Anders Widmark, Alberto Bossi, Adam Dicker, Thomas Wiegel,<br />
Neal D. Shore, Matthew Raymond Smith, Margaret K. Yu, Thian Kheoh, Shibu Thomas, David P. Dearnaley<br />
Abstract #: TPS5087<br />
Presentation Date/Time: Saturday, June 4: 1:00 - 4:30 PM<br />
Location: Hall A, Poster Board #437a<br />
Session: Genitourinary (Prostate) Cancer<br />
Citation: J Clin Oncol 34, 2016 (suppl; abstr TPS5087)<br />
__________________________________________________________________________<br />
Intense exercise for survival among men with metastatic castrateresistant<br />
prostate cancer (INTERVAL – MCRPC): A Movember funded<br />
multicenter, randomized, controlled phase III study.<br />
Authors*: Fred Saad, Stacey A. Kenfield, June M. Chan, Nicolas H. Hart, Kerry S. Courneya, James Catto,<br />
Stephen P. Finn, Rosemary Greenwood, Daniel C Hughes, Lorelei A. Mucci, Stephen R Plymate,<br />
Michael N. Pollak, Stephan F.E. Praet, Aaron P. Russell, Emer M. Guinan, Erin Van Blarigan, Orla Casey,<br />
Mark Buzza, Charles J. Ryan, Robert Usher Newton<br />
Abstract #: TPS5092<br />
Presentation Date/Time: Saturday, June 4: 1:00 - 4:30 PM<br />
Location: Hall A, Poster Board #439b<br />
Poster Session: Genitourinary (Prostate) Cancer<br />
Citation: J Clin Oncol 34, 2016 (suppl; abstr TPS5092)<br />
Ryan Research Interests: Dr. Ryan’s clinical practice focuses predominantly on advanced prostate cancer<br />
as well as germ cell (testicular) tumors and other malignancies of the genitourinary tract. His clinical<br />
and research work centers on the design and conduct of clinical trials of novel therapies for advanced<br />
prostate cancer, specifically secondary hormonal therapies targeting adrenal androgen signaling, androgen<br />
receptor targeted therapy and chemotherapy. In addition to clinical trials, Dr. Ryan collaborates with many<br />
laboratories researching the role of the androgen receptor and other signaling mechanisms in prostate<br />
cancer patients.<br />
http://cancer.ucsf.edu/people/profiles/ryan_charles.3649<br />
*<strong>UCSF</strong> authors in bold<br />
35
Presentations<br />
Clinical activity of anti-programmed death-1 (PD-1) agents in acral and<br />
mucosal melanoma.<br />
Authors*: Rodrigo Ramella Munhoz, Alexander Noor Shoushtari, Deborah Kuk, Patrick Alexander Ott,<br />
Douglas Buckner Johnson, Katy K. Tsai, Suthee Rapisuwon, Zeynep Eroglu, Ryan J. Sullivan,<br />
Jason John Luke, Tara C. Gangadhar, April K. Salama, Varina Clark, Clare Burias, Igor Puzanov,<br />
Michael B. Atkins, Alain Patrick Algazi, Antoni Ribas, Jedd D. Wolchok, Michael Andrew Postow<br />
Abstract #: 9516<br />
Presentation Date/Time: Saturday, June 4: 1:00 - 4:30 PM<br />
Location: Hall A, Poster Board #121<br />
Poster Session: Melanoma/Skin Cancers<br />
Citation: J Clin Oncol 34, 2016 (suppl; abstr 9516)<br />
__________________________________________________________________________<br />
Randomized phase II/III trial of active immunotherapy with OPT-822/<br />
OPT-821 in patients with metastatic breast cancer.<br />
Authors*: Chiun-Sheng Huang, Alice L Yu, Ling-Ming Tseng, Louis W. C. Chow, Ming-Feng Hou,<br />
Sara A. Hurvitz, Richard B. Schwab, Chi-Huey Wong, James L. Murray, Hsien-Kun Chang, Hong-Tai Chang,<br />
Shin-Cheh Chen, Sung-Bae Kim, Youe-Kong Shue, Hope S. Rugo<br />
Abstract #: 1003<br />
Presentation Date/Time: Saturday, June 4: 1:15 - 4:15 PM<br />
Location: Hall D2<br />
Session: Breast Cancer - Triple-Negative/Cytotoxics/Local Therapy<br />
Citation: J Clin Oncol 34, 2016 (suppl; abstr 1003)<br />
Rugo Research Interests: Dr. Rugo, Director of Breast Oncology & Clinical Trials Education, is PI on multiple<br />
clinical trials focusing on combining novel targeted therapeutics to improve the treatment of both early & late<br />
stage breast cancer (BC). She also works on studies to improve supportive care for early & late stage BC<br />
patients, including with <strong>UCSF</strong>’s Advanced Breast Cancer Program. Dr. Rugo has numerous collaborations with<br />
large academic medical centers & consortia in order to expand the novel therapies available to patients. She<br />
was the director of the 2016 ASCO Breast Cancer Education Committee meeting, is a member of the Alliance<br />
& is a founding member of the Breast Cancer Research Consortium where she co-leads the triple negative<br />
working group. She is on the novel agents committee for the neoadjuvant multi-center I SPY2 trial. At <strong>UCSF</strong>,<br />
Dr. Rugo runs the Breast Forum, a bimonthly educational session for breast cancer patients, families & friends<br />
from throughout the bay area.<br />
http://cancer.ucsf.edu/people/profiles/rugo_hope.3648<br />
*<strong>UCSF</strong> authors in bold<br />
36
Presentations<br />
A prospective analysis of surgery and survival in stage IV breast<br />
cancer (TBCRC 013).<br />
Authors*: Tari A. King, Jaclyn Lyman, Mithat Gonen, Sylvia Reyes, Eun-Sil Shelley Hwang, Hope S. Rugo,<br />
Minetta C. Liu, Judy Caroline Boughey, Lisa K. Jacobs, Kandace P. McGuire, Anna Maria Storniolo,<br />
Claudine Isaacs, Ingrid M. Meszoely, Catherine H. Van Poznak, Gildy Babiera, Larry Norton, Monica Morrow,<br />
Antonio C. Wolff, Eric P. Winer, Clifford A. Hudis, Translational Breast Cancer Research Consortium (TBCRC)<br />
Abstract #: 1006<br />
Presentation Date/Time: Saturday, June 4: 1:15 - 4:15 PM<br />
Location: Hall D2<br />
Session: Breast Cancer - Triple-Negative/Cytotoxics/Local Therapy<br />
Citation: J Clin Oncol 34, 2016 (suppl; abstr 1006)<br />
Rugo Research Interests: Dr. Rugo, Director of Breast Oncology & Clinical Trials Education, is PI on multiple<br />
clinical trials focusing on combining novel targeted therapeutics to improve the treatment of both early & late<br />
stage breast cancer (BC). She also works on studies to improve supportive care for early & late stage BC<br />
patients, including with <strong>UCSF</strong>’s Advanced Breast Cancer Program. Dr. Rugo has numerous collaborations with<br />
large academic medical centers & consortia in order to expand the novel therapies available to patients. She<br />
was the director of the 2016 ASCO Breast Cancer Education Committee meeting, is a member of the Alliance<br />
& is a founding member of the Breast Cancer Research Consortium where she co-leads the triple negative<br />
working group. She is on the novel agents committee for the neoadjuvant multi-center I SPY2 trial. At <strong>UCSF</strong>,<br />
Dr. Rugo runs the Breast Forum, a bimonthly educational session for breast cancer patients, families & friends<br />
from throughout the bay area.<br />
http://cancer.ucsf.edu/people/profiles/rugo_hope.3648<br />
*<strong>UCSF</strong> authors in bold<br />
37
Presentations<br />
Genes Versus T-Cells<br />
Authors*: Chloe Evelyn Atreya<br />
Abstract #:<br />
Presentation Date/Time: Saturday, June 4: 1:51-2:03 PM<br />
Location: Hall D1<br />
Poster Discussion Session: Gastrointestinal (Colorectal) Cancer<br />
Citation:<br />
Atreya Research Interests: Dr. Atreya specializes in gastrointestinal cancer, particularly colorectal cancer. Her<br />
research focuses on the interplay of tumor genetics and response to therapies for colorectal cancer, with the<br />
goal of improving patient outcomes and quality of life by personalizing treatment. Dr. Atreya is the recipient<br />
of numerous awards, including the Conquer Cancer Foundation of the American Society of Clinical Oncology<br />
Young Investigator Award and Alliance for Clinical Trials in Oncology Foundation Investigator Award. She<br />
is the recipient of a National Cancer Institute/National Institutes of Health K08 Career Development Award<br />
for Targeting of Aberrant Signaling in Patient-Derived Colorectal Cancer Models. Dr. Atreya is a member of<br />
the American Society of Clinical Oncologists, American Association of Cancer Researchers and Alliance for<br />
Clinical Trials in Oncology, Gastrointestinal Committee.<br />
http://cancer.ucsf.edu/gi/chloe-atreya<br />
__________________________________________________________________________<br />
Developing a Road Map to Guide Immunotherapy<br />
Authors*: Lawrence Fong<br />
Abstract #:<br />
Presentation Date/Time: Saturday, June 4: 2:51 - 3:03 PM<br />
Location: Hall B1<br />
Oral Abstract Session: Developmental Therapeutics - Immunotherapy<br />
Citation:<br />
Fong Research Interests: My lab focuses on how the immune system interacts with cancer as well as exploring<br />
tumor immunotherapies in mouse models and in patients. Our primary focus is in cancer immunotherapy.<br />
We investigate how immunotherapies such as immune checkpoint inhibitors and cancer vaccines can<br />
enhance anti-tumor immunity both systemically and in the tumor microenvironment. Performing neoadjuvant<br />
immunotherapy trials, we determine how specific therapies can recruit immune effectors in cancer patients.<br />
Moreover, we have studied how clinical responders may differ from clinical non-responders. We are applying<br />
unbiased approaches to studying antigen-specific responses that are modulated in these patients and are<br />
currently developing biomarkers that may be redictive of clinical efficacy.<br />
http://hemonc.ucsf.edu/fonglab/<br />
*<strong>UCSF</strong> authors in bold<br />
38
Presentations<br />
Circulating Biomarkers: Where Are We Now?<br />
Authors*: Terrence W. Friedlander<br />
Abstract #:<br />
Presentation Date/Time: Saturday, June 4: 4:45 - 4:57 Pm<br />
Location: Hall D1<br />
Poster Discussion Session: Genitourinary (Prostate) Cancer<br />
Citation:<br />
Friedlander Research Interests: I am a clinical and translational oncologist specializing in cancers of the<br />
genitourinary tract, specifically bladder and prostate cancers. My research is focused on understanding<br />
the basic biology of these malignancies and in developing novel therapeutic ways to treat disease. In<br />
recent years my works has explored the prognostic and predictive value of circulating tumor cells (CTCs)<br />
in these malignancies. In addition to work exploring CTCs as biomarkers of response and resistance, I have<br />
investigated the structural and epigenetic state of advanced prostate cancer, and this work has led to a number<br />
of grants and publications. Additionally I have a research focus in immunology, particularly in bladder cancer.<br />
As a clinical academic oncologist I serve as principal investigator or co-investigator on a number of clinical trials<br />
in advanced prostate and bladder cancer, which allows us to recruit patients for much of our biomarker work.<br />
http://cancer.ucsf.edu/people/profiles/friedlander_terence.4963<br />
__________________________________________________________________________<br />
Early Phase Clinical Trials<br />
Authors*: Nicholas A. Butowski<br />
Abstract #:<br />
Presentation Date/Time: Saturday, June 4: 4:45 - 4:57 PM<br />
Location: S102<br />
Poster Discussion Session: Central Nervous System Tumors<br />
Citation:<br />
Butowski Research Interests: My research includes translational research and a wide range of clinical trials,<br />
including those with convection-enhanced delivery (CED) with real-time MRI imaging, targeted agents,<br />
immunotherapy, and combination strategies. I am the Director of Translational Research in Neuro-Oncology<br />
and lead the translational effort on behalf of the <strong>UCSF</strong> Brain Tumor Research Center and Preclinical Core.<br />
My work has helped to create the groundwork for allied research in neuro-oncology and an extensive<br />
<strong>UCSF</strong> clinical trial portfolio for patients with primary brain and spine tumors, including an assortment of<br />
immunotherapy trials and surgically based trials. I have also designed investigator initiated trials, including a<br />
clinical trial employing intratumoral delivery with real-time MRI imaging as well as those with a range of novel<br />
targets, molecular markers and imaging biomarkers. I have also authored a number of peer-reviewed papers<br />
and presented work at national and international meetings.<br />
https://www.ucsfhealth.org/nicholas.butowski<br />
*<strong>UCSF</strong> authors in bold<br />
39
Presentations<br />
Clinical and genomic characterization of metastatic small cell/<br />
neuroendocrine prostate cancer (SCNC) and intermediate atypical<br />
prostate cancer (IAC): Results from the SU2C/PCF/AARCWest Coast<br />
Prostate Cancer Dream Team (WCDT).<br />
Authors*: Eric Jay Small, Rahul Raj Aggarwal, Jiaoti Huang, Artem Sokolov, Li Zhang, Joshi J. Alumkal,<br />
Jack Youngren, Charles J. Ryan, Adam Foye, Robert Evan Reiter, Christopher P. Evans, Martin Gleave,<br />
Owen Witte, Josh Stuart, Theodore C. Goldstein, George V. Thomas, Lawrence D. True, Himisha Beltran,<br />
Mark A. Rubin, Tomasz M. Beer<br />
Abstract #: 5019<br />
Presentation Date/Time: Saturday, June 4: 4:45 - 6:00 PM<br />
Location: Hall D1<br />
Poster Discussion Session: Genitourinary (Prostate) Cancer<br />
Citation: J Clin Oncol 34, 2016 (suppl; abstr 5019)<br />
Small Research Interests: The Stand Up To Cancer Dream Team led by Dr. Eric Small is exploring the<br />
idea that resistance to hormonal therapy occurs as a result of the prostate cancer cells using common<br />
cellular responses - what the Dream Team calls “adaptive pathways” - to escape the current prostate<br />
cancer therapies. They believe that, by identifying these pathways and inhibiting them, they will be able to<br />
overcome treatment resistance and profoundly improve the care of men affected by this fatal disease. This<br />
team is a six institution consortium to include UC Los Angeles, UC Davis, UC Santa Cruz, University of<br />
British Columbia, Oregon Health and Sciences University, with <strong>UCSF</strong> as the lead administrative site.<br />
http://cancer.ucsf.edu/people/profiles/small_eric.3671<br />
*<strong>UCSF</strong> authors in bold<br />
40
Presentations<br />
Extended follow-up results of a phase 1B study (BRIM7) of<br />
cobimetinib (C ) and vemurafenib (V) in BRAF-mutant melanoma.<br />
Authors*: Adil Daud, Anna C. Pavlick, Antoni Ribas, Rene Gonzalez, Karl D. Lewis, Omid Hamid,<br />
Thomas Gajewski, Igor Puzanov, Jessie J. Hsu, Daniel O. Koralek, Nicholas W. Choong, Grant A. McArthur<br />
Abstract #: 9510<br />
Presentation Date/Time: Saturday, June 4: 4:45 - 6:00 PM<br />
Location: E354b<br />
Poster Discussion Session: Melanoma/Skin Cancers<br />
Citation: J Clin Oncol 34, 2016 (suppl; abstr 9510)<br />
Daud Research Interests: Our group at <strong>UCSF</strong> is focused on developing new immunotherapy agents and<br />
specifically understanding the biology of the immune response to PD-1 in melanoma. We developed IL-<br />
12 gene therapy in melanoma and carried out the first in human clinical trial in 2005-2007. Based on this<br />
work, IL-12 electroporation is being explored in many cancers as an immune agent and as a combination<br />
treatment with PD-1 and other checkpoint inhibitors in melanoma. I have been involved in the development<br />
of anti-PD-1 antibodies for melanoma. With my colleagues Michael Rosenblum and Max Krummel at<br />
<strong>UCSF</strong>, we have developed a novel assay that profiles the intra-tumoral microenvironment in depth and can<br />
predict non-response to PD-1. We are currently exploring novel strategies for PD-1 non-responsive subsets<br />
of melanoma (and potentially other cancers).<br />
http://cancer.ucsf.edu/people/profiles/daud_adil.3622<br />
*<strong>UCSF</strong> authors in bold<br />
41
Presentations<br />
Derivation and validation of a prediction scale for response to<br />
PD-1 monotherapy.<br />
Authors*: Adi Nosrati, Simone M. Goldinger, Katy K. Tsai, Kimberly Loo, Paul Tumeh, Omid Hamid,<br />
Alain Patrick Algazi, Mitchell P. Levesque, Reinhard Dummer, Adil Daud<br />
Abstract #: 9514<br />
Presentation Date/Time: Saturday, June 4: 4:45 - 6:00 PM<br />
Location: E354b<br />
Poster Discussion Session: Melanoma/Skin Cancers<br />
Citation: J Clin Oncol 34, 2016 (suppl; abstr 9514)<br />
Daud Research Interests: Our group at <strong>UCSF</strong> is focused on developing new immunotherapy agents and<br />
specifically understanding the biology of the immune response to PD-1 in melanoma. We developed IL-<br />
12 gene therapy in melanoma and carried out the first in human clinical trial in 2005-2007. Based on this<br />
work, IL-12 electroporation is being explored in many cancers as an immune agent and as a combination<br />
treatment with PD-1 and other checkpoint inhibitors in melanoma. I have been involved in the development<br />
of anti-PD-1 antibodies for melanoma. With my colleagues Michael Rosenblum and Max Krummel at<br />
<strong>UCSF</strong>, we have developed a novel assay that profiles the intra-tumoral microenvironment in depth and can<br />
predict non-response to PD-1. We are currently exploring novel strategies for PD-1 non-responsive subsets<br />
of melanoma (and potentially other cancers).<br />
http://cancer.ucsf.edu/people/profiles/daud_adil.3622<br />
*<strong>UCSF</strong> authors in bold<br />
42
Presentations<br />
Adjuvant temozolomide for low grade gliomas: Molecular and<br />
radiographic correlates of treatment response in a phase II clinical trial.<br />
Authors*: Michael Traut Wahl, Joanna J Phillips, Annette M Molinaro, Yi Lin, Arie Perry,<br />
Daphne Haas-Kogan, Joseph F Costello, Manisha Dayal, Nicholas A. Butowski, Jennifer Leigh Clarke,<br />
Michael Prados, Mitchel S. Berger, Sarah J. Nelson, Susan Marina Chang<br />
Abstract #: 2002<br />
Presentation Date/Time: Sunday, June 5: 8:00 - 11:00 AM<br />
Location: S100a<br />
Oral Abstract Session: Central Nervous System Tumors<br />
Citation: J Clin Oncol 34, 2016 (suppl; abstr 2002)<br />
Chang Research Interests: My research interest is in the development of novel therapies for patients with<br />
brain tumors, as well as the assessment of novel imaging biomarkers in the management of patients.<br />
My research seeks to integrate advances in physiologic and metabolic imaging with tissue biomarkers in<br />
order to optimize the management of patients with glioblastoma (GBM). My clinical research evaluates a<br />
wide spectrum of therapeutic interventions that span chemotherapy, targeted agents, immunotherapy and<br />
convection enhanced delivery of novel agents. I am the site PI of an NIH-funded adult brain tumor<br />
consortium and am a member of the Brain Malignancy Steering Committee and the Developmental<br />
Therapeutics Study Section at the NIH. I am the program leader for the Neuro-Oncology Program at the<br />
HDFCCC. I am the clinical co-PI for the <strong>UCSF</strong> Brain Tumor SPORE and a co-Leader of a SPORE Project<br />
evaluating the role of physiologic imaging in the determination of malignant progression of low-grade glioma.<br />
http://cancer.ucsf.edu/people/profiles/chang_susan.3565<br />
*<strong>UCSF</strong> authors in bold<br />
43
Presentations<br />
Impact of primary (1º) tumor location on overall survival (OS) and<br />
progression-free survival (PFS) in patients (pts) with metastatic<br />
colorectal cancer (mCRC): Analysis of CALGB/SWOG 80405 (Alliance).<br />
Authors*: Alan P. Venook, Donna Niedzwiecki, Federico Innocenti, Briant Fruth, Claire Greene, Bert H.<br />
O’Neil, James Edward Shaw, James Norman Atkins, Laura E. Horvath, Blase N. Polite, Jeffrey A. Meyerhardt,<br />
Eileen Mary O’Reilly, Richard M. Goldberg, Howard S. Hochster, Charles David Blanke, Richard L. Schilsky,<br />
Robert J. Mayer, Monica M. Bertagnolli, Heinz-Josef Lenz<br />
Abstract #: 3504<br />
Presentation Date/Time: Sunday, June 5: 8:00 - 11:00 AM<br />
Location: Hall B1<br />
Session: Gastrointestinal (Colorectal) Cancer<br />
Citation: J Clin Oncol 34, 2016 (suppl; abstr 3504)<br />
Venook Research Interests: Dr. Alan Venook is a nationally renowned expert in colorectal and liver cancers at<br />
the <strong>UCSF</strong> Helen Diller Family Comprehensive Cancer Center. He is highly regarded for his expertise in the<br />
effective use of the newest approaches and therapies to the treatment of colorectal cancer, as well treating<br />
primary and metastatic tumors to the liver. Dr. Venook has chaired and/or authored six major studies within<br />
the cooperative groups and he now Chairs the GI Committee of the Alliance for Clinical Trials in Oncology<br />
(formerly CALGB.)<br />
http://cancer.ucsf.edu/people/profiles/venook_alan.3698<br />
__________________________________________________________________________<br />
The relationship between primary tumor sidedness and prognosis in<br />
colorectal cancer.<br />
Authors*: Deborah Schrag, Shicheng Weng, Gabriel Brooks, Jeffrey A. Meyerhardt, Alan P. Venook<br />
Abstract #: 3505<br />
Presentation Date/Time: Sunday, June 5: 8:00 - 11:00 AM<br />
Location: Hall B1<br />
Session: Gastrointestinal (Colorectal) Cancer<br />
Citation: J Clin Oncol 34, 2016 (suppl; abstr 3505)<br />
Venook Research Interests: Dr. Alan Venook is a nationally renowned expert in colorectal and liver cancers at<br />
the <strong>UCSF</strong> Helen Diller Family Comprehensive Cancer Center. He is highly regarded for his expertise in the<br />
effective use of the newest approaches and therapies to the treatment of colorectal cancer, as well treating<br />
primary and metastatic tumors to the liver. Dr. Venook has chaired and/or authored six major studies within<br />
the cooperative groups and he now Chairs the GI Committee of the Alliance for Clinical Trials in Oncology<br />
(formerly CALGB.)<br />
http://cancer.ucsf.edu/people/profiles/venook_alan.3698<br />
*<strong>UCSF</strong> authors in bold<br />
44
Presentations<br />
Ribociclib (LEE011) and letrozole in estrogen receptor-positive (ER+),<br />
HER2-negative (HER2–) advanced breast cancer (aBC): Phase Ib<br />
safety, preliminary efficacy and molecular analysis.<br />
Authors*: Dejan Juric, Pamela N. Munster, Mario Campone, Roohi Ismail-Khan, Laura García-Estevez,<br />
Erika Paige Hamilton, Carlos Becerra, Richard H. De Boer, Rina Hui, Anthony Goncalves, Yingbo Wang,<br />
Shyeilla V. Dhuria, Ghulam H. Kalimi, Karen Cristina Rodriguez Lorenc, Ingrid A. Mayer<br />
Abstract #: 568<br />
Presentation Date/Time: Sunday, June 5: 8:00 - 11:30 AM<br />
Location: Hall A, Poster Board #56<br />
Session: Breast Cancer - HER2/ER<br />
Citation: J Clin Oncol 34, 2016 (suppl; abstr 568)<br />
Munster Research Interests: My clinical research interests are first-in-human early phase clinical trials of<br />
novel compounds and alternative strategies for the treatment and prevention of cancer. I have been involved<br />
in clinical and translational research in early phase clinical trials since 1998. As the program leader for<br />
Development Therapeutics and the PI of a peer-reviewed basic science lab, my main focus is on translating<br />
preclinical findings into early-stage clinical trials with extensive PK and integration of PD correlative studies<br />
and molecular imaging for patients with advanced stage cancer. My basic research interest is centered on<br />
the role of epigenetic modification in therapy resistance in breast cancer and epigenetic priming. In addition<br />
to studying basic mechanisms of hormone therapy resistance, we have shown that epigenetic modification<br />
plays a crucial role in the hormonal regulation and carcinogenesis of breast cancer.<br />
http://cancer.ucsf.edu/people/profiles/munster_pamela.3449<br />
__________________________________________________________________________<br />
Outcome disparities by age and 21-gene recurrence score (RS) in<br />
hormone receptor positive (HR+) breast cancer (BC).<br />
Authors*: Valentina I. Petkov, Dave P. Miller, Nadia Howlader, Nathan Gliner, Will Howe, Nicola C. Schussler,<br />
Kathleen Cronin, Frederick L. Baehner, Lynne Penberthy, Steven Shak<br />
Abstract #: 574<br />
Presentation Date/Time: Sunday, June 5: 8:00 - 11:30 AM<br />
Location: Hall A, Poster Board #62<br />
Session: Breast Cancer- HER2/ER<br />
Citation: J Clin Oncol 34, 2016 (suppl; abstr 574)<br />
*<strong>UCSF</strong> authors in bold<br />
45
Presentations<br />
Phase 1 study of CB-839, a small molecule inhibitor of glutaminase<br />
(GLS) in combination with paclitaxel (Pac) in patients (pts) with triple<br />
negative breast cancer (TNBC).<br />
Authors*: Angela DeMichele, James J. Harding, Melinda L. Telli, Pamela N. Munster, Rana McKay,<br />
Othon Iliopoulos, Keith W. Orford, Mark K. Bennett, James Walter Mier, Taofeek Kunle Owonikoko,<br />
Manish R. Patel, Richard D. Carvajal, Funda Meric-Bernstam, Jeffrey R. Infante<br />
Abstract #: 1011<br />
Presentation Date/Time: Sunday, June 5: 8:00 - 11:30 AM<br />
Location: Hall A, Poster Board #116<br />
Session: Breast Cancer - Triple-Negative/Cytotoxics/Local Therapy<br />
Citation: J Clin Oncol 34, 2016 (suppl; abstr 1011)<br />
Munster Research Interests: My clinical research interests are first-in-human early phase clinical trials of<br />
novel compounds and alternative strategies for the treatment and prevention of cancer. I have been involved<br />
in clinical and translational research in early phase clinical trials since 1998. As the program leader for<br />
Development Therapeutics and the PI of a peer-reviewed basic science lab, my main focus is on translating<br />
preclinical findings into early-stage clinical trials with extensive PK and integration of PD correlative studies<br />
and molecular imaging for patients with advanced stage cancer. My basic research interest is centered on<br />
the role of epigenetic modification in therapy resistance in breast cancer and epigenetic priming. In addition<br />
to studying basic mechanisms of hormone therapy resistance, we have shown that epigenetic modification<br />
plays a crucial role in the hormonal regulation and carcinogenesis of breast cancer.<br />
http://cancer.ucsf.edu/people/profiles/munster_pamela.3449<br />
*<strong>UCSF</strong> authors in bold<br />
46
Presentations<br />
Androgen receptor (AR) expression in primary breast cancer (BC):<br />
Correlations with clinical characteristics and outcomes.<br />
Authors*: Neelima Vidula, Christina Yau, Denise M Wolf, Hope S. Rugo<br />
Abstract #: 1072<br />
Presentation Date/Time: Sunday, June 5: 8:00 - 11:30 AM<br />
Location: Hall A, Poster Board #177<br />
Poster Session: Breast Cancer - Triple-Negative/Cytotoxics/Local Therapy<br />
Citation: J Clin Oncol 34, 2016 (suppl; abstr 1072)<br />
Rugo Research Interests: Dr. Rugo, Director of Breast Oncology & Clinical Trials Education, is PI on multiple<br />
clinical trials focusing on combining novel targeted therapeutics to improve the treatment of both early & late<br />
stage breast cancer (BC). She also works on studies to improve supportive care for early & late stage BC<br />
patients, including with <strong>UCSF</strong>’s Advanced Breast Cancer Program. Dr. Rugo has numerous collaborations with<br />
large academic medical centers & consortia in order to expand the novel therapies available to patients. She<br />
was the director of the 2016 ASCO Breast Cancer Education Committee meeting, is a member of the Alliance<br />
& is a founding member of the Breast Cancer Research Consortium where she co-leads the triple negative<br />
working group. She is on the novel agents committee for the neoadjuvant multi-center I SPY2 trial. At <strong>UCSF</strong>,<br />
Dr. Rugo runs the Breast Forum, a bimonthly educational session for breast cancer patients, families & friends<br />
from throughout the bay area.<br />
http://cancer.ucsf.edu/people/profiles/rugo_hope.3648<br />
*<strong>UCSF</strong> authors in bold<br />
47
Presentations<br />
Efficacy of a novel antibody-drug conjugate (ADC), ABT-414, as<br />
monotherapy in epidermal growth factor receptor (EGFR) amplified,<br />
recurrent glioblastoma (GBM).<br />
Authors*: Martin J. Van Den Bent, Hui Kong Gan, Andrew B. Lassman, Priya Kumthekar, Ryan Merrell,<br />
Nicholas A. Butowski, Zarnie Lwin, Tom Mikkelsen, Louis B. Nabors, Kyriakos P. Papadopoulos,<br />
Marta Penas-Prado, John Simes, Helen Wheeler, Erica J. Gomez, Ho-Jin Lee, Lisa Roberts-Rapp,<br />
Hao Xiong, Earle E. Bain, Kyle D. Holen, David A. Reardon<br />
Abstract #: 2542<br />
Presentation Date/Time: Sunday, June 5: 8:00 - 11:30 AM<br />
Location: Hall A, Poster Board #242<br />
Session: Developmental Therapeutics - Clinical Pharmacology and Experimental Therapeutics<br />
Citation: J Clin Oncol 34, 2016 (suppl; abstr 2542)<br />
Butowski Research Interests: My research includes translational research and a wide range of clinical trials,<br />
including those with convection-enhanced delivery (CED) with real-time MRI imaging, targeted agents,<br />
immunotherapy, and combination strategies. I am the Director of Translational Research in Neuro-Oncology<br />
and lead the translational effort on behalf of the <strong>UCSF</strong> Brain Tumor Research Center and Preclinical Core.<br />
My work has helped to create the groundwork for allied research in neuro-oncology and an extensive<br />
<strong>UCSF</strong> clinical trial portfolio for patients with primary brain and spine tumors, including an assortment of<br />
immunotherapy trials and surgically based trials. I have also designed investigator initiated trials, including a<br />
clinical trial employing intratumoral delivery with real-time MRI imaging as well as those with a range of novel<br />
targets, molecular markers and imaging biomarkers. I have also authored a number of peer-reviewed papers<br />
and presented work at national and international meetings.<br />
https://www.ucsfhealth.org/nicholas.butowski<br />
*<strong>UCSF</strong> authors in bold<br />
48
Presentations<br />
Efficacy and hematologic toxicity of carboplatin and talazoparib<br />
combination therapy in BRCA mutated patients.<br />
Authors*: Mallika Sachdev Dhawan, Rahul Raj Aggarwal, Imke Bartelink, Jim Leng, Scott Thomas,<br />
Nela Pawlowska, Laurie Stevenson, Amy Jo Chien, Robin Kate Kelley, Julia Clennell, Pamela N. Munster<br />
Abstract #: 2557<br />
Presentation Date/Time: Sunday, June 5: 8:00 - 11:30 AM<br />
Location: Hall A, Poster Board #257<br />
Poster Session: Developmental Therapeutics - Clinical Pharmacology and Experimental Therapeutics<br />
Citation: J Clin Oncol 34, 2016 (suppl; abstr 2557)<br />
Munster Research Interests: My clinical research interests are first-in-human early phase clinical trials of<br />
novel compounds and alternative strategies for the treatment and prevention of cancer. I have been involved<br />
in clinical and translational research in early phase clinical trials since 1998. As the program leader for<br />
Development Therapeutics and the PI of a peer-reviewed basic science lab, my main focus is on translating<br />
preclinical findings into early-stage clinical trials with extensive PK and integration of PD correlative studies<br />
and molecular imaging for patients with advanced stage cancer. My basic research interest is centered on<br />
the role of epigenetic modification in therapy resistance in breast cancer and epigenetic priming. In addition<br />
to studying basic mechanisms of hormone therapy resistance, we have shown that epigenetic modification<br />
plays a crucial role in the hormonal regulation and carcinogenesis of breast cancer.<br />
http://cancer.ucsf.edu/people/profiles/munster_pamela.3449<br />
*<strong>UCSF</strong> authors in bold<br />
49
Presentations<br />
Association between T cell repertoire diversification and both clinical<br />
response as well as toxicity following immune checkpoint blockade in<br />
metastatic cancer patients.<br />
Authors*: David Yoonsuk Oh, Jason Cham, Li Zhang, Grant Fong, Mark Klinger, Malek Faham,<br />
Lawrence Fong<br />
Abstract #: 3029<br />
Presentation Date/Time: Sunday, June 5: 8:00 - 11:30 AM<br />
Location: Hall A, Poster Board # 351<br />
Post Session: Developmental Therapeutics - Immunotherapy<br />
Citation: J Clin Oncol 34, 2016 (suppl; abstr 3029)<br />
Fong Research Interests: My lab focuses on how the immune system interacts with cancer as well as exploring<br />
tumor immunotherapies in mouse models and in patients. Our primary focus is in cancer immunotherapy.<br />
We investigate how immunotherapies such as immune checkpoint inhibitors and cancer vaccines can<br />
enhance anti-tumor immunity both systemically and in the tumor microenvironment. Performing neoadjuvant<br />
immunotherapy trials, we determine how specific therapies can recruit immune effectors in cancer patients.<br />
Moreover, we have studied how clinical responders may differ from clinical non-responders. We are applying<br />
unbiased approaches to studying antigen-specific responses that are modulated in these patients and are<br />
currently developing biomarkers that may be redictive of clinical efficacy.<br />
http://hemonc.ucsf.edu/fonglab/<br />
*<strong>UCSF</strong> authors in bold<br />
50
Presentations<br />
IMpassion130: a Phase III randomized trial of atezolizumab with nabpaclitaxel<br />
for first-line treatment of patients with metastatic triplenegative<br />
breast cancer (mTNBC).<br />
Authors*: Leisha A. Emens, Sylvia Adams, Sherene Loi, Andreas Schneeweiss, Hope S. Rugo, Eric P. Winer,<br />
Carlos H. Barrios, Veronique Dieras, Juan de la Haba-Rodriguez, Luca Gianni, Stephen Y. Chui, Peter Schmid<br />
Abstract #: TPS1104<br />
Presentation Date/Time: Sunday, June 5: 8:00 - 11:30 AM<br />
Location: Hall A, Poster Board #205a<br />
Session: Breast Cancer - Triple-Negative/Cytotoxics/Local Therapy<br />
Citation: J Clin Oncol 34, 2016 (suppl; abstr TPS1104)<br />
Rugo Research Interests: Dr. Rugo, Director of Breast Oncology & Clinical Trials Education, is PI on multiple<br />
clinical trials focusing on combining novel targeted therapeutics to improve the treatment of both early & late<br />
stage breast cancer (BC). She also works on studies to improve supportive care for early & late stage BC<br />
patients, including with <strong>UCSF</strong>’s Advanced Breast Cancer Program. Dr. Rugo has numerous collaborations with<br />
large academic medical centers & consortia in order to expand the novel therapies available to patients. She<br />
was the director of the 2016 ASCO Breast Cancer Education Committee meeting, is a member of the Alliance<br />
& is a founding member of the Breast Cancer Research Consortium where she co-leads the triple negative<br />
working group. She is on the novel agents committee for the neoadjuvant multi-center I SPY2 trial. At <strong>UCSF</strong>,<br />
Dr. Rugo runs the Breast Forum, a bimonthly educational session for breast cancer patients, families & friends<br />
from throughout the bay area.<br />
http://cancer.ucsf.edu/people/profiles/rugo_hope.3648<br />
*<strong>UCSF</strong> authors in bold<br />
51
Presentations<br />
A randomized, double-blind, placebo-controlled study of ibrutinib, a<br />
Bruton tyrosine kinase inhibitor, with nab-paclitaxel and gemcitabine<br />
in the first-line treatment of patients with metastatic pancreatic<br />
adenocarcinoma (RESOLVE).<br />
Authors*: Margaret A. Tempero, Lisa M Coussens, Lawrence Fong, Robert Manges, Priyanka Singh,<br />
Yunfeng Li, George W. Cole, Danelle Frances James, Josep Tabernero<br />
Abstract #: TPS2601<br />
Presentation Date/Time: Sunday, June 5: 8:00 - 11:30 AM<br />
Location: Hall A, Poster Board #296a<br />
Poster Session: Developmental Therapeutics - Clinical Pharmacology and Experimental Therapeutics<br />
Citation: J Clin Oncol 34, 2016 (suppl; abstr TPS2601)<br />
Tempero Research Interests: My research focuses on pancreatic ductal adenocarcinoma, especially in<br />
investigational therapeutics. I was a pioneer in the use of mAb-based therapies and helped develop the fixed<br />
dose rate concept for gemcitabine. My group developed effective gemcitabine combinations, provided a<br />
foundation for using CA19-9 as a clinical surrogate for survival and currently is assessing molecular subtypes<br />
and molecular enrichment for selecting new drugs for clinical evaluation. We have a strong emphasis on<br />
immunotherapy. I am a SU2C Dream Team member evaluating innovative immunotherapy approaches in this<br />
disease. I am also co-PI of a U01 award to establish high risk cohorts for testing candidate early diagnosis<br />
biomarkers. I am the <strong>UCSF</strong> Pancreas Center Director and Pancreas Cancer Program Leader. I have served<br />
as the NCCN Guidelines Panel Chair on Pancreatic Cancer since 2000. I serve on SABs to many groups and<br />
institutions including the Mayo Clinic Pancreas Cancer SPORE and MDACC’s Moon Shot Program.<br />
http://cancer.ucsf.edu/people/profiles/tempero_margaret.3701<br />
*<strong>UCSF</strong> authors in bold<br />
52
Presentations<br />
Randomized phase II trial of a DNA vaccine encoding prostatic<br />
acid phosphatase (PAP) versus GM-CSF adjuvant in patients with<br />
biochemically recurrent prostate cancer.<br />
Authors*: Glenn Liu, Lawrence Fong, Emmanuel S. Antonarakis, Jens C. Eickhoff, Laura E. Johnson,<br />
Douglas G. McNeel<br />
Abstract #: TPS3114<br />
Presentation Date/Time: Sunday, June 5: 8:00 - 11:30 AM<br />
Location: Hall A, Poster Board #426b<br />
Session: Developmental Therapeutics - Immunotherapy<br />
Citation: J Clin Oncol 34, 2016 (suppl; abstr TPS3114)<br />
Fong Research Interests: My lab focuses on how the immune system interacts with cancer as well as exploring<br />
tumor immunotherapies in mouse models and in patients. Our primary focus is in cancer immunotherapy.<br />
We investigate how immunotherapies such as immune checkpoint inhibitors and cancer vaccines can<br />
enhance anti-tumor immunity both systemically and in the tumor microenvironment. Performing neoadjuvant<br />
immunotherapy trials, we determine how specific therapies can recruit immune effectors in cancer patients.<br />
Moreover, we have studied how clinical responders may differ from clinical non-responders. We are applying<br />
unbiased approaches to studying antigen-specific responses that are modulated in these patients and are<br />
currently developing biomarkers that may be redictive of clinical efficacy.<br />
http://hemonc.ucsf.edu/fonglab/<br />
*<strong>UCSF</strong> authors in bold<br />
53
Presentations<br />
SOLAR-1: A phase III study of alpelisib + fulvestrant in men and<br />
postmenopausal women with HR+/HER2– advanced breast cancer<br />
(BC) progressing on or after prior aromatase inhibitor therapy.<br />
Authors*: Fabrice Andre, Mario Campone, Eva M. Ciruelos, Hiroji Iwata, Sibylle Loibl, Hope S. Rugo,<br />
Celine Wilke, David Mills, Marie Chol, Anne-Sophie Longin, Dejan Juric<br />
Abstract #: TPS618<br />
Presentation Date/Time: Sunday, June 5: 8:00 - 11:30 AM<br />
Location: Hall A, Poster Board #103b<br />
Session: Breast Cancer - HER2/ER<br />
Citation: J Clin Oncol 34, 2016 (suppl; abstr TPS618)<br />
Rugo Research Interests: Dr. Rugo, Director of Breast Oncology & Clinical Trials Education, is PI on multiple<br />
clinical trials focusing on combining novel targeted therapeutics to improve the treatment of both early & late<br />
stage breast cancer (BC). She also works on studies to improve supportive care for early & late stage BC<br />
patients, including with <strong>UCSF</strong>’s Advanced Breast Cancer Program. Dr. Rugo has numerous collaborations with<br />
large academic medical centers & consortia in order to expand the novel therapies available to patients. She<br />
was the director of the 2016 ASCO Breast Cancer Education Committee meeting, is a member of the Alliance<br />
& is a founding member of the Breast Cancer Research Consortium where she co-leads the triple negative<br />
working group. She is on the novel agents committee for the neoadjuvant multi-center I SPY2 trial. At <strong>UCSF</strong>,<br />
Dr. Rugo runs the Breast Forum, a bimonthly educational session for breast cancer patients, families & friends<br />
from throughout the bay area.<br />
http://cancer.ucsf.edu/people/profiles/rugo_hope.3648<br />
*<strong>UCSF</strong> authors in bold<br />
54
Presentations<br />
Phase II trial with tamoxifen in combination with vorinostat and<br />
pembrolizumab in estrogen receptor (+) hormone therapy resistant<br />
metastatic breast cancer patients (NCT02395627).<br />
Authors*: Manuela Terranova Barberio, Scott Thomas, Amy Jo Chien, Hope S. Rugo, Michelle E. Melisko,<br />
Austin Nicholas Angelidakis, Nela Pawlowska, Travis Deal, Pamela N. Munster<br />
Abstract #: TPS620<br />
Presentation Date/Time: Sunday, June 5: 8:00 - 11:30 AM<br />
Location: Hall A, Poster Board #104b<br />
Poster Session: Breast Cancer - HER2/ER<br />
Citation: J Clin Oncol 34, 2016 (suppl; abstr TPS620)<br />
Munster Research Interests: My clinical research interests are first-in-human early phase clinical trials of<br />
novel compounds and alternative strategies for the treatment and prevention of cancer. I have been involved<br />
in clinical and translational research in early phase clinical trials since 1998. As the program leader for<br />
Development Therapeutics and the PI of a peer-reviewed basic science lab, my main focus is on translating<br />
preclinical findings into early-stage clinical trials with extensive PK and integration of PD correlative studies<br />
and molecular imaging for patients with advanced stage cancer. My basic research interest is centered on<br />
the role of epigenetic modification in therapy resistance in breast cancer and epigenetic priming. In addition<br />
to studying basic mechanisms of hormone therapy resistance, we have shown that epigenetic modification<br />
plays a crucial role in the hormonal regulation and carcinogenesis of breast cancer.<br />
http://cancer.ucsf.edu/people/profiles/munster_pamela.3449<br />
*<strong>UCSF</strong> authors in bold<br />
55
Presentations<br />
A phase 2 randomized, double-blind, placebo-controlled trial of<br />
endocrine therapy ± radium-223 dichloride (Ra-223) in HER2- hormone<br />
receptor+breast cancer patients with bone metastases.<br />
Authors*: Robert E. Coleman, Rui Li, Amrita G. Sawhney, Oana Petrenciuc, Hope S. Rugo<br />
Abstract #: TPS622<br />
Presentation Date/Time: Sunday, June 5: 8:00 - 11:30 AM<br />
Location: Hall A, Poster Board #105b<br />
Session: Breast Cancer - HER2/ER<br />
Citation: J Clin Oncol 34, 2016 (suppl; abstr TPS622)<br />
Rugo Research Interests: Dr. Rugo, Director of Breast Oncology & Clinical Trials Education, is PI on multiple<br />
clinical trials focusing on combining novel targeted therapeutics to improve the treatment of both early & late<br />
stage breast cancer (BC). She also works on studies to improve supportive care for early & late stage BC<br />
patients, including with <strong>UCSF</strong>’s Advanced Breast Cancer Program. Dr. Rugo has numerous collaborations with<br />
large academic medical centers & consortia in order to expand the novel therapies available to patients. She<br />
was the director of the 2016 ASCO Breast Cancer Education Committee meeting, is a member of the Alliance<br />
& is a founding member of the Breast Cancer Research Consortium where she co-leads the triple negative<br />
working group. She is on the novel agents committee for the neoadjuvant multi-center I SPY2 trial. At <strong>UCSF</strong>,<br />
Dr. Rugo runs the Breast Forum, a bimonthly educational session for breast cancer patients, families & friends<br />
from throughout the bay area.<br />
http://cancer.ucsf.edu/people/profiles/rugo_hope.3648<br />
*<strong>UCSF</strong> authors in bold<br />
56
Presentations<br />
Academic and Community Cancer Research United (ACCRU)<br />
RU011301I: Adjuvant ado-trastuzumab emtansine (T-DM1) for older<br />
patients with human epidermal growth factor receptor 2 (HER2)-<br />
positive breast cancer.<br />
Authors*: Rachel A. Freedman, Mei-Yin Polley, Amylou C. Dueck, Arti Hurria, Hyman B. Muss,<br />
Kathryn Jean Ruddy, Joleen Marie Hubbard, Heshan Liu, Lauren J. Rogak, Ethan M. Basch,<br />
Shaker R. Dakhil, Jason D. Huff, Madhuri Bajaj, Mary Wilkinson, Tareq Al Baghadadi, Sam Benjamin,<br />
Rex B Mowat, Clifford A. Hudis, Hope S. Rugo, Eric P. Winer<br />
Abstract #: TPS629<br />
Presentation Date/Time: Sunday, June 5: 8:00 - 11:30 AM<br />
Location: Hall A, Poster Board #109a<br />
Session: Breast Cancer - HER2/ER<br />
Citation: J Clin Oncol 34, 2016 (suppl; abstr TPS629)<br />
Rugo Research Interests: Dr. Rugo, Director of Breast Oncology & Clinical Trials Education, is PI on multiple<br />
clinical trials focusing on combining novel targeted therapeutics to improve the treatment of both early & late<br />
stage breast cancer (BC). She also works on studies to improve supportive care for early & late stage BC<br />
patients, including with <strong>UCSF</strong>’s Advanced Breast Cancer Program. Dr. Rugo has numerous collaborations with<br />
large academic medical centers & consortia in order to expand the novel therapies available to patients. She<br />
was the director of the 2016 ASCO Breast Cancer Education Committee meeting, is a member of the Alliance<br />
& is a founding member of the Breast Cancer Research Consortium where she co-leads the triple negative<br />
working group. She is on the novel agents committee for the neoadjuvant multi-center I SPY2 trial. At <strong>UCSF</strong>,<br />
Dr. Rugo runs the Breast Forum, a bimonthly educational session for breast cancer patients, families & friends<br />
from throughout the bay area.<br />
http://cancer.ucsf.edu/people/profiles/rugo_hope.3648<br />
*<strong>UCSF</strong> authors in bold<br />
57
Presentations<br />
SOPHIA: A phase 3, randomized study of margetuximab (M) plus<br />
chemotherapy (CTX) vs trastuzumab (T) plus CTX in the treatment of<br />
patients with HER2+ metastatic breast cancer (MBC).<br />
Authors*: Hope S. Rugo, Mark D. Pegram, William John Gradishar, Javier Cortes, Giuseppe Curigliano,<br />
Jon M. Wigginton, Robert Joseph Lechleider, Fatima Cardoso<br />
Abstract #: TPS630<br />
Presentation Date/Time: Sunday, June 5: 8:00 - 11:30 AM<br />
Location: Hall A, Poster Board #109b<br />
Poster Session: Breast Cancer - HER2/ER<br />
Citation: J Clin Oncol 34, 2016 (suppl; abstr TPS630)<br />
Rugo Research Interests: Dr. Rugo, Director of Breast Oncology & Clinical Trials Education, is PI on multiple<br />
clinical trials focusing on combining novel targeted therapeutics to improve the treatment of both early & late<br />
stage breast cancer (BC). She also works on studies to improve supportive care for early & late stage BC<br />
patients, including with <strong>UCSF</strong>s Advanced Breast Cancer Program. Dr. Rugo has numerous collaborations with<br />
large academic medical centers & consortia in order to expand the novel therapies available to patients. She<br />
was the director of the 2016 ASCO Breast Cancer Education Committee meeting, is a member of the Alliance<br />
& is a founding member of the Breast Cancer Research Consortium where she co-leads the triple negative<br />
working group. She is on the novel agents committee for the neoadjuvant multi-center I SPY2 trial. At <strong>UCSF</strong>,<br />
Dr. Rugo runs the Breast Forum, a bimonthly educational session for breast cancer patients, families & friends<br />
from throughout the bay area.<br />
http://cancer.ucsf.edu/people/profiles/rugo_hope.3648<br />
*<strong>UCSF</strong> authors in bold<br />
58
Presentations<br />
Prevention of everolimus/exemestane (EVE/EXE) stomatitis in<br />
postmenopausal (PM) women with hormone receptor-positive (HR+)<br />
metastatic breast cancer (MBC) using a dexamethasone-based<br />
mouthwash (MW): Results of the SWISH trial.<br />
Authors*: Hope S. Rugo, Lasikas Seneviratne, J. Thaddeus Beck, John A. Glaspy, Julio Antonio Peguero,<br />
Timothy J. Pluard, Navneet Dhillon, Leon C. Hwang, Chaitali Singh Nangia, Ingrid A. Mayer, Timothy F. Meiller,<br />
Mark Steven Chambers, Ghulam Warsi, Robert William Sweetman, J. Randy Sabo, Jennifer Keating Litton<br />
Abstract #: 525<br />
Presentation Date/Time: Sunday, June 5: 8:00 - 11:30 AM<br />
Location: Hall A, Poster Board #13<br />
Poster Session: Breast Cancer - HER2/ER<br />
Citation: J Clin Oncol 34, 2016 (suppl; abstr 525)<br />
Rugo Research Interests: Dr. Rugo, Director of Breast Oncology & Clinical Trials Education, is PI on multiple<br />
clinical trials focusing on combining novel targeted therapeutics to improve the treatment of both early & late<br />
stage breast cancer (BC). She also works on studies to improve supportive care for early & late stage BC<br />
patients, including with <strong>UCSF</strong>s Advanced Breast Cancer Program. Dr. Rugo has numerous collaborations with<br />
large academic medical centers & consortia in order to expand the novel therapies available to patients. She<br />
was the director of the 2016 ASCO Breast Cancer Education Committee meeting, is a member of the Alliance<br />
& is a founding member of the Breast Cancer Research Consortium where she co-leads the triple negative<br />
working group. She is on the novel agents committee for the neoadjuvant multi-center I SPY2 trial. At <strong>UCSF</strong>,<br />
Dr. Rugo runs the Breast Forum, a bimonthly educational session for breast cancer patients, families & friends<br />
from throughout the bay area.<br />
http://cancer.ucsf.edu/people/profiles/rugo_hope.3648<br />
*<strong>UCSF</strong> authors in bold<br />
59
Presentations<br />
Addition of pazopanib (PZ) to endocrine therapy in hormone resistant<br />
advanced breast cancer (ABC.)<br />
Authors*: Melanie Catherine Majure, Ariadna Gasol Cudós, Austin Nicholas Angelidakis,<br />
Michelle E. Melisko, Ariel R. Karwat, Amy Jo Chien, Andrei Goga, Mark M. Moasser, John W. Park,<br />
Amy N. DeLuca, Hope S. Rugo<br />
Abstract #: 560<br />
Presentation Date/Time: Sunday, June 5: 8:00 - 11:30 AM<br />
Location: Hall A, Poster Board #48<br />
Poster Session: Breast Cancer- HER2/ER<br />
Citation: J Clin Oncol 34, 2016 (suppl; abstr 560)<br />
Rugo Research Interests: Dr. Rugo, Director of Breast Oncology & Clinical Trials Education, is PI on multiple<br />
clinical trials focusing on combining novel targeted therapeutics to improve the treatment of both early & late<br />
stage breast cancer (BC). She also works on studies to improve supportive care for early & late stage<br />
BC patients, including with <strong>UCSF</strong>s Advanced Breast Cancer Program. Dr. Rugo has numerous collaborations<br />
with large academic medical centers & consortia in order to expand the novel therapies available to patients.<br />
She was the director of the 2016 ASCO Breast Cancer Education Committee meeting, is a member of the<br />
Alliance & is a founding member of the Breast Cancer Research Consortium where she co-leads the triple<br />
negative working group. She is on the novel agents committee for the neoadjuvant multi-center I SPY2 trial.<br />
At <strong>UCSF</strong>, Dr. Rugo runs the Breast Forum, a bimonthly educational session for breast cancer patients, families<br />
& friends from throughout the bay area.<br />
http://cancer.ucsf.edu/people/profiles/rugo_hope.3648<br />
*<strong>UCSF</strong> authors in bold<br />
60
Presentations<br />
A phase 2 randomized, double-blind, placebo-controlled trial of<br />
radium-223 dichloride with exemestane and everolimus in patients<br />
with HER2-negative hormone receptor-positive breast cancer and<br />
bone metastases.<br />
Authors*: Hope S. Rugo, Rui Li, Oana Petrenciuc, Amily Zhang, Robert E. Coleman<br />
Abstract #: TPS621<br />
Presentation Date/Time: Sunday, June 5: 8:00 - 11:30 AM<br />
Location: Hall A, Poster Board #105a<br />
Poster Session: Breast Cancer - HER2/ER<br />
Citation: J Clin Oncol 34, 2016 (suppl; abstr TPS621)<br />
Rugo Research Interests: Dr. Rugo, Director of Breast Oncology & Clinical Trials Education, is PI on multiple<br />
clinical trials focusing on combining novel targeted therapeutics to improve the treatment of both early & late<br />
stage breast cancer (BC). She also works on studies to improve supportive care for early & late stage BC<br />
patients, including with <strong>UCSF</strong>s Advanced Breast Cancer Program. Dr. Rugo has numerous collaborations with<br />
large academic medical centers & consortia in order to expand the novel therapies available to patients. She<br />
was the director of the 2016 ASCO Breast Cancer Education Committee meeting, is a member of the Alliance<br />
& is a founding member of the Breast Cancer Research Consortium where she co-leads the triple negative<br />
working group. She is on the novel agents committee for the neoadjuvant multi-center I SPY2 trial. At <strong>UCSF</strong>,<br />
Dr. Rugo runs the Breast Forum, a bimonthly educational session for breast cancer patients, families & friends<br />
from throughout the bay area.<br />
http://cancer.ucsf.edu/people/profiles/rugo_hope.3648<br />
*<strong>UCSF</strong> authors in bold<br />
61
Presentations<br />
Impact of primary (1˚) tumor location on overall survival (OS) and<br />
progression-free survival (PFS) in patients (pts) with metastatic<br />
colorectal cancer (mCRC): Analysis of CALGB/SWOG 80405 (Alliance).<br />
Authors*: Alan P. Venook, Donna Niedzwiecki, Federico Innocenti, Briant Fruth,Claire Greene, Bert H. O’Neil,<br />
James Edward Shaw, James Norman Atkins, Laura E. Horvath, Blase N. Polite, Jeffrey A. Meyerhardt,<br />
Eileen Mary O’Reilly, Richard M. Goldberg, Howard S. Hochster, Charles David Blanke, Richard L. Schilsky,<br />
Robert J. Mayer, Monica M. Bertagnolli, Heinz-Josef Lenz<br />
Abstract #: 3504<br />
Presentation Date/Time: Sunday, June 5: 8:00 – 11:00AM<br />
Location: Hall B1<br />
Oral Abstract Session: Gastrointestinal (Colorectal) Cancer<br />
Citation: J Clin Oncol 34, 2016 (suppl; abstr 3504)<br />
Venook Research Interests: Dr. Alan Venook is a nationally renowned expert in colorectal and liver cancers at<br />
the <strong>UCSF</strong> Helen Diller Family Comprehensive Cancer Center. He is highly regarded for his expertise in the<br />
effective use of the newest approaches and therapies to the treatment of colorectal cancer, as well treating<br />
primary and metastatic tumors to the liver. Dr. Venook has chaired and/or authored six major studies within<br />
the cooperative groups and he now Chairs the GI Committee of the Alliance for Clinical Trials in Oncology<br />
(formerly CALGB.)<br />
http://cancer.ucsf.edu/people/profiles/venook_alan.3698<br />
*<strong>UCSF</strong> authors in bold<br />
62
Presentations<br />
PD-L1 expression, Cancer Genome Atlas (TCGA) subtype, and<br />
mutational load as independent predictors of response to<br />
atezolizumab (atezo) in metastatic urothelial carcinoma (mUC;<br />
IMvigor210).<br />
Authors*: Jonathan E. Rosenberg, Daniel Peter Petrylak, Michiel Simon Van Der Heijden, Andrea Necchi,<br />
Peter H. O’Donnell, Yohann Loriot, Margitta Retz, Jose Luis Perez-Gracia, Joaquim Bellmunt, Petros Grivas,<br />
Richard Wayne Joseph, Lawrence Fong, Edward E. Kadel, Zachary Boyd, Dorothee Nickles,<br />
Garrett Michael Frampton, Richard Bourgon, Priti S. Hegde, Sanjeev Mariathasan, Thomas Powles<br />
Abstract #: 104<br />
Presentation Date/Time: Sunday, June 5: 9:45 - 11:15 AM<br />
Location: Hall D1<br />
Session: Immunotherapy: Now We’re Getting Personal - Using Genomics and Biomarkers to Predict Response<br />
Citation: J Clin Oncol 34, 2016 (suppl; abstr 104)<br />
Fong Research Interests: My lab focuses on how the immune system interacts with cancer as well as exploring<br />
tumor immunotherapies in mouse models and in patients. Our primary focus is in cancer immunotherapy.<br />
We investigate how immunotherapies such as immune checkpoint inhibitors and cancer vaccines can<br />
enhance anti-tumor immunity both systemically and in the tumor microenvironment. Performing neoadjuvant<br />
immunotherapy trials, we determine how specific therapies can recruit immune effectors in cancer patients.<br />
Moreover, we have studied how clinical responders may differ from clinical non-responders. We are applying<br />
unbiased approaches to studying antigen-specific responses that are modulated in these patients and are<br />
currently developing biomarkers that may be redictive of clinical efficacy.<br />
http://hemonc.ucsf.edu/fonglab/<br />
*<strong>UCSF</strong> authors in bold<br />
63
Presentations<br />
Pembrolizumab in patients with advanced cervical squamous cell<br />
cancer: Preliminary results from the phase Ib KEYNOTE-028 study.<br />
Authors*: Jean-Sebastien Frenel, Christophe Le Tourneau, Bert H. O’Neil, Patrick Alexander Ott,<br />
Sarina Anne Piha-Paul, Carlos Alberto Gomez-Roca, Emilie Van Brummelen, Hope S. Rugo, Shari Thomas,<br />
Sanatan Saraf, Mei Chen, Andrea Varga<br />
Abstract #: 5515<br />
Presentation Date/Time: Sunday, June 5: 9:45 AM - 12:45 PM<br />
Location: E450ab<br />
Session: Gynecologic Cancer<br />
Citation: J Clin Oncol 34, 2016 (suppl; abstr 5515)<br />
Rugo Research Interests: Dr. Rugo, Director of Breast Oncology & Clinical Trials Education, is PI on multiple<br />
clinical trials focusing on combining novel targeted therapeutics to improve the treatment of both early & late<br />
stage breast cancer (BC). She also works on studies to improve supportive care for early & late stage BC<br />
patients, including with <strong>UCSF</strong>s Advanced Breast Cancer Program. Dr. Rugo has numerous collaborations with<br />
large academic medical centers & consortia in order to expand the novel therapies available to patients. She<br />
was the director of the 2016 ASCO Breast Cancer Education Committee meeting, is a member of the Alliance<br />
& is a founding member of the Breast Cancer Research Consortium where she co-leads the triple negative<br />
working group. She is on the novel agents committee for the neoadjuvant multi-center I SPY2 trial. At <strong>UCSF</strong>,<br />
Dr. Rugo runs the Breast Forum, a bimonthly educational session for breast cancer patients, families & friends<br />
from throughout the bay area.<br />
http://cancer.ucsf.edu/people/profiles/rugo_hope.3648<br />
*<strong>UCSF</strong> authors in bold<br />
64
Presentations<br />
The Heart of the Matter<br />
Authors*: Pamela N. Munster<br />
Abstract #:<br />
Presentation Date/Time: Sunday, June 5: 5:21 - 5:33 PM<br />
Location: Hall D2<br />
Poster Discussion Session: Breast Cancer - Triple-Negative/Cytotoxics/Local Therapy<br />
Citation:<br />
Munster Research Interests: My clinical research interests are first-in-human early phase clinical trials of<br />
novel compounds and alternative strategies for the treatment and prevention of cancer. I have been involved<br />
in clinical and translational research in early phase clinical trials since 1998. As the program leader for<br />
Development Therapeutics and the PI of a peer-reviewed basic science lab, my main focus is on translating<br />
preclinical findings into early-stage clinical trials with extensive PK and integration of PD correlative studies<br />
and molecular imaging for patients with advanced stage cancer. My basic research interest is centered on<br />
the role of epigenetic modification in therapy resistance in breast cancer and epigenetic priming. In addition<br />
to studying basic mechanisms of hormone therapy resistance, we have shown that epigenetic modification<br />
plays a crucial role in the hormonal regulation and carcinogenesis of breast cancer.<br />
http://cancer.ucsf.edu/people/profiles/munster_pamela.3449<br />
*<strong>UCSF</strong> authors in bold<br />
65
Presentations<br />
Phase III randomized study of sorafenib plus doxorubicin versus<br />
sorafenib in patients with advanced hepatocellular carcinoma (HCC):<br />
CALGB 80802 (Alliance).<br />
Authors*: Ghassan K. Abou-Alfa, Donna Niedzwieski, Jennifer J. Knox, Andreas Kaubisch, James Posey,<br />
Benjamin R. Tan, Petr Kavan, Rakesh Goel, Philip Edward Lammers, Tanios S. Bekaii-Saab,<br />
Vincent Channing Tam, Lakshmi Rajdev, Robin Kate Kelley, Abby B. Siegel, Jennifer Balletti,<br />
James J. Harding, Lawrence Howard Schwartz, Richard M. Goldberg, Monica M. Bertagnolli, Alan P. Venook<br />
Abstract #: 4003<br />
Presentation Date/Time: Monday, June 6: 8:00 - 11:00 AM<br />
Location: Hall B1<br />
Session: Gastrointestinal (Noncolorectal) Cancer<br />
Citation: J Clin Oncol 34, 2016 (suppl; abstr 4003)<br />
Venook Research Interests: Dr. Alan Venook is a nationally renowned expert in colorectal and liver cancers at<br />
the <strong>UCSF</strong> Helen Diller Family Comprehensive Cancer Center. He is highly regarded for his expertise in the<br />
effective use of the newest approaches and therapies to the treatment of colorectal cancer, as well treating<br />
primary and metastatic tumors to the liver. Dr. Venook has chaired and/or authored six major studies within<br />
the cooperative groups and he now Chairs the GI Committee of the Alliance for Clinical Trials in Oncology<br />
(formerly CALGB.)<br />
http://cancer.ucsf.edu/people/profiles/venook_alan.3698<br />
*<strong>UCSF</strong> authors in bold<br />
66
Presentations<br />
4-year results of the ponatinib phase II PACE trial in patients (pts)<br />
with heavily pretreated leukemia.<br />
Authors*: Jorge E. Cortes, Javier Pinilla-Ibarz, Philipp D. Le Coutre, Ronald Paquette, Charles Chuah,<br />
Franck E. Nicolini, Jane Apperley, Hanna Jean Khoury, Moshe Talpaz, Michele Baccarani, Stephanie Lustgarten,<br />
Frank G. Haluska, Francois Guilhot, Michael W.N. Deininger, Andreas Hochhaus, Timothy P Hughes,<br />
Neil P. Shah, Hagop M. Kantarjian<br />
Abstract #: 7013<br />
Presentation Date/Time: Monday, June 6: 8:00 - 11:30 Am<br />
Location: Hall A, Poster Board #5<br />
Session: Hematologic Malignancies - Leukemia, Myelodysplastic Syndromes, and Allotransplant<br />
Citation: J Clin Oncol 34, 2016 (suppl; abstr 7013)<br />
Shah Research Interests: The Shah lab is interested in advancing targeted therapeutics for hematologic<br />
malignancies through basic studies of in vitro and in vivo model systems to gain a better understanding of<br />
the critical vulnerabilities of malignant cells, and through translational/clinical studies of samples obtained<br />
from patients participating in early phase monotherapy clinical studies to identify, validate and override<br />
mechanisms of resistance to these agents.<br />
http://shah.ucsf.edu/<br />
*<strong>UCSF</strong> authors in bold<br />
67
Presentations<br />
Pharmacokinetics and pharmacodynamics of gliteritinib in patients<br />
with relapsed or refractory acute myeloid leukemia.<br />
Authors*: Catherine Choy Smith, Mark J. Levis, Mark Robert Litzow, Alexander E. Perl, Jessica K. Altman,<br />
Stan Gill, Geoffrey Yuen, Peter Bonate, Takeshi Kadokura, Angela Joubert James, Charles Liu, Itsuro Nagase,<br />
Ogert Fisniku, Erkut Bahceci<br />
Abstract #: 7026<br />
Presentation Date/Time: Monday, June 6: 8:00 - 11:30 AM<br />
Location: Hall A, Poster Board #18<br />
Poster Session - Hematologic Malignancies - Leukemia, Myelodysplastic Syndromes, and Allotransplant.<br />
Citation: J Clin Oncol 34, 2016 (suppl; abstr 7026)<br />
Smith Research Interests: Our laboratory focuses on identification of therapeutic resistance mechanisms<br />
and novel treatment strategies for acute myeloid leukemia (AML), particularly AML associated with mutations<br />
in Fms-like Tyrosine Kinase-3 (FLT3). FLT3 is the most frequently mutated gene in AML, with constitutively<br />
activating FLT3 internal tandem duplication (ITD) mutations conferring a poor prognosis. We employ<br />
a prototypical “bedside to bench and back” approach to the problem of cancer drug resistance, founded on<br />
the belief that the ultimate pathway to improved cancer therapy begins with translational studies that utilize<br />
samples from patients who have undergone therapy in real time. This strategy allows us to interrogate how<br />
tumors can evolve under the selective pressure of cancer therapy and allows us to devise ways to circumvent<br />
these evolutionary adaptations.<br />
http://cancer.ucsf.edu/people/profiles/smith_catherine.3369<br />
*<strong>UCSF</strong> authors in bold<br />
68
Presentations<br />
Impact of landmark responses on 3-year (yr) outcomes with ponatinib<br />
in heavily pretreated CP-CML patients (pts).<br />
Authors*: Martin C. Müller, Michele Baccarani, Michael W.N. Deininger, Francois Guilhot, Andreas Hochhaus,<br />
Timothy P. Hughes, Neil P. Shah, Moshe Talpaz, Stephanie Lustgarten, Victor M Rivera, Timothy Piers Clackson,<br />
Frank G. Haluska, Jorge E. Cortes<br />
Abstract #: 7053<br />
Presentation Date/Time: Monday, June 6: 8:00 - 11:30 AM<br />
Location: Hall A, Poster Board #45<br />
Session: Hematologic Malignancies - Leukemia, Myelodysplastic Syndromes, and Allotransplant<br />
Citation: J Clin Oncol 34, 2016 (suppl; abstr 7053)<br />
Shah Research Interests: The Shah lab is interested in advancing targeted therapeutics for hematologic<br />
malignancies through basic studies of in vitro and in vivo model systems to gain a better understanding of<br />
the critical vulnerabilities of malignant cells, and through translational/clinical studies of samples obtained<br />
from patients participating in early phase monotherapy clinical studies to identify, validate and override<br />
mechanisms of resistance to these agents.<br />
http://shah.ucsf.edu/<br />
*<strong>UCSF</strong> authors in bold<br />
69
Presentations<br />
Early molecular response in patients (pts) with chronic myeloid<br />
leukemia in chronic phase (CML-CP) treated with dasatinib (DAS) or<br />
imatinib (IM) from DASISION.<br />
Authors*: Neil P. Shah, Giuseppe Saglio, Andreas Hochhaus, Robyn Bilmes, Li Li, Jorge E. Cortes<br />
Abstract #: 7055<br />
Presentation Date/Time: Monday, June 6: 8:00 - 11:30 AM<br />
Location: Hall A, poster Board #47<br />
Poster Session - Hematologic Malignancies - Leukemia, Myelodysplastic Syndromes, and Allotransplant.<br />
Citation: J Clin Oncol 34, 2016 (suppl; abstr 7055)<br />
Shah Research Interests: The Shah lab is interested in advancing targeted therapeutics for hematologic<br />
malignancies through basic studies of in vitro and in vivo model systems to gain a better understanding of<br />
the critical vulnerabilities of malignant cells, and through translational/clinical studies of samples obtained<br />
from patients participating in early phase monotherapy clinical studies to identify, validate and override<br />
mechanisms of resistance to these agents.<br />
http://shah.ucsf.edu/<br />
__________________________________________________________________________<br />
Clinical, biologic, and outcome differences according to MIBG avidity<br />
in children with neuroblastoma: A report from the Children’s Oncology<br />
Group (COG).<br />
Authors*: Steven G. DuBois, Rajen Mody, Collin Van Ryn, Arlene Naranjo, Susan G. Kreissman, David Baker,<br />
Marguerite T Parisi, Barry L. Shulkin, John M. Maris, Vandana Batra, Julie R. Park, Katherine K. Matthay,<br />
Gregory A Yanik<br />
Abstract #: 10526<br />
Presentation Date/Time: Monday, June 6: 8:00 - 11:30 AM<br />
Location: Hall A, Poster Board #217<br />
Session: Pediatric Oncology I<br />
Citation: J Clin Oncol 34, 2016 (suppl; abstr 10526)<br />
*<strong>UCSF</strong> authors in bold<br />
70
Presentations<br />
Phase II study of alisertib, irinotecan, and temozolomide in children<br />
with relapsed and refractory neuroblastoma: A report from the New<br />
Approaches to Neuroblastoma Therapy (NANT) consortium.<br />
Authors*: Steven G. DuBois, Araz Marachelian, Elizabeth Fox, Rachel A. Kudgus, Joel M. Reid,<br />
Susan G. Groshen, Jemily Malvar, Rochelle Bagatell, Lars M. Wagner, John M. Maris, Randall Hawkins,<br />
Jesse Courtier, Hollie Lai, Fariba Goodarzian, Hiroyuki Shimada, Najee Boucher, Scarlett Czarnecki,<br />
Denice D Tsao-Wei, Katherine K. Matthay, Yael P. Mosse<br />
Abstract #: 10556<br />
Presentation Date/Time: Monday, June 6: 8:00 - 11:30 AM<br />
Location: Hall A, Poster Board #247<br />
Poster Session: Pediatric Oncology<br />
Citation: J Clin Oncol 34, 2016 (suppl; abstr 10556)<br />
__________________________________________________________________________<br />
Women informed to screen depending on measures of risk (WISDOM):<br />
A RCT of personalized vs. annual screening for breast cancer.<br />
Authors*: Sarah Rosenberg-Wohl, Martin Eklund, Jeffrey Tice, Elad Ziv, Celia Kaplan, Laura Van’t Veer,<br />
Andrea LaCroix, Lisa Madlensky, Arash Naeim, Neil Wenger, Alexander D. Borowsky, Joshua Fenton,<br />
Hoda Anton-Culver, Michael Hogarth, Thomas Cink, Susie Brain, Diane Heditsian, Vivian Lee,<br />
Allison S Fiscalini, Laura Esserman<br />
Abstract #: TPS1594<br />
Presentation Date/Time: Monday, June 6: 8:00 - 11:30 AM<br />
Location: Hall A, Poster Board #417<br />
Poster Session: Cancer Prevention, Genetics, and Epidemiology<br />
Citation: J Clin Oncol 34, 2016 (suppl; abstr TPS1594)<br />
Esserman Research Interests: Dr. Esserman, surgeon & breast cancer oncology specialist, is the Carol Franc<br />
Buck Breast Care Center Director and co-leads the Breast Oncology Program. Her research is on improving<br />
healthcare value through integrating translational science, clinical informatics, systems re-engineering<br />
& clinical care delivery. In 2005, she received the NCI SPORE Investigator of the Year Award. In 2016 she<br />
received the Arbuckle Award from Stanford Graduate School of Business for Excellence in Management &<br />
was named to TIME’s 100 most influential people list. She is PI of the I-SPY TRIAL program, now a model for<br />
translational research & innovation in clinical trial design. She launched the Athena Breast Health Network to<br />
follow women from screening through treatment & outcomes, incorporating the latest in molecular testing &<br />
web-based tools. Athena just launched the WISDOM study to compare personalized vs annual breast cancer<br />
screening in 100,000 women and to predict who gets what kind of cancer.<br />
http://profiles.ucsf.edu/laura.esserman<br />
*<strong>UCSF</strong> authors in bold<br />
71
Presentations<br />
Phase I trial of dual TOR kinase and DNA-PK inhibitor (CC-115) in<br />
advanced solid and hematologic cancers.<br />
Authors*: Pamela N. Munster, Amit Mahipal, John J. Nemunaitis, Monica M. Mita, Luis G. Paz-Ares,<br />
Christophe Massard, Tom Mikkelsen, Cristina Cruz, Dana E. Rathkopf, George R. Blumenschein,<br />
Manuel Hidalgo, David C. Smith, Barbara Eichhorst, Timothy Francis Cloughesy, Brett Garrick,<br />
Torsten Trowe, Ellen Filvaroff, Kristen Hege, Johanna C. Bendell<br />
Abstract #: 2505<br />
Presentation Date/Time: Monday, June 6: 8:00 – 11:00AM<br />
Location: E354b<br />
Oral Abstract Session: Developmental Therapeutics -<br />
Clinical Pharmacology and Experimental Therapeutics<br />
Citation: J Clin Oncol 34, 2016 (suppl; abstr 2505)<br />
Munster Research Interests: My clinical research interests are first-in-human early phase clinical trials of<br />
novel compounds and alternative strategies for the treatment and prevention of cancer. I have been involved<br />
in clinical and translational research in early phase clinical trials since 1998. As the program leader for<br />
Development Therapeutics and the PI of a peer-reviewed basic science lab, my main focus is on translating<br />
preclinical findings into early-stage clinical trials with extensive PK and integration of PD correlative studies<br />
and molecular imaging for patients with advanced stage cancer. My basic research interest is centered on<br />
the role of epigenetic modification in therapy resistance in breast cancer and epigenetic priming. In addition<br />
to studying basic mechanisms of hormone therapy resistance, we have shown that epigenetic modification<br />
plays a crucial role in the hormonal regulation and carcinogenesis of breast cancer.<br />
http://cancer.ucsf.edu/people/profiles/munster_pamela.3449<br />
__________________________________________________________________________<br />
FGFR pathway genetic aberrations in cholangiocarcinoma:<br />
Demographics and experience with targeted therapy.<br />
Authors*: Apurva Jain, Rachna T. Shroff, Robin Kate Kelley, Ahmed Omar Kaseb, Ying Wang,<br />
Reham Abdel-Wahab, Daniel H. Ahn, Andrea Grace Bocobo, Funda Meric-Bernstam, Randi Isaacs,<br />
Tanios S. Bekaii-Saab, Milind M. Javle<br />
Abstract #: 109<br />
Presentation Date/Time: Monday, June 6: 9:45 - 11:15 AM<br />
Location: Hall D1<br />
Session: Actionable Mutations Redefined<br />
Citation: J Clin Oncol 34, 2016 (suppl; abstr 109)<br />
*<strong>UCSF</strong> authors in bold<br />
72
Presentations<br />
Can lay health workers achieve the triple aim? Results from the<br />
Engagement of Patients with Advanced Cancer (EPAC) trial.<br />
Authors*: Manali I. Patel, VJ Periyakoil, Kate Bundorf, David Thom, Arnold Milstein, Steven M Asch, James Kahn<br />
Abstract #: 6507<br />
Presentation Date/Time: Monday, June 6: 9:45 AM - 12:45 PM<br />
Location: S100a<br />
Session: Health Services Research and Quality of Care<br />
Citation: J Clin Oncol 34, 2016 (suppl; abstr 6507)<br />
__________________________________________________________________________<br />
Phase I investigation of lenalidomide plus rituximab and outcomes of<br />
lenalidomide maintenance in recurrent CNS lymphoma.<br />
Authors*: James L. Rubenstein, Eleanor Fraser, Paul Formaker, James Chi-Chiang Lee, Nianhang Chen,<br />
Mallory Kock, Wesley Cheung, Xiaomin Wang, Pamela N. Munster, Bertil Damato<br />
Abstract #: 7502<br />
Presentation Date/Time: Sunday, June 5: 9:45 AM - 12:45 PM<br />
Location: E354b<br />
Oral Abstract Session: Hematologic Malignancies - Lymphoma and Chronic Lymphocytic Leukemia<br />
Citation: J Clin Oncol 34, 2016 (suppl; abstr 7502)<br />
Rubenstein Research Interests: Our goals are to develop innovative therapies that are based upon the<br />
biological properties of cancer, that have both enhanced efficacy as well as less toxicity compared to<br />
established interventions. Our major interests are: 1) identification of genetic factors associated with<br />
therapeutic resistance; 2) molecular basis of tumor cell tropism within the brain; 3) elucidation of the tumor<br />
immune microenvironment. We are simultaneously engaged in leading phase I and II trials , in correlative<br />
studies involving novel immunotherapeutic strategies, in the development of novel preclinical models that<br />
facilitate both insights into disease mechanisms as well as the testing of novel therapeutic strategies.<br />
https://bms.ucsf.edu/directory/faculty/james-rubenstein-md-phd<br />
*<strong>UCSF</strong> authors in bold<br />
73
Presentations<br />
Abexinostat (ABX) as a means to reverse pazopanib (PAZ) resistance:<br />
A phase 1 study in advanced solid tumor malignancies.<br />
Authors*: Rahul Raj Aggarwal, Scott Thomas, Jennifer A. Grabowsky, Armand Harb, Jim Leng,<br />
Anne Reinert, Ilaria Mastroserio, Thach-Giao Truong, Pamela N. Munster<br />
Abstract #: 2519<br />
Presentation Date/Time: Sunday, June 5: 11:30 AM - 12:45 PM<br />
Location: Arie Crown Theater<br />
Poster Disussion Session: Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics<br />
Citation: J Clin Oncol 34, 2016 (suppl; abstr 2519)<br />
Munster Research Interests: My clinical research interests are first-in-human early phase clinical trials of<br />
novel compounds and alternative strategies for the treatment and prevention of cancer. I have been involved<br />
in clinical and translational research in early phase clinical trials since 1998. As the program leader for<br />
Development Therapeutics and the PI of a peer-reviewed basic science lab, my main focus is on translating<br />
preclinical findings into early-stage clinical trials with extensive PK and integration of PD correlative studies<br />
and molecular imaging for patients with advanced stage cancer. My basic research interest is centered on<br />
the role of epigenetic modification in therapy resistance in breast cancer and epigenetic priming. In addition<br />
to studying basic mechanisms of hormone therapy resistance, we have shown that epigenetic modification<br />
plays a crucial role in the hormonal regulation and carcinogenesis of breast cancer.<br />
http://cancer.ucsf.edu/people/profiles/munster_pamela.3449<br />
__________________________________________________________________________<br />
Risk Reduction Through Lifestyle Modifications<br />
Authors*: Michelle E. Melisko<br />
Abstract #:<br />
Presentation Date/Time: Monday, June 6: 8:15 - 8:30 AM<br />
Location: S100a<br />
Education Session: Breast Cancer Survivorship: Strategies for Optimal Care<br />
Citation:<br />
*<strong>UCSF</strong> authors in bold<br />
74
Presentations<br />
Medical Management of Low-Grade Gliomas<br />
Authors*: Susan Marina Chang<br />
Abstract #:<br />
Presentation Date/Time: Monday, June 6: 11:50 AM - 12:10 PM<br />
Location: S404<br />
Education Session: Treatment of Low-Grade Gliomas in the Era of Genomic Medicine<br />
Citation:<br />
Chang Research Interests: My research interest is in the development of novel therapies for patients with brain<br />
tumors, as well as the assessment of novel imaging biomarkers in the management of patients. My research<br />
seeks to integrate advances in physiologic and metabolic imaging with tissue biomarkers in order to optimize<br />
the management of patients with glioblastoma (GBM). My clinical research evaluates a wide spectrum of<br />
therapeutic interventions that span chemotherapy, targeted agents, immunotherapy and convection enhanced<br />
delivery of novel agents. I am the site PI of an NIH-funded adult brain tumor consortium and am a member<br />
of the Brain Malignancy Steering Committee and the Developmental Therapeutics Study Section at the NIH. I<br />
am the program leader for the Neuro-Oncology Program at the HDFCCC. I am the clinical co-PI for the <strong>UCSF</strong><br />
Brain Tumor SPORE and a co-Leader of a SPORE Project evaluating the role of physiologic imaging in the<br />
determination of malignant progression of low-grade glioma.<br />
http://cancer.ucsf.edu/people/profiles/chang_susan.3565<br />
*<strong>UCSF</strong> authors in bold<br />
75
Presentations<br />
Programmed death-ligand 1 (PD-L1) characterization of circulating tumor<br />
cells (CTCs) in muscle invasive and metastatic bladder cancer patients.<br />
Authors*: Archana Anantharaman, Terence W. Friedlander, David Lu, Rachel Krupa, Gayatri Premasekharan,<br />
Jeffrey Hough, Matthew Edwards, Ryon Graf, Adam Jendrisak, Jessica Louw, Lyndsey Dugan,<br />
Dena C. Marrinucci, Ryan Vance Dittamore, Pamela Paris<br />
Abstract #: 4527<br />
Presentation Date/Time: Monday, June 6: 1:00 - 4:30 PM<br />
Location: Hall A, Poster Board # 150<br />
Poster Session: Genitourinary (Nonprostate) Cancer<br />
Citation: J Clin Oncol 34, 2016 (suppl; abstr 4527)<br />
Paris Research Interests: My background is in biophysical chemistry. My research focuses on biomarker<br />
discovery. As a <strong>UCSF</strong> Prostate SPORE program Research Fellow, I discovered a DNA-based biomarker set to<br />
assess risk of recurrence after primary treatment. My landmark paper in the American Journal of Pathology<br />
set the stage for the use of formalin-fixed paraffin-embedded (FFPE) prostate cancer tissue with microarrays<br />
for copy-number assessment. I was the first to demonstrate FFPE prostate biopsy tissue could be profiled on<br />
high-resolution microarrays. As Professor, I work as a translational researcher in prostate cancer, both in solid<br />
tumor and circulating biomarkers. I helped move the circulating tumor cell (CTC) field beyond enumeration<br />
and was the first to genomically profile prostate cancer CTCs. Recently, I have applied similar approaches to<br />
identify clinically relevant bladder cancer biomarkers. My research goal is to identify predictive and prognostic<br />
biomarkers to aid in clinical cancer decision-making.<br />
http://urology.ucsf.edu/research/cancer/cancer-research-programs/paris-laboratory<br />
*<strong>UCSF</strong> authors in bold<br />
76
Presentations<br />
Prospective evaluation of circulating cell-free DNA sequencing in<br />
patients with metastatic renal cell carcinoma treated with pazopanib<br />
plus abexinostat.<br />
Authors*: Jim Leng, Armand Harb, Kamran Abri, Ilaria Mastroserio, Anne Reinert, Jennifer A. Grabowsky,<br />
Charles J. Ryan, Terence W. Friedlander, Amy M. Lin, Richard Burnham Lanman, Kimberly C. Banks,<br />
Rahul Raj Aggarwal, Pamela N. Munster<br />
Abstract #: 4551<br />
Presentation Date/Time: Monday, June 6: 1:00 - 4:30 PM<br />
Location: Hall A, Poster Board #173<br />
Poster Session: Genitourinary (Nonprostate) Cancer<br />
Citation: J Clin Oncol 34, 2016 (suppl; abstr 4551)<br />
Munster Research Interests: My clinical research interests are first-in-human early phase clinical trials of<br />
novel compounds and alternative strategies for the treatment and prevention of cancer. I have been involved<br />
in clinical and translational research in early phase clinical trials since 1998. As the program leader for<br />
Development Therapeutics and the PI of a peer-reviewed basic science lab, my main focus is on translating<br />
preclinical findings into early-stage clinical trials with extensive PK and integration of PD correlative studies<br />
and molecular imaging for patients with advanced stage cancer. My basic research interest is centered on the<br />
role of epigenetic modification in therapy resistance in breast cancer and epigenetic priming. In addition to<br />
studying basic mechanisms of hormone therapy resistance, we have shown that epigenetic modification plays<br />
a crucial role in the hormonal regulation and carcinogenesis of breast cancer.<br />
http://cancer.ucsf.edu/people/profiles/munster_pamela.3449<br />
*<strong>UCSF</strong> authors in bold<br />
77
Presentations<br />
Phase 1 study of CB-839, a small molecule inhibitor of glutaminase<br />
(GLS), alone and in combination with everolimus (E) in patients (pts)<br />
with renal cell cancer (RCC).<br />
Authors*: Funda Meric-Bernstam, Nizar M. Tannir, James Walter Mier, Angela DeMichele, Melinda L. Telli,<br />
Alice C. Fan, Pamela N. Munster, Richard D. Carvajal, Keith W. Orford, Mark K. Bennett, Othon Iliopoulos,<br />
Taofeek Kunle Owonikoko, Manish R. Patel, Rana McKay, Jeffrey R. Infante, Martin Henner Voss,<br />
James J. Harding<br />
Abstract #: 4568<br />
Presentation Date/Time: Monday, June 6: 1:00 - 4:30 PM<br />
Location: Hall A, Poster Board #190<br />
Poster Session: Genitourinary (Nonprostate) Cancer<br />
Citation: J Clin Oncol 34, 2016 (suppl; abstr 4568)<br />
Munster Research Interests: My clinical research interests are first-in-human early phase clinical trials of<br />
novel compounds and alternative strategies for the treatment and prevention of cancer. I have been involved<br />
in clinical and translational research in early phase clinical trials since 1998. As the program leader for<br />
Development Therapeutics and the PI of a peer-reviewed basic science lab, my main focus is on translating<br />
preclinical findings into early-stage clinical trials with extensive PK and integration of PD correlative studies<br />
and molecular imaging for patients with advanced stage cancer. My basic research interest is centered on<br />
the role of epigenetic modification in therapy resistance in breast cancer and epigenetic priming. In addition<br />
to studying basic mechanisms of hormone therapy resistance, we have shown that epigenetic modification<br />
plays a crucial role in the hormonal regulation and carcinogenesis of breast cancer.<br />
http://cancer.ucsf.edu/people/profiles/munster_pamela.3449<br />
__________________________________________________________________________<br />
ADXS11-001 immunotherapy in squamous or non-squamous<br />
persistent/recurrent metastatic cervical cancer: Results from<br />
stage I of the phase II GOG/NRG0265 study.<br />
Authors*: Warner King Huh, Don S. Dizon, Matthew A. Powell, Charles A. Leath, Lisa Michelle Landrum,<br />
Edward Tanner, Robert Higgins, Stefanie M. Ueda, Michael T. McHale, Bradley J. Monk, Carol Aghajanian<br />
Abstract #: 5516<br />
Presentation Date/Time: Monday, June 6: 1:00 - 4:30 PM<br />
Location: Hall A, Poster Board #339<br />
Session: Gynecologic Cancer<br />
Citation: J Clin Oncol 34, 2016 (suppl; abstr 5516)<br />
*<strong>UCSF</strong> authors in bold<br />
78
Presentations<br />
A phase II randomized, double-blind trial of a polyvalent vaccine-KLH<br />
conjugate (NSC 748933 IND# 14384) + OPT-821 versus OPT-821 in<br />
patients with epithelial ovarian (EOC), fallopian tube, or peritoneal<br />
cancer who are in second or third complete remission.<br />
Authors*: Paul Sabbatini, Lee-may Chen, Joseph A. Lucci, Kian Behbakht, Nicola M. Spirtos, Carolyn Muller,<br />
Benedict B. Benigno, Matthew A. Powell, Emily Berry, Krishnansu Sujata Tewari, Parviz Hanjani, Wei Deng,<br />
Heather A. Lankes, Carol Aghajanian<br />
Abstract #: 5517<br />
Presentation Date/Time: Monday, June 6: 1:00 - 4:30 PM<br />
Location: Hall A, Poster Board #340<br />
Session: Gynecologic Cancer<br />
Citation: J Clin Oncol 34, 2016 (suppl; abstr 5517)<br />
__________________________________________________________________________<br />
Pembrolizumab in advanced endometrial cancer: Preliminary results<br />
from the phase Ib KEYNOTE-028 study.<br />
Authors*: Patrick Alexander Ott, Yung-Jue Bang, Dominique Berton-Rigaud, Elena Elez, Michael J. Pishvaian,<br />
Hope S. Rugo, Igor Puzanov, Mark Aloysuis Morgan, Janice M. Mehnert, Kyaw Lwin Aung, Marion Carrigan,<br />
Sanatan Saraf, Mei Chen, Jean-Charles Soria<br />
Abstract #: 5581<br />
Presentation Date/Time: Monday, June 6: 1:00 - 4:30 PM<br />
Location: Hall A, Poster Board #404<br />
Session: Gynecologic Cancer<br />
Citation: J Clin Oncol 34, 2016 (suppl; abstr 5581)<br />
Rugo Research Interests: Dr. Rugo, Director of Breast Oncology & Clinical Trials Education, is PI on multiple<br />
clinical trials focusing on combining novel targeted therapeutics to improve the treatment of both early & late<br />
stage breast cancer (BC). She also works on studies to improve supportive care for early & late stage BC<br />
patients, including with <strong>UCSF</strong>s Advanced Breast Cancer Program. Dr. Rugo has numerous collaborations with<br />
large academic medical centers & consortia in order to expand the novel therapies available to patients. She<br />
was the director of the 2016 ASCO Breast Cancer Education Committee meeting, is a member of the Alliance<br />
& is a founding member of the Breast Cancer Research Consortium where she co-leads the triple negative<br />
working group. She is on the novel agents committee for the neoadjuvant multi-center I SPY2 trial. At <strong>UCSF</strong>,<br />
Dr. Rugo runs the Breast Forum, a bimonthly educational session for breast cancer patients, families & friends<br />
from throughout the bay area.<br />
http://cancer.ucsf.edu/people/profiles/rugo_hope.3648<br />
*<strong>UCSF</strong> authors in bold<br />
79
Presentations<br />
Impact of age and comorbidity on treatment of non-small cell lung<br />
cancer (NSCLC) recurrence (AFT-03).<br />
Authors*: Melisa L. Wong, Timothy L. McMurry, George J. Stukenborg, Amanda B. Francescatti,<br />
Jessica R. Schumacher, Louise C. Walter, Benjamin D. Kozower<br />
Abstract #: 10037<br />
Presentation Date/Time: Monday, June 6: 1:00 - 4:30 PM<br />
Location: Hall A, Poster Board #25<br />
Poster Session: Patient and Survivor Care<br />
Citation: J Clin Oncol 34, 2016 (suppl; abstr 10037)<br />
Walter Research Interests: Dr. Walter is a clinician-researcher who is a national leader in evaluating the<br />
real-world risks and benefits of cancer screening in older patients. Dr. Walter joined the <strong>UCSF</strong> faculty<br />
in July 2001, and she is a geriatrician at the San Francisco VA Medical Center. She has developed novel<br />
methodology demonstrating the fundamental importance of life expectancy rather than age in determining<br />
benefits and risks of screening. Virtually every cancer screening guideline cites her research. In addition,<br />
Dr. Walter led a series of seminal studies demonstrating decisions to screen older adults for cancer are often<br />
dictated more by age than health such that many patients in poor health continue to undergo screening<br />
while many healthy older patients fail to get screened. Also, she discovered that cancer screening frequently<br />
leads to significant harms without benefit in patients in poor health and developed a taxonomy and<br />
quantification of screening harms.<br />
http://cancer.ucsf.edu/people/profiles/walter_louise.3728<br />
*<strong>UCSF</strong> authors in bold<br />
80
Presentations<br />
Early, molecular detection of cancer utilizing circulating cell-free DNA<br />
assay with ultra high accuracy and sensitivity.<br />
Authors*: Stefanie Mortimer, Katharine Dilger, Diana Abdueva, Darya Chudova, Ankit Sarin,<br />
Chloe Evelyn Atreya, Jim Leng, Jeeyun Lee, Helmy Eltoukhy, Pamela N. Munster, AmirAli Talasaz<br />
Abstract #: 11540<br />
Presentation Date/Time: Monday, June 6: 1:00 - 4:30 PM<br />
Location: Hall A, Poster Board #237<br />
Poster Session: Tumor Biology<br />
Citation: J Clin Oncol 34, 2016 (suppl; abstr 11540)<br />
__________________________________________________________________________<br />
Development and safety of a novel, irreversibly-binding PSMAtargeted<br />
prostate cancer radiodiagnostic.<br />
Authors*: Elizabeth Whalley, Clifford Berkman, Henry Vanbrocklin, Beatrice Langton-Webster<br />
Abstract #: 11568<br />
Presentation Date/Time: Monday, June 6: 1:00 - 4:30 PM<br />
Location: Hall A, Poster Board #265<br />
Session: Tumor Biology<br />
Citation: J Clin Oncol 34, 2016 (suppl; abstr 11568)<br />
VanBrocklin Research Interests: The VanBrocklin laboratory focuses on developing nuclear imaging<br />
agents targeting cell surface proteins (receptors, enzymes and transporters) and signalling pathways and<br />
mechanisms by PET and SPECT imaging. We have developed imaging agents covering a broad range of<br />
molecular motifs from small molecules, antibodies, antibody fragments (e.g., Fabs, scFv, and diabodies),<br />
and aptamers, to proteins and peptides. We synthesize, evaluate and validate tracer mechanisms of<br />
localization and retention at the target site. We utilize in vitro and in vivo model systems to test the probes<br />
and interpret the data collected from these systems to determine their utility for research or as a future<br />
diagnostic. We have successfully translated many of these tracers into humans for drug development or<br />
evaluation as future diagnostics.<br />
http://cancer.ucsf.edu/people/profiles/vanbrocklin_henry.3696<br />
*<strong>UCSF</strong> authors in bold<br />
81
Presentations<br />
Correlation between local 18F-fluorodeoxyglucose PET/CT and<br />
T-cell exhaustion for predicting treatment response in patients with<br />
advanced melanoma treated with checkpoint inhibitor mono-therapy.<br />
Authors*: Miguel Hernandez Pampaloni, Lorenzo Nardo, Alain Patrick Algazi, Katy K. Tsai, Kimberly<br />
Loo, Luca Facchetti, Susana Ortiz-Urda, Adil Daud<br />
Abstract #: 11572<br />
Presentation Date/Time: Monday, June 6: 1:00 - 4:30 PM<br />
Location: Hall A, Poster Board # 269<br />
Poster Session: Tumor Biology<br />
Citation: J Clin Oncol 34, 2016 (suppl; abstr 11572)<br />
Daud Research Interests: Our group at <strong>UCSF</strong> is focused on developing new immunotherapy agents and<br />
specifically understanding the biology of the immune response to PD-1 in melanoma. We developed IL-<br />
12 gene therapy in melanoma and carried out the first in human clinical trial in 2005-2007. Based on this<br />
work, IL-12 electroporation is being explored in many cancers as an immune agent and as a combination<br />
treatment with PD-1 and other checkpoint inhibitors in melanoma. I have been involved in the development<br />
of anti-PD-1 antibodies for melanoma. With my colleagues Michael Rosenblum and Max Krummel at<br />
<strong>UCSF</strong>, we have developed a novel assay that profiles the intra-tumoral microenvironment in depth and can<br />
predict non-response to PD-1. We are currently exploring novel strategies for PD-1 non-responsive subsets<br />
of melanoma (and potentially other cancers).<br />
http://cancer.ucsf.edu/people/profiles/daud_adil.3622<br />
__________________________________________________________________________<br />
CHK1 inhibition as a therapeutic approach in KRAS mutated and<br />
squamous cell carcinoma NSCLC patients.<br />
Authors*: Daniela Morales-Espinosa, Silvia García-Román, Miguel Angel Molina-Vila, Ana Gimenez Capitan,<br />
Jordi Bertran-Alamillo, Pedro Mendez, Santiago Viteri Ramirez, Niki Karachaliou, Rafael Rosell<br />
Abstract #: 11581<br />
Presentation Date/Time: Monday, June 6: 1:00 - 4:30 PM<br />
Location: Hall A, Poster Board #278<br />
Session: Tumor Biology<br />
Citation: J Clin Oncol 34, 2016 (suppl; abstr 11581)<br />
*<strong>UCSF</strong> authors in bold<br />
82
Presentations<br />
Metastatic melanoma, glioblastoma and high-grade extrapulmonary<br />
neuroendocrine carcinomas (NECs) as novel indications for<br />
rovalpituzumab tesirine: A delta-like protein 3 (DLL3)-targeted<br />
antibody-drug conjugate (ADC).<br />
Authors*: Stanford L. Peng, Laura Saunders, Sheila Bheddah, Sam Williams, Rahul Raj Aggarwal,<br />
Jill E. Shea, Eun Y Lee, Jiaoti Huang, Allison J Zemek, Teri A. Longacre, Douglas Wilmot Ball,<br />
Courtney L. Scaife, Barry Nelkin, Lowell Brian Anthony, Pamela L. Kunz, Eric Jay Small, Scott Dylla<br />
Abstract #: 11611<br />
Presentation Date/Time: Monday, June 6: 1:00 - 4:30 PM<br />
Location: Hall A, Poster Board #308<br />
Poster Session: Tumor Biology<br />
Citation: J Clin Oncol 34, 2016 (suppl; abstr 11611)<br />
Small Research Interests: The Stand Up To Cancer Dream Team led by Dr. Eric Small is exploring the idea<br />
that resistance to hormonal therapy occurs as a result of the prostate cancer cells using common cellular<br />
responses - what the Dream Team calls “adaptive pathways” - to escape the current prostate cancer<br />
therapies. They believe that, by identifying these pathways and inhibiting them, they will be able to overcome<br />
treatment resistance and profoundly improve the care of men affected by this fatal disease. This team is a six<br />
institution consortium to include UC Los Angeles, UC Davis, UC Santa Cruz, University of British Columbia,<br />
Oregon Health and Sciences University, with <strong>UCSF</strong> as the lead administrative site.<br />
http://cancer.ucsf.edu/people/profiles/small_eric.3671<br />
*<strong>UCSF</strong> authors in bold<br />
83
Presentations<br />
PALOMA-2: Primary results from a phase III trial of palbociclib (P) with<br />
letrozole (L) compared with letrozole alone in postmenopausal women<br />
with ER+/HER2– advanced breast cancer (ABC).<br />
Authors*: Richard S. Finn, Miguel Martin, Hope S. Rugo, Stephen E. Jones, Seock-Ah Im, Karen A. Gelmon,<br />
Nadia Harbeck, Oleg N. Lipatov, Janice Maria Walshe, Stacy L. Moulder, Eric Roland Gauthier, Dongrui (Ray) Lu,<br />
Sophia Randolph, Véronique Diéras, Dennis J. Slamon<br />
Abstract #: 507<br />
Presentation Date/Time: Monday, June 6: 1:15 - 4:15 PM<br />
Location: Hall D1<br />
Session: Breast Cancer - HER2/ER<br />
Citation: J Clin Oncol 34, 2016 (suppl; abstr 507)<br />
Rugo Research Interests: Dr. Rugo, Director of Breast Oncology & Clinical Trials Education, is PI on multiple<br />
clinical trials focusing on combining novel targeted therapeutics to improve the treatment of both early &<br />
late stage breast cancer (BC). She also works on studies to improve supportive care for early & late stage<br />
BC patients, including with <strong>UCSF</strong>s Advanced Breast Cancer Program. Dr. Rugo has numerous collaborations<br />
with large academic medical centers & consortia in order to expand the novel therapies available to patients.<br />
She was the director of the 2016 ASCO Breast Cancer Education Committee meeting, is a member of the<br />
Alliance & is a founding member of the Breast Cancer Research Consortium where she co-leads the triple<br />
negative working group. She is on the novel agents committee for the neoadjuvant multi-center I SPY2<br />
trial. At <strong>UCSF</strong>, Dr. Rugo runs the Breast Forum, a bimonthly educational session for breast cancer patients,<br />
families & friends from throughout the bay area.<br />
http://cancer.ucsf.edu/people/profiles/rugo_hope.3648<br />
*<strong>UCSF</strong> authors in bold<br />
84
Presentations<br />
Three-year overall survival for patients with advanced melanoma<br />
treated with pembrolizumab in KEYNOTE-001.<br />
Authors*: Caroline Robert, Antoni Ribas, Omid Hamid, Adil Daud, Jedd D. Wolchok, Anthony M. Joshua,<br />
Wen-Jen Hwu, Jeffrey S. Weber, Tara C. Gangadhar, Richard Wayne Joseph, Roxana Stefania Dronca,<br />
Amita Patnaik, Hassane M. Zarour, Richard Kefford, Peter Hersey, Xiaoyun Li, Scott J. Diede,<br />
Scot Ebbinghaus, F. Stephen Hodi<br />
Abstract #: 9503<br />
Presentation Date/Time: Monday, June 6: 1:15 - 4:15 PM<br />
Location: Arie Crown Theater<br />
Session: Melanoma/Skin Cancers<br />
Citation: J Clin Oncol 34, 2016 (suppl; abstr 9503)<br />
Daud Research Interests: Our group at <strong>UCSF</strong> is focused on developing new immunotherapy agents and<br />
specifically understanding the biology of the immune response to PD-1 in melanoma. We developed IL-<br />
12 gene therapy in melanoma and carried out the first in human clinical trial in 2005-2007. Based on this<br />
work, IL-12 electroporation is being explored in many cancers as an immune agent and as a combination<br />
treatment with PD-1 and other checkpoint inhibitors in melanoma. I have been involved in the development<br />
of anti-PD-1 antibodies for melanoma. With my colleagues Michael Rosenblum and Max Krummel at<br />
<strong>UCSF</strong>, we have developed a novel assay that profiles the intra-tumoral microenvironment in depth and can<br />
predict non-response to PD-1. We are currently exploring novel strategies for PD-1 non-responsive subsets<br />
of melanoma (and potentially other cancers).<br />
http://cancer.ucsf.edu/people/profiles/daud_adil.3622<br />
*<strong>UCSF</strong> authors in bold<br />
85
Presentations<br />
Pembrolizumab versus ipilimumab for advanced melanoma: Final<br />
overall survival analysis of KEYNOTE-006.<br />
Authors*: Jacob Schachter, Antoni Ribas, Georgina V. Long, Ana Arance, Jean Jacques Grob, Laurent Mortier,<br />
Adil Daud, Matteo S. Carlino, Catriona M. McNeil, Michal Lotem, James M. G. Larkin, Paul Lorigan,<br />
Bart Neyns, Christian U. Blank, Teresa M. Petrella, Omid Hamid, Honghong Zhou, Scot Ebbinghaus,<br />
Nageatte Ibrahim, Caroline Robert<br />
Abstract #: 9504<br />
Presentation Date/Time: Monday, June 6: 1:15 - 4:15 PM<br />
Location: Arie Crown Theater<br />
Session: Melanoma/Skin Cancers<br />
Citation: J Clin Oncol 34, 2016 (suppl; abstr 9504)<br />
Daud Research Interests: Our group at <strong>UCSF</strong> is focused on developing new immunotherapy agents and<br />
specifically understanding the biology of the immune response to PD-1 in melanoma. We developed IL-<br />
12 gene therapy in melanoma and carried out the first in human clinical trial in 2005-2007. Based on this<br />
work, IL-12 electroporation is being explored in many cancers as an immune agent and as a combination<br />
treatment with PD-1 and other checkpoint inhibitors in melanoma. I have been involved in the development<br />
of anti-PD-1 antibodies for melanoma. With my colleagues Michael Rosenblum and Max Krummel at<br />
<strong>UCSF</strong>, we have developed a novel assay that profiles the intra-tumoral microenvironment in depth and can<br />
predict non-response to PD-1. We are currently exploring novel strategies for PD-1 non-responsive subsets<br />
of melanoma (and potentially other cancers).<br />
http://cancer.ucsf.edu/people/profiles/daud_adil.3622<br />
*<strong>UCSF</strong> authors in bold<br />
86
Presentations<br />
Heritage: A phase III safety and efficacy trial of the proposed<br />
trastuzumab biosimilar Myl-1401O versus herceptin.<br />
Authors*: Hope S. Rugo, Abhijit Barve, Cornelius F. Waller, Miguel Hernandez-Bronchud, Jay Herson,<br />
Jinyu Yuan, Alexey Manikhas, Igor Bondarenko, Guzel Mukhametshina, Gia Nemsadze, Joseph D. Parra,<br />
Maria Luisa T. Abesamis Tiambeng, Kakhaber Baramidze, Charuwan Akewanlop, Ihor Vynnychenko,<br />
Virote Sriuranpong, Gopichand Manillapalli, Sirshendu Ray, Eduardo Patricio Yanez Ruiz, Eduardo J. Pennella<br />
Abstract #: LBA503<br />
Presentation Date/Time: Monday, June 6: 2:15 - 2:27 PM<br />
Location: Hall D1<br />
Oral Abstract Session: Breast Cancer - HER2/ER<br />
Citation: J Clin Oncol 34, 2016 (suppl; abstr LBA503)<br />
Rugo Research Interests: Dr. Rugo, Director of Breast Oncology & Clinical Trials Education, is PI on multiple<br />
clinical trials focusing on combining novel targeted therapeutics to improve the treatment of both early &<br />
late stage breast cancer (BC). She also works on studies to improve supportive care for early & late stage<br />
BC patients, including with <strong>UCSF</strong>s Advanced Breast Cancer Program. Dr. Rugo has numerous collaborations<br />
with large academic medical centers & consortia in order to expand the novel therapies available to patients.<br />
She was the director of the 2016 ASCO Breast Cancer Education Committee meeting, is a member of the<br />
Alliance & is a founding member of the Breast Cancer Research Consortium where she co-leads the triple<br />
negative working group. She is on the novel agents committee for the neoadjuvant multi-center I SPY2<br />
trial. At <strong>UCSF</strong>, Dr. Rugo runs the Breast Forum, a bimonthly educational session for breast cancer patients,<br />
families & friends from throughout the bay area.<br />
http://cancer.ucsf.edu/people/profiles/rugo_hope.3648<br />
__________________________________________________________________________<br />
Efficacy and safety of programmed death receptor-1 (PD-1) blockade in<br />
metastatic uveal melanoma (UM).<br />
Authors*: Katy K. Tsai, Alexander Noor Shoushtari, Rodrigo Ramella Munhoz, Zeynep Eroglu, Josep M. Piulats,<br />
Patrick Alexander Ott, Douglas Buckner Johnson, Jimmy Hwang, Adil Daud, Jeffrey Alan Sosman,<br />
Richard D. Carvajal, Bartosz Chmielowski, Michael Andrew Postow, Jeffrey S. Weber, Ryan J. Sullivan,<br />
Alain Patrick Algazi<br />
Abstract #: 9507<br />
Presentation Date/Time: Monday, June 6: 1:15 – 4:15PM<br />
Location: Arie Crown Theater<br />
Oral Abstract Session: Melanoma/Skin Cancers<br />
Citation: J Clin Oncol 34, 2016 (suppl; abstr 9507)<br />
*<strong>UCSF</strong> authors in bold<br />
87
Presentations<br />
Beyond Hormone Therapy for Breast Cancer:<br />
Who Needs Targeted Agents?<br />
Authors*: Hope S. Rugo<br />
Abstract #:<br />
Presentation Date/Time: Monday, June 6: 4:45 - 5:05 PM<br />
Location: Hall D1<br />
Education Session: Targeted Therapies in Hormone Receptor-Positive Breast Cancer<br />
Citation:<br />
Rugo Research Interests: Dr. Rugo, Director of Breast Oncology & Clinical Trials Education, is PI on multiple<br />
clinical trials focusing on combining novel targeted therapeutics to improve the treatment of both early &<br />
late stage breast cancer (BC). She also works on studies to improve supportive care for early & late stage<br />
BC patients, including with <strong>UCSF</strong>s Advanced Breast Cancer Program. Dr. Rugo has numerous collaborations<br />
with large academic medical centers & consortia in order to expand the novel therapies available to patients.<br />
She was the director of the 2016 ASCO Breast Cancer Education Committee meeting, is a member of the<br />
Alliance & is a founding member of the Breast Cancer Research Consortium where she co-leads the triple<br />
negative working group. She is on the novel agents committee for the neoadjuvant multi-center I SPY2<br />
trial. At <strong>UCSF</strong>, Dr. Rugo runs the Breast Forum, a bimonthly educational session for breast cancer patients,<br />
families & friends from throughout the bay area.<br />
http://cancer.ucsf.edu/people/profiles/rugo_hope.3648<br />
__________________________________________________________________________<br />
Emerging Insights Into Molecular Profiling<br />
Authors*: Wolfgang Michael Korn<br />
Abstract #:<br />
Presentation Date/Time: Monday, June 6: 5:39 - 5:51 PM<br />
Location: S406<br />
Poster Discussion Session: Tumor Biology<br />
Citation:<br />
Korn Research Interests: Dr. Korn is a physician-scientist focused on the science and management of<br />
gastrointestinal cancers. Furthermore, he is the leader of the <strong>UCSF</strong> Molecular Oncology Initiative and<br />
founding Chair of the <strong>UCSF</strong> Molecular Tumor Board. He is principal investigator of clinical trials exploring<br />
new treatments for gastrointestinal cancers and conducts molecularly driven, disease-independent basket<br />
trials. His laboratory conducts research aimed at developing combination therapies for gastrointestinal<br />
cancers, based on the analysis of signal transduction and DNA repair pathways.<br />
http://cancer.ucsf.edu/gi/michael-korn<br />
*<strong>UCSF</strong> authors in bold<br />
88
Presentations<br />
Determining barriers to effective data sharing in cancer genomic<br />
sequencing initiatives: A Global Alliance for Genomics and Health<br />
(GA4GH) survey.<br />
Authors*: Jeremy Howard Lewin, Daniel J Vis, Emile E. Voest, Rachel Liao, Petra M Nederlof, Barbara A. Conley,<br />
David B. Solit, Christopher L. Corless, Paulo V Campregher, Vanessa Tyrell, George Chong, Michael Watson,<br />
Sun Young Rha, Tim Maughan, Mark Caulfield, Vladimir Lazar, Laura Esserman, Charles L. Sawyers,<br />
Lillian L. Siu, Mark Lawler<br />
Abstract #: 11502<br />
Presentation Date/Time: Tuesday, June 7: 8:00 - 11:00 AM<br />
Location: S100a<br />
Session: Tumor Biology<br />
Citation: J Clin Oncol 34, 2016 (suppl; abstr 11502)<br />
Esserman Research Interests: Dr. Esserman, surgeon & breast cancer oncology specialist, is the Carol Franc<br />
Buck Breast Care Center Director and co-leads the Breast Oncology Program. Her research is on improving<br />
healthcare value through integrating translational science, clinical informatics, systems re-engineering<br />
& clinical care delivery. In 2005, she received the NCI SPORE Investigator of the Year Award. In 2016 she<br />
received the Arbuckle Award from Stanford Graduate School of Business for Excellence in Management &<br />
was named to TIME’s 100 most influential people list. She is PI of the I-SPY TRIAL program, now a model for<br />
translational research & innovation in clinical trial design. She launched the Athena Breast Health Network to<br />
follow women from screening through treatment & outcomes, incorporating the latest in molecular testing &<br />
web-based tools. Athena just launched the WISDOM study to compare personalized vs annual breast cancer<br />
screening in 100,000 women and to predict who gets what kind of cancer.<br />
http://profiles.ucsf.edu/laura.esserman<br />
*<strong>UCSF</strong> authors in bold<br />
89
Presentations<br />
A phase Ib dose escalation trial of isatuximab (SAR650984, anti-CD38<br />
mAb) plus lenalidomide and dexamethasone (Len/Dex) in relapsed/<br />
refractory multiple myeloma (RRMM): Interim results from two new<br />
dose cohorts.<br />
Authors*: Ravi Vij, Nikoletta Lendvai, Thomas G. Martin, Rachid C. Baz, Frank Campana, Florent Mazuir,<br />
Eric Charpentier, Don M. Benson<br />
Abstract #: 8009<br />
Presentation Date/Time: Tuesday, June 7: 9:45 - 11:15 AM<br />
Location: E354b<br />
Session: Novel Combination Therapies in Myeloma<br />
Citation: J Clin Oncol 34, 2016 (suppl; abstr 8009)<br />
Martin Research Interests: A leading expert in hematology-oncology, Dr. Thomas Martin is the associate<br />
director of the Myeloma Institute and director of the Unrelated Donor Transplantation Program for adults at<br />
<strong>UCSF</strong> Medical Center. He is also clinical research director of hematologic malignancies, or blood cancers,<br />
at the <strong>UCSF</strong> Helen Diller Family Comprehensive Cancer Center. His research interests include developing<br />
treatments for myeloma and leukemia as well as expanding the use of bone marrow transplants. He has<br />
a special interest in umbilical cord blood transplants and is involved in efforts to improve the outcomes<br />
following unrelated donor transplants.<br />
http://cancer.ucsf.edu/research/multiple-myeloma/mmti/mmti_team#martin<br />
*<strong>UCSF</strong> authors in bold<br />
90
Presentations<br />
Controversies in Local Therapy: Surgery and Radiation<br />
Authors*: Laura Esserman<br />
Abstract #:<br />
Presentation Date/Time: Tuesday, June 7: 11:50 AM - 12:10 PM<br />
Location: S406<br />
Education Session: Less is More: A Multidisciplinary Conversation on Treatment Options<br />
Citation:<br />
Esserman Research Interests: Dr. Esserman, surgeon & breast cancer oncology specialist, is the Carol Franc<br />
Buck Breast Care Center Director and co-leads the Breast Oncology Program. Her research is on improving<br />
healthcare value through integrating translational science, clinical informatics, systems re-engineering<br />
& clinical care delivery. In 2005, she received the NCI SPORE Investigator of the Year Award. In 2016 she<br />
received the Arbuckle Award from Stanford Graduate School of Business for Excellence in Management &<br />
was named to TIME’s 100 most influential people list. She is PI of the I-SPY TRIAL program, now a model for<br />
translational research & innovation in clinical trial design. She launched the Athena Breast Health Network to<br />
follow women from screening through treatment & outcomes, incorporating the latest in molecular testing &<br />
web-based tools. Athena just launched the WISDOM study to compare personalized vs annual breast cancer<br />
screening in 100,000 women and to predict who gets what kind of cancer.<br />
http://profiles.ucsf.edu/laura.esserman<br />
*<strong>UCSF</strong> authors in bold<br />
91
Presentations<br />
ERASE: Elimination of recurring artifacts and stochastic errors: An<br />
NGS analysis approach and its application to liquid biopsy samples.<br />
Authors*: Nicholas Kamps-Hughes, Tony Tran, Reynolds Brobey, Robert J. Amato, Ajjai Shivaram Alva,<br />
Pamela Paris, Terence W. Friedlander, Gayatri Premasekharan, Cristian Ionescu-Zanetti<br />
Abstract #: e13002<br />
Presentation Date/Time: Publication Only<br />
Location: Publication Only<br />
Session: Publication Only<br />
Citation: J Clin Oncol 34, 2016 (suppl; abstr e13002)<br />
Paris Research Interests: My background is in biophysical chemistry. My research focuses on biomarker<br />
discovery. As a <strong>UCSF</strong> Prostate SPORE program Research Fellow, I discovered a DNA-based biomarker set to<br />
assess risk of recurrence after primary treatment. My landmark paper in the American Journal of Pathology<br />
set the stage for the use of formalin-fixed paraffin-embedded (FFPE) prostate cancer tissue with microarrays<br />
for copy-number assessment. I was the first to demonstrate FFPE prostate biopsy tissue could be profiled on<br />
high-resolution microarrays. As Professor, I work as a translational researcher in prostate cancer, both in solid<br />
tumor and circulating biomarkers. I helped move the circulating tumor cell (CTC) field beyond enumeration<br />
and was the first to genomically profile prostate cancer CTCs. Recently, I have applied similar approaches to<br />
identify clinically relevant bladder cancer biomarkers. My research goal is to identify predictive and prognostic<br />
biomarkers to aid in clinical cancer decision-making.<br />
http://urology.ucsf.edu/research/cancer/cancer-research-programs/paris-laboratory<br />
__________________________________________________________________________<br />
The WISDOM study pilot: Evaluating a preference-tolerant RCT of riskbased<br />
vs. annual breast cancer screening.<br />
Authors*: Sarah Theiner, Celia Kaplan, Setareh Sarrafan, Julissa Cabrera, Sarah Dilys Sawyer,<br />
April S Liang, Sarah Rosenberg-Wohl, Miya Frick, Emily Claire Wong, Jeffrey Tice, Elad Ziv,<br />
Alexander D. Borowsky, Hoda Anton-Culver, Arash Naeim, Andrea LaCroix, Thomas Cink, Laura Esserman,<br />
Laura Van’t Veer, Allison S Fiscalini<br />
Abstract #: e13035<br />
Presentation Date/Time: Publication Only<br />
Location: Publication Only<br />
Session: Publication Only<br />
Citation: J Clin Oncol 34, 2016 (suppl; abstr e13035)<br />
*<strong>UCSF</strong> authors in bold<br />
92
Presentations<br />
A pharmacodynamic study of pre-prostatectomy buparlisib in men<br />
with high-risk, localized prostate cancer.<br />
Authors*: Archana Anantharaman, Hao Gia Nguyen, Matthew R. Cooperberg, Maxwell V. Meng,<br />
Peter Carroll, Terence W. Friedlander, Li Zhang, Miles Thomas, Phillip G. Febbo, Felix Yi-Chung Feng,<br />
Charles J. Ryan, Won Kim<br />
Abstract #: e14110<br />
Presentation Date/Time: Publication Only<br />
Location: Publication Only<br />
Session: Publication Only<br />
Citation: J Clin Oncol 34, 2016 (suppl; abstr e14110)<br />
__________________________________________________________________________<br />
Second-line chemotherapy (CTx) outcomes in advanced biliary<br />
cancers (ABC): A retrospective multicenter analysis.<br />
Authors*: Laura Williams Goff, Maeve Aine Lowery, Emmet Jordan, Rui Wang, Andrea Grace Bocobo,<br />
Joanne F. Chou, Eileen Mary O’Reilly, James J. Harding, Nancy E. Kemeny, Marinela Capanu,<br />
Ann C. Griffin, Joseph P. McGuire, Alan P. Venook, Ghassan K. Abou-Alfa, Robin Kate Kelley<br />
Abstract #: e15636<br />
Presentation Date/Time: Publication Only<br />
Location: Publication Only<br />
Session: Publication Only<br />
Citation: J Clin Oncol 34, 2016 (suppl; abstr e15636)<br />
*<strong>UCSF</strong> authors in bold<br />
93
Presentations<br />
Next-generation sequencing (NGS) in an advanced hepatocellular<br />
carcinoma (HCC) cohort: Analysis of common mutations, clinical<br />
covariates, and overall survival (OS).<br />
Authors*: Robin Kate Kelley, Paige M. Bracci, John Dozier Gordan, Kimberley Evason, Nancy M. Joseph,<br />
Andrea Grace Bocobo, Blake K. Rosenthal, Hubert J. Stoppler, Halla Sayed Nimeiri, Alan P. Venook<br />
Abstract #: e15641<br />
Presentation Date/Time: Publication Only<br />
Location: Publication Only<br />
Session: Publication Only<br />
Citation: J Clin Oncol 34, 2016 (suppl; abstr e15641)<br />
Venook Research Interests: Dr. Alan Venook is a nationally renowned expert in colorectal and liver cancers<br />
at the <strong>UCSF</strong> Helen Diller Family Comprehensive Cancer Center. He is highly regarded for his expertise<br />
in the effective use of the newest approaches and therapies to the treatment of colorectal cancer, as well<br />
treating primary and metastatic tumors to the liver. Dr. Venook has chaired and/or authored six major<br />
studies within the cooperative groups and he now Chairs the GI Committee of the Alliance for Clinical Trials<br />
in Oncology (formerly CALGB.)<br />
http://cancer.ucsf.edu/people/profiles/venook_alan.3698<br />
*<strong>UCSF</strong> authors in bold<br />
94
Presentations<br />
Final results of a phase Ib dose-escalation study of PRI-724, a CBP/<br />
beta-catenin modulator, plus gemcitabine (GEM) in patients with<br />
advanced pancreatic adenocarcinoma (APC) as second-line therapy<br />
after FOLFIRINOX or FOLFOX.<br />
Authors*: Andrew H. Ko, E. Gabriela Chiorean, Eunice Lee Kwak, Heinz-Josef Lenz, Paul I. Nadler,<br />
Debra L. Wood, Masamoto Fujimori, Tetsuhi Inada, Hiroyuki Kouji, Robert R. McWilliams<br />
Abstract #: e15721<br />
Presentation Date/Time: Publication Only<br />
Location: Publication Only<br />
Session: Publication Only<br />
Citation: J Clin Oncol 34, 2016 (suppl; abstr e15721)<br />
Ko Research Interests: My work focuses on gastrointestinal malignancies, where I have developed and<br />
led multiple clinical trials, both within <strong>UCSF</strong> and across multiple sites. I am interested in the development<br />
and evaluation of new therapeutic agents ranging from novel cytotoxics to molecular targeted agents to<br />
immunotherapies, with a particular emphasis in pancreatic cancer. This work entails collaborating with<br />
laboratory-based investigators on translational science to identify individual patient/tumor characteristics that<br />
influence prognosis and response to specific therapies. I lead the <strong>UCSF</strong> site committee for gastrointestinal<br />
cancer-specific clinical trial development and serve as chair of the scientific Protocol Review Committee.<br />
Nationally, I sit on the editorial board for multiple peer-reviewed oncology journals, am a member of NCI’s<br />
Pancreatic Cancer Task Force and the NCCN Pancreatic Cancer guidelines committee.<br />
http://cancer.ucsf.edu/people/profiles/ko_andrew.3444<br />
__________________________________________________________________________<br />
Microarray-based tumor ploidy and its association with lymph node<br />
involvement in bladder cancer.<br />
Authors*: Karla Lindquist, Thomas Sanford, Maxwell V. Meng, Pamela Paris, Sima P. Porten<br />
Abstract #: e16012<br />
Presentation Date/Time: Publication Only<br />
Location: Publication Only<br />
Session: Publication Only<br />
Citation: J Clin Oncol 34, 2016 (suppl; abstr e16012)<br />
*<strong>UCSF</strong> authors in bold<br />
95
Presentations<br />
Treatment patterns for metastatic castration-resistant prostate cancer<br />
(mCRPC) in oncology (ONC) urology (URO) practices: Data from the<br />
PROCEED registry.<br />
Authors*: Nicholas J. Vogelzang, Andrew J. Armstrong, Celestia S. Higano, A. Oliver Sartor,<br />
Christopher Michael Pieczonka, Raoul S. Concepcion, Ronald F. Tutrone, Carl A. Olsson, James L. Bailen,<br />
David F. Penson, Nancy N. Chang, Jennifer Susan LIll, Robert Claude Tyler, Matthew R. Cooperberg<br />
Abstract #: e16503<br />
Presentation Date/Time: Publication Only<br />
Location: Publication Only<br />
Session: Publication Only<br />
Citation: J Clin Oncol 34, 2016 (suppl; abstr e16503)<br />
__________________________________________________________________________<br />
Dehydroepiandrosterone (DHEA) in metastatic castration-resistant<br />
prostate cancer (mCRPC): Preliminary results from the SU2C/PCF/<br />
AACR West Coast Dream Team (WCDT)<br />
Authors*: Won Kim, Charles J. Ryan, Li Zhang, Jack Youngren, John Wilton, Joshi J. Alumkal,<br />
Tomasz M. Beer, Robert Baertsch, Josh Stuart, Kim N. Chi, Martin Gleave, Matthew Rettig,<br />
Robert Evan Reiter, Primo Lara, Christopher P. Evans, Eric Jay Small<br />
Abstract #: e16598<br />
Presentation Date/Time: Publication Only<br />
Location: Publication Only<br />
Session: Publication Only<br />
Citation: J Clin Oncol 34, 2016 (suppl; abstr e16598)<br />
Small Research Interests: The Stand Up To Cancer Dream Team led by Dr. Eric Small is exploring the<br />
idea that resistance to hormonal therapy occurs as a result of the prostate cancer cells using common<br />
cellular responses - what the Dream Team calls “adaptive pathways” - to escape the current prostate<br />
cancer therapies. They believe that, by identifying these pathways and inhibiting them, they will be able to<br />
overcome treatment resistance and profoundly improve the care of men affected by this fatal disease. This<br />
team is a six institution consortium to include UC Los Angeles, UC Davis, UC Santa Cruz, University of<br />
British Columbia, Oregon Health and Sciences University, with <strong>UCSF</strong> as the lead administrative site.<br />
http://cancer.ucsf.edu/people/profiles/small_eric.3671<br />
*<strong>UCSF</strong> authors in bold<br />
96
Presentations<br />
Comparative performance of surveillance mammography and breast<br />
MRI in women with a history of breast cancer.<br />
Authors*: Karen Wernli, Laura E Ichikawa, Karla Kerlikowske, Mary Bush, Dianne Johnson, Diana SM Buist,<br />
Susan Brandzel, Wendy DeMartini, Louise Henderson, Lariss Nekhlyudov, Tracy Onega, Brian Sprague,<br />
Diana Miglioretti<br />
Abstract #: e18051<br />
Presentation Date/Time: Publication Only<br />
Location: Publication Only<br />
Session: Publication Only<br />
Citation: J Clin Oncol 34, 2016 (suppl; abstr e18051)<br />
Kerlikowske Research Interests: My lab focuses on breast imaging and the epidemiology of invasive breast<br />
cancer, DCIS and breast density, and risk prediction models for invasive breast cancer. We have developed<br />
cohorts of women at risk for invasive breast cancer and DCIS and developed comprehensive databases<br />
that include breast imaging, pathologic, clinical, biomarker, and risk factor data, as well as follow-up for<br />
subsequent disease and death.<br />
http://cancer.ucsf.edu/people/profiles/kerlikowske_karla.3457<br />
*<strong>UCSF</strong> authors in bold<br />
97
Presentations<br />
Enabling a paradigm shift: A preference-tolerant RCT of personalized<br />
vs. annual screening for breast cancer.<br />
Authors*: Sarah Rosenberg-Wohl, Prihatha Narasimmaraj, Allison S Fiscalini, Karyn DiGiorgio, Lisa Latts,<br />
Marcus Thygeson, Martin Eklund, Jason Connor, Kristine Broglio, Jeffrey Tice, MaryBeth Kramer,<br />
Andrea LaCroix, Robert A. Hiatt, Barbara A. Parker, Tracy M. Layton, Laura Esserman<br />
Abstract #: e18281<br />
Presentation Date/Time: Publication Only<br />
Location: Publication Only<br />
Session: Publication Only<br />
Citation: J Clin Oncol 34, 2016 (suppl; abstr e18281)<br />
Esserman Research Interests: Dr. Esserman, surgeon & breast cancer oncology specialist, is the Carol Franc<br />
Buck Breast Care Center Director and co-leads the Breast Oncology Program. Her research is on improving<br />
healthcare value through integrating translational science, clinical informatics, systems re-engineering<br />
& clinical care delivery. In 2005, she received the NCI SPORE Investigator of the Year Award. In 2016 she<br />
received the Arbuckle Award from Stanford Graduate School of Business for Excellence in Management &<br />
was named to TIME’s 100 most influential people list. She is PI of the I-SPY TRIAL program, now a model for<br />
translational research & innovation in clinical trial design. She launched the Athena Breast Health Network to<br />
follow women from screening through treatment & outcomes, incorporating the latest in molecular testing &<br />
web-based tools. Athena just launched the WISDOM study to compare personalized vs annual breast cancer<br />
screening in 100,000 women and to predict who gets what kind of cancer.<br />
http://profiles.ucsf.edu/laura.esserman<br />
__________________________________________________________________________<br />
Non-invasive detection of crizotinib resistance in ALK-rearranged lung<br />
adenocarcinoma directs treatment with next-generation ALK inhibitors.<br />
Authors*: Nnamdi Ihuegbu, Kimberly C. Banks, Stephen R Fairclough, Oliver A. Zill, Darya Chudova,<br />
Richard Burnham Lanman, Collin M. Blakely<br />
Abstract #: e20643<br />
Presentation Date/Time: Publication Only<br />
Location: Publication Only<br />
Session: Publication Only<br />
Citation: J Clin Oncol 34, 2016 (suppl; abstr e20643)<br />
*<strong>UCSF</strong> authors in bold<br />
98
Presentations<br />
Identification of symptom clusters by occurrence and severity in lung<br />
cancer patients receiving chemotherapy.<br />
Authors*: Melisa L. Wong, Bruce A. Cooper, Judy Mastick, Steven M. Paul, Christine Miaskowski<br />
Abstract #: e21657<br />
Presentation Date/Time: Publication Only<br />
Location: Publication Only<br />
Session: Publication Only<br />
Citation: J Clin Oncol 34, 2016 (suppl; abstr e21657)<br />
__________________________________________________________________________<br />
Circulating tumor DNA sequencing to reveal the genomic complexity<br />
of advanced EGFR-mutant lung adenocarcinoma.<br />
Authors*: Collin M. Blakely, Kimberly C. Banks, Richard Burnham Lanman, Jonathan Riess, Philip C. Mack,<br />
Trever Grant Bivona<br />
Abstract #: e23079<br />
Presentation Date/Time: Publication Only<br />
Location: Publication Only<br />
Session: Publication Only<br />
Citation: J Clin Oncol 34, 2016 (suppl; abstr e23079)<br />
Bivona Research Interests: Our team uses the tools of precision medicine to improve the molecular<br />
diagnosis and targeted therapy of patients with solid cancers, including lung cancer. Our program focuses<br />
on identifying and functionally characterizing the molecular drivers of tumor growth in individual patients.<br />
We study patient samples and clinical data to identify novel potential drivers of tumor initiation, progression,<br />
and therapy resistance. We functionally annotate the putative molecular drivers using an integrated approach<br />
of genetic and pharmacologic tools. This precision approach to understanding the molecular pathogenesis<br />
of lung cancer (and other cancers) has led to the discovery of new biomarkers and targets that provide<br />
rationale for novel clinical trials we are launching to improve patient survival.<br />
http://www.bivonalab.net/<br />
*<strong>UCSF</strong> authors in bold<br />
99
Presentations<br />
Functional annotation of cancer driver genes in breast cancer patientderived<br />
xenografts to identify a novel target for PARP inhibitors.<br />
Authors*: Xiaosong Zhang, Meng Li, Olga Momcilovic, Andrew Beardsley, Roman Camarda, Andrei Goga<br />
Abstract #: e23192<br />
Presentation Date/Time: Publication Only<br />
Location: Publication Only<br />
Session: Publication Only<br />
Citation: J Clin Oncol 34, 2016 (suppl; abstr e23192)<br />
Goga Research Interests: Tumor cells are driven to proliferate, alter their metabolism, and deregulate<br />
cell death pathways by oncogene over-expression or the loss of tumor-suppressor genes. We seek to<br />
understand how oncogenes alter these pathways using cell-based and transgenic animal models. We are<br />
especially interested in how the prototypical oncogene Myc acts in diverse tumor types, including amongst<br />
the most aggressive breast and liver cancers and lymphomas. Myc has also been postulated to drive a<br />
‘stem cell like’ gene expression pattern which may regulate tumor stem cell function. We seek to elucidate<br />
the genes and pathways that are indispensable for Myc function, and thus uncover potential ‘achilles heels’<br />
of tumor cells. Our ultimate goal is to translate our basic discoveries to novel cancer therapeutics.<br />
http://oncogenes.net/Goga_Lab/Home.html<br />
*<strong>UCSF</strong> authors in bold<br />
100